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ABSTRACT 
The assessment of medicines has moved from efficacy and safety to that of a 
benefit-risk balance and regulatory agencies and pharmaceutical companies are 
improving their processes in order to achieve greater consistency and transparency 
in decision-making. However, their efforts are largely independent and do not 
address the lack of consistency in decisions by different countries, albeit for the same 
medicine, resulting in the potential inaccessibility of important medicines. The aim of 
this study was the development and validation of a universal benefit-risk framework 
for use by regulatory authorities. 
A questionnaire, specifically developed for this study, was used to evaluate the 
current approaches to benefit-risk assessment of medicines by 14 regulatory 
agencies and 24 pharmaceutical companies. None of the 11 agencies (79%) and 20 
companies (83%) that responded used a fully quantitative approach, but the majority 
used a qualitative system for benefit-risk assessment. The development of a 
universal benefit-risk framework for use by both regulators and industry, with the 
involvement of all stakeholders, was supported by the study participants.  
A comparison of the existing benefit-risk assessment frameworks used by agencies 
and companies identified the common elements. As no major differences were 
observed, an 8-step universal framework was developed which incorporated the 
other frameworks. To support the framework in the assessment of benefits and risks, 
a template for documenting the benefit-risk decision together with a user manual was 
also developed. Four regulatory agencies conducted a retrospective pilot study to 
investigate the feasibility of this framework, the benefit-risk template and user 
manual.  
Subsequently, a prospective study was conducted by TGA of Australia, Health 
Canada and HSA of Singapore. The agencies found the benefit-risk template was ‘fit 
for purpose’ in terms of the relevance of information supporting the benefit-risk 
decision, the documentation and communication and the relative importance and 
values of the benefits and risks. The results showed that the benefit-risk summary 
template was adequate to document benefits and risks, relevant summaries and 
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conclusions for the emerging markets. The applicability and validity of the summary 
component of the benefit-risk template was evaluated by sixteen HSA clinical 
reviewers in a retrospective study. They found that the BR Summary Template was 
adequate to document benefits, risks, relevant summaries and conclusions. 
However, a revision of the BR Summary Template should include technical 
improvements and more details of safety information. The BR Summary Template 
was thought to be a useful tool for communicating benefit-risk decisions to a variety 
of stakeholders.  
 
The formats of publicly available reports from major regulatory agencies were 
compared and found to be generally similar. When compared to the BR Template, 
the listing of benefits and risks, assigning of weights and values, visualisation and a 
more detailed, systematic standardised structure were found to be absent. This 
research has demonstrated that the 8-step universal framework is of value for the 
assessment of benefits and risks of medicines by regulatory agencies and the 
template was found to be useful for documenting and communicating benefit-risk 
decisions. 
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Glossary of terms 
Adverse event Also known as adverse experience, it is any untoward 
medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and 
which does not necessarily have to have a causal 
relationship with this treatment. 
 
Adverse reaction/effect In the pre-approval setting when the therapeutic 
dose(s) may not be established, it is all noxious and 
unintended responses to a medicinal product related 
to any dose should be considered adverse drug 
reactions. 
For marketed medicinal products, it refers to a 
response to a drug which is noxious and unintended 
and which occurs at doses normally used in man for 
prophylaxis, diagnosis, or therapy of disease or for 
modification of physiological function. 
 
Benefit A potential favourable effect seen to be promoting or 
enhancing the current state of health, resulting from 
the treatment using the product 
 
Benefit-risk assessment Also referred to as assessment and known as benefit-
risk evaluation, it is the review of scientific data in 
support of the proposed indication of the product, 
conducted by a reviewer/assessor 
 
Benefit-risk balance Also known to as benefit-risk profile or outcome, it is 
the expert opinion cumulative of the consideration of 
the benefits and risks - weighing the relative 
contribution and the uncertainties of the evidence 
provided, incorporating the current medical knowledge 
and experience - and recommending a positive or 
negative outcome 
 
Benefit-Risk Summary Part of the Benefit-Risk Template; consist of the 
conclusions of various aspects of assessment, and the 
final benefit-risk balance 
 
Benefit-Risk Template A product of this research which documents and 
communications the assessment findings supporting 
the benefit-risk balance and decision; includes the 
Benefit-risk Summary and proforma 
viii 
Benefit-Risk Summary 
Template 
A product of this research which documents and 
communications the assessment findings supporting 
the benefit-risk balance and decision, extracted from 
the main Benefit-Risk Template 
 
Company/Sponsor 
 
Refers to the owner of the product, and whom initiates 
the submission 
 
Comparator An investigational or marketed product (i.e. active 
control) used as a reference in a clinical trial 
 
Effect size The quantum of difference arising from the 
comparison between treatment outcomes of the 
product with the comparator; it contributes to the 
overall interpretation of effectiveness and clinical 
relevance 
 
Investigated product Also referred to as the product, it is the entity on which 
the submission of an application for market 
authorization is based, and for which the clinical 
studies are conducted 
 
Medicines Refers to pharmacological products for use in human 
with the intention of medical intervention 
 
Methodology A tool, concept or set of principles that guides the 
assessment of benefits and risks 
 
Multi criteria decision 
analysis (MCDA) 
A decision analysis technique which disaggregates a 
complex problem, measures the extent to which the 
options achieve its objectives, applies weights to the 
objectives and finally reassembles these information 
to contribute to the decision 
Patient reported outcomes Observations as part of a study related to the results 
obtained directly from the patients, which may include 
patients’ satisfaction, tolerability, symptoms, patient 
preferences, quality of life and interruptions to daily 
living 
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Proforma Part of the Benefit-Risk Template; consist of various 
sections providing the details of the basis on benefit-
risk balance decisions 
 
Reviewer Also known as evaluator or assessor, personnel 
trained in the scientific evaluation of data, and using 
clinical judgment to provide a recommendation on the 
benefit-risk balance of the product 
 
Risk Also known as harm, an unfavourable effect or 
adverse reactions/effects on patients’ health, public 
health or the environment resulting from exposure to 
the product 
 
Scoring The process of assessing the performance of each 
option against a relevant criteria by assigning a 
numerical value 
Seriousness (of adverse 
event/reaction/effect)* 
A serious adverse event (experience) or reaction is 
any untoward medical occurrence that at any dose:  
• results in death,  
• is life-threatening (at risk of death at the time of the 
event) 
• requires inpatient hospitalisation or prolongation of 
existing hospitalisation,  
• results in persistent or significant 
disability/incapacity, or  
• is a congenital anomaly/birth defect. 
 
Severity (of adverse 
event/reaction/effect)* 
The intensity of a specific adverse event which may or 
may not be of medical significance or seriousness, 
which is defined by a set of criteria.  
Submission An application sent for review to the regulatory 
authorities by the company, for the market 
authorization of the proposed indications of the 
product 
 
Value tree A methodology used in multi-criteria decision analysis 
for incorporating and organising the different criteria in 
the model structure. It clusters the criteria in a 
hierarchical way 
x 
Valuing An exercise of providing qualitative or quantitative 
figure (values) reflecting of the effect observed from 
the studies; this assist in the interpretation of effect 
size and relevance of treatment  
Weighting An exercise of expert judgment indicating the relative 
importance of the available options, commonly done 
through a logical system of rank assignment (weights) 
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General introduction 
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The regulation of medicines is essentially conducted to ensure patients’ accessibility 
to medicines that fulfil the criteria of quality, safety and efficacy. As patients are not 
equipped to make a scientific assessment, regulators play an important role in 
controlling the access to safe and effective medicines. Two of the key elements 
highlighted by the World Health Organisation (WHO, 2003) for effective regulation of 
medicines included strong cooperation and collaboration between stakeholders and 
transparency and accountability. The latter is deemed critical for the communication 
of the basis of decisions and building public confidence. In the WHO’s strategic 
directions for medicines (WHO, 2010), new policy and guidance was developed to 
ensure transparency and good governance in pricing, procurement and regulation. 
 
The review of medicines by regulatory agencies is largely based on the submission 
of clinical data collected from clinical trials phases I to IV. The US FDA may 
occasionally be involved in the developmental phases of a product through 
investigational new drug (IND) applications, where the trial data generated will 
subsequently feed into the new drug application (NDA) for a marketing authorization. 
The assessment of clinical efficacy of a medicine is supported by studies which are 
statistically designed to provide a reliable and robust conclusion through the scientific 
investigation of suitable endpoints. It is expected that these measured endpoints 
would be translated to meaningful benefits to the patients intended for the treatment. 
However, due to practical reasons to conduct and complete a trial in a timely manner 
for generating the required clinical data, these measured endpoints may be 
surrogates of the actual clinical benefits on the basis of the observed effect on these 
endpoints. These types of endpoints include parameters like blood pressure, 
cholesterol levels or microbial eradication which may not translate to reduced 
cardiovascular events or a faster recovery from an infection. To establish the utility of 
a medicine, some trials are required to produce clinical endpoints that could directly 
benefit a patient, such as overall survival, reduction in hospital stay or an improved 
quality of life from a chronic debilitating disease. However, a clinical trial is limited by 
its scientific robustness in taking into account the many other factors that would 
constitute a benefit to a patient. Indeed the definition of a benefit may differ among 
physicians, patients and between diseases. This may be due to differences in 
severity of the disease itself and the subjective perception of the expectations arising 
from the treatment. Moreover, a benefit should also take into account the trade-off 
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incurred from the potential adverse effects of the treatment. As a result, the 
endpoints from a well-designed clinical trial may not always produce a meaningful 
beneficial treatment for the patient. A proven clinical efficacy in a study therefore may 
not always translate into a benefit for the patient. 
 
In the assessment of risk or harm, safety data are collected alongside the conduct of 
the clinical studies which are primarily designed for the purpose of proving clinical 
efficacy. As such, there could be more subjectivity in the perception and conclusion 
of risks to the patients and how the safety information may be rationalised into 
objective outcomes (Slovic et al., 2004). In a study conducted by the EMA as part of 
the benefit-risk methodology project, the variability in the individual risk perception of 
regulators was reviewed (EMA, 2011a). The differences appeared to be related to 
gender, years of regulatory experience, the medicine itself and specific benefit and 
risk dimensions. It was recommended that a tool be included as part of a benefit-risk 
assessment framework to increase the awareness of this subjective component in 
decision-making and therefore introduce transparency and consistency into the 
process. Moreover, the number of patients in a clinical trial could not always 
elucidate the rare adverse effects which could be medically severe and significant. At 
the point of a product approval for market authorisation, there is only limited 
information on the potential risks. This is mitigated by post-market risk management 
plans and pharmacovigilance activities to further monitor the safe use of the product, 
so as not to further impede the timely access of a potentially useful medicine.  
 
In a discussion of the changing role of clinical pharmacology on drug development 
(Zineh et al., 2013), it was commented that given the review staff at US FDA had a 
different preference for strategies, a robust framework is now needed to help them 
understand if their review strategy is appropriate for the medicine. This is to help 
reduce the uncertainties relating to their decisions that may have contributed to an 
observed excessive aversion to risks. This may also contribute to an understanding 
and addressing the current issue of the huge financial investment in drug 
development and an unexpected high failure rate during development. 
 
Given the limitations and uncertainties in confirming the individual benefits and risks 
to patients, it will be a challenging task to justify the likely outcomes to a patient. In 
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making any decision, it should always entail the perspectives of expected 
advantages and the potential disadvantages that may be incurred. Likewise, for 
exploring options in managing the medical condition, the treatment should be viewed 
in terms of the benefits, risks and the uncertainties involved. The traditional method 
of assessing efficacy and safety separately could not be logically collated to provide 
a balanced view. It can be assumed that agencies would have gone through much 
deliberation on the trade-offs between the benefits and risks, but these are generally 
not documented or made known to the public. 
 
Breckenridge (2010) shared his views on the challenges in the assessment of 
benefits and risks of medicines, where the shift is mainly to review the overall 
balance between the benefits of a drug and the associated risks rather than the 
individual impact. This balance could be expressed in a transparent manner using a 
structured framework which aids in the communication of the differences in opinions 
between regulators and the drug developers. Indeed, for the regulatory challenges to 
be adequately addressed there must be further integration among the stakeholders. 
 
This shift in paradigm had already been observed much earlier, when there was a 
movement from safety, efficacy and quality to relative safety, comparative efficacy 
and relative quality. In moving from a risk-centric approach, the risk management 
strategy assesses the identified potential safety issue in the light of an overall change 
in the benefit-risk balance, as well as exploring new benefits in addition to managing 
the risks (CMR, 2002). The EMA (2008) realised the importance of reviewing both 
benefits and risks as an overall balance in their regulatory decision-making and 
therefore produced a reflection paper on the benefit-risk assessment of medicines. 
This movement added to the ICH final concept paper (ICH, 2010) to review the 
current periodic safety update reports (PSUR) and focus on benefit-risk evaluation, 
leading to the current periodic benefit-risk evaluation report (PBRER). It is however 
noted that the benefit-risk evaluation can be carried out qualitatively without the need 
for a formal mathematical or quantitative tool. In early 2013, EMA put the PBRER into 
effect (EMA, 2013a), supporting this initiative as there is now greater emphasis on 
risk management planning and recognising that new safety information can only be 
meaningfully assessed in the context of the medicine’s benefits. 
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A study of clinical practice guidelines, to assess how well patient preferences are 
incorporated showed that current practice guidelines did not integrate patient 
preferences (Chong et al., 2009). Given the differences in the understanding of 
scientific evidence and values in decision-making, there is an expected variability in 
the contribution (Umschied, 2009). Yet we know that the regulation of medicines is 
moving towards being patient-centric, so that decisions are made in the view of the 
wide-ranging needs of patients which can only be obtained if communications with 
stakeholders is part of the process (Walker et al., 2006). Indeed the increasing 
importance of patients’ perspectives in the form of patient reported outcomes in 
clinical trials can complement the traditional efficacy endpoints (Hareendran et al., 
2012). With various examples of how patient decisions had influenced the availability 
of some medicines including HIV drugs and monoclonal antibodies, it is only prudent 
to include the views of the patients in expressing the benefit-risk balance 
(Breckenridge, 2011).  
 
Both EMA and US FDA have indicated their plans to incorporate stakeholders’ views 
into their benefit-risk assessment and decision-making process. In a workshop 
conducted to review the patient’s role in benefit-risk assessment (CIRS, 2012a), it 
was proposed that patients’ preferences and their values be brought into the 
regulatory decision-making system through public hearings, patient representation or 
incorporation of such measures into clinical trials. In another workshop on framework 
development, patient inputs were identified as important when the medical condition 
involves subjective benefits and risks (CIRS, 2011). The US FDA alluded to the 
agency’s plans, as part of the Prescription Drug User Fee Act (PDUFA) V (FDA, 
2012a and 2013), to obtain patient perspectives on disease severity and unmet 
medical needs. Therefore, it is expected that a framework for the assessment of 
benefits and risks should be able to reflect the contribution of patients’ perspectives 
in the benefit-risk balance and the final regulatory decision.  
 
In a study on the effect of format on understanding the benefits and risks of clinical 
trials, it was found that pictographs are superior in providing an adequate overall 
understanding (Tait et al., 2010). The use of graphics and other visual displays are 
being used more often and also as an adjunct to verbal and numerical 
communications of risks (Lipkus, 2007). In a workshop to discuss the development of 
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a framework that informs stakeholder perspective and clarity of decision-making 
(CIRS, 2011), it was agreed that visualisation tools could provide a focus for benefit-
risk discussions on critical issues, identifying gaps and exposing overlapping benefits 
and harms and providing a succinct summary of the information needed to make 
benefit risk decisions. Hence it would be appropriate, that a framework for the 
assessment of benefits and risks, to incorporate visualisation of the outcomes to 
facilitate the communication to stakeholders. 
 
Recent significant contributions by various stakeholders 
Academia 
Mussen et al. (2007a; 2009), in the course of their published works for developing a 
systematic approach to decision-making during the assessment of medicines, 
reviewed benefit and risk criteria through identifying these from the ICH’s Common 
Technical Documents (CTD), EMA’s European Product Assessment Report (EPAR) 
and US FDA’s Medical Review.  The identified criteria were subsequently verified 
through a survey, refined in a workshop conducted by CMR (CMR, 2008) and 
produced recommendations for a future framework. The following efficacy 
parameters should be included in a benefit-risk framework: 
• Magnitude of treatment effect as observed in the pivotal studies 
• Clinical relevance of the observed magnitude 
• Statistical significance 
• Relevance of primary endpoints  and studied population of the pivotal studies 
• Discussions on dose and comparators 
• Methodology and study design issues 
• Validation of scales and outcome measures 
• Evidence of efficacy in relevant subgroups 
• Confirmation of efficacy by secondary endpoints and supporting studies 
• Patient reported outcomes 
• Patient compliance 
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The framework should also include the following safety parameters: 
• Overall incidence of serious side effects 
• Discontinuation rates due to adverse effects 
• Incidence, seriousness and duration of specific adverse effects 
• Extrapolation of safety profile to intended population for the indication 
• Adverse effects of the pharmacological class and other related classes 
• Safety in subgroups 
• Concerns arising from non-clinical evaluation 
• Overall incidence of adverse effects by categories 
• Drug-drug and drug-food interactions 
• Potential for off-label use and safety concerns 
• Risk mitigation plans and strategies 
 
In constructing a benefit-risk balance, Mussen et al. (2009) recommended the 
following parameters as part of the framework: 
• Description of alternative therapies or interventions 
• Calculation of uncertainties on benefits and risks 
• Direct comparison of gains versus harms in terms of lives saved or lost or clinical 
events 
• Evaluation of acceptable risk with regards to the clinical benefit in the specified 
context 
• Evolution of the benefit-risk balance over time 
• Evaluation of benefit-risk in major subgroups 
• Identification of outstanding issues and potential post-market commitments 
• Consideration of different regulatory options for approval 
 
In a review of the benefit-risk assessment models, Mussen et al. (2009) reviewed 
three general models, namely “Principle of Threes” (Edwards et al., 1996), evidence-
based model (Beckmann, 1999) and Transparent Uniform Risk Benefit Overview 
(TURBO) (CIOMS, 1998). They were found unable to balance the benefits and risks 
and did not meet his criteria for a framework to assess benefits and risks. These 
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models did not define clearly the type, quality and relative importance of the data 
required. The models were simple, could not account for different attributing factors 
and were not validated in practice. However, these models would collate the thoughts 
and considerations of the assessment and hence contribute to decision-making. 
Mussen et al. proceeded to develop a new framework which would function as a 
model for decision analysis. The MCDA (Belton V et al., 2001) formed the foundation 
of this framework, as it allowed the balancing of multiple criteria, namely the different 
benefits and risks of treatment with the medicine being assessed. This is a process 
described in the Multi-criteria analysis (MCA) manual (Dodgson et al., 2009) which 
aimed at exploring the individual contributing aspects of the decision-making process 
before collating the outcomes to form the basis of the decision. There are three key 
phases of the MCDA process. The problem is first identified and structured, secondly 
the decision-maker’s preferences are taken into account and lastly, action plans are 
developed.  
 
A final 7-step framework based on the MCDA principles was eventually developed 
(CMR, 2010). The assessment of the benefit-risk balance was recommended to be 
carried out as follows: 
1. Establish the background and context of the decision  
2. Identify the options to be considered (treatment, placebo or active comparator) 
3. Identify the criteria (benefits and risks) and arrange these into a value tree 
4. Establish scales for the criteria and score the options on the criteria 
5. Assign weights for each criterion 
6. Normalise the weights, calculate the weighted scores and overall preference 
score for each option 
7. Examine the results and conduct sensitivity analysis by varying the weights of the 
criteria 
 
A framework uses a set of underlying principles to provide an overarching structure in 
which essential processes can be carried out to achieve its objectives. Therefore, 
despite the use of values and weights, both the MCDA and the above 7-step 
approach should be considered as frameworks rather than quantitative 
methodologies, in recognition of the underlying MCA principles described above. 
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 Part of the framework development involved participants in two CMR workshops 
(CMR, 2004 and 2005) who applied the framework in two clinical settings. The first 
involved the use of a new recombinant necrosis factor receptor inhibitor compared 
against methotrexate in managing rheumatoid arthritis, and the other a hypothetical 
drug with cardiovascular safety concerns for treating schizophrenia. One utility of the 
framework was the provision of a platform for structured conversation and decision 
conferencing, which allowed an agreement despite a divergence in the opinions of 
the data. In addition, the workshops demonstrated that use of values and weights are 
required to provide a complete judgment on the benefits and risks. The framework 
was also applied to various other clinical scenarios (Mussen et al., 2007b). The final 
conceptual framework was adopted by CIRS (2009, 2010) and further refined 
through future workshops. 
 
As part of the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) Risk-Benefit Management Working Group, Guo et al. (2010) conducted a 
literature review on quantitative methodologies for the assessment of benefits and 
risks of medicines. The search was not limited to a single stakeholder’s perspective 
and thus included tools used by regulatory agencies, pharmaceutical companies and 
academia. They identified and reviewed 12 quantitative benefit-risk assessment 
models, which included the Quality-adjusted Time Without Symptoms and Toxicity 
(Q-TWiST) (Gelber et al., 1993; Cole et al., 2004), number need to treat (NNT)/ 
number needed to harm (NNH) (Holden et al., 2003a, 2003b; Laupacis et al., 1988; 
Cook et al., 1995), incremental net health benefit (INHB) (Garrison et al., 2007; Lynd 
2010), probabilistic simulation methods (PSM) and Monte Carlo simulation (Lynd et 
al., 2004; Shaffer et al., 2006), multi-criteria decision analysis (MCDA) and stated 
preference method (SPM) (Ryan et al., 1998; Gan et al., 2004). Some models like 
the NNT used subjective weighting and allow a non-statistical or qualitative 
assessment and others like the MCDA and SPM were useful in allowing joint 
assessment of both benefits and risks. Simple methods like the NNT and NNH are 
widely used, but it could not account for the quantum or value of the benefits and 
harms, or allow the contribution of several relevant benefits and harms into the same 
context for decision-making. In addition MCDA was found to be capable of handling 
missing data and uncertainties through use of relevant modelling tools and 
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application of weights, as well as exploring the robustness of the outcomes through 
sensitivity analyses. While MCDA could account for the various factors contributing to 
the decision-making, it is nonetheless a relatively new and intensive tool that may be 
limited to more complex evaluations. The SPM is a theoretical tool that could 
incorporate patients’ preferences and the evaluation of benefit-risk trade-offs. This 
method would require the collection of patients’ treatment preferences, for which the 
current best practice to achieve this is still being developed. However, the SPM may 
be considered by healthcare professionals as it involves the opinions of the patients. 
Overall, it appeared that the reviewed methodologies were not adopted by the 
agencies and companies and were primarily for research purposes. Guo et al. (2010) 
concluded that some of these methodologies would be helpful to lessen concerns 
over the subjective component of assessment and provide the required transparency, 
but all have their own set of limitations. None was found to be able to function across 
all scenarios and it was recommended that various tools be used to appropriately 
profile the benefit-risk balance. Due to the limited published information for net 
clinical benefit analysis, the principle of threes and net-benefit-adjusted for-utility 
analysis, these methods were not reviewed. 
 
Regulatory agencies 
As expectations of stakeholders change with the rapid advancement of science, 
regulatory agencies make plans to adapt and meet these changing needs. In EMA’s 
roadmap to 2015, they identified one of the strategic areas to be facilitating the 
access of medicines through reinforcing the benefit-risk balance assessment model, 
to be achieved through a set of priority activities (EMA, 2011b). These included 
looking at appropriate quantitative tools, improving the quality and consistency of the 
outcomes, reviewing the EPAR’s to improve communication of benefit-risk decisions 
to stakeholders and increasing the involvement of patients, academia and healthcare 
professionals in the assessment of medicines to ensure their views are taken into 
consideration. A CHMP working group was formed in 2006 to look into methods to 
improve the transparency, consistency and communication of benefit-risk 
assessment. A preliminary review of NNT/ NNH, “Principles of Three”, Transparent 
Uniform Risk Benefit Overview (TURBO) and MCDA was conducted and the 
advantages and limitations of each were discussed. In their report, they emphasised 
that qualitative evaluation and expert judgment are not to be replaced by quantitative 
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benefit-risk assessment. They recommended that a model for benefit-risk 
assessment should be structured and of a qualitative approach, be able to describe 
explicitly the importance of benefits and risks in the context of the decision and the 
impact of the uncertainties on the benefit-risk assessment (EMA, 2007). This led to 
the reflection paper for benefit-risk assessment of medicines as mentioned above 
and also the benefit-risk methodology project.  
 
The benefit-risk methodology project was aimed at looking at tools and processes 
that provide aid to regulatory decision-making, training of assessors and 
communicating benefit-risk decisions to stakeholders (EMA 2009), through a series 
of five work packages.  The first work package (EMA, 2011c) was to describe the 
practices of benefit-risk assessment within the EU for the centralised procedure. The 
key findings steered the movement of the remaining work packages and these 
findings appeared to be reflective of the global environment. Among the key findings 
were: 
1. Variability in the understanding and definitions of “benefit” and “risk” 
2. The benefit-risk balance is assessed mainly intuitively and by matter of expert 
judgment or extensive discussion 
3. Importance of consistency in decisions and the process of decision-making 
4. There is no system or model currently used by any agency and many felt there 
could be improvement made for the existing processes 
In addition, the EMA produced a set of five criteria to verify a model’s applicability for 
benefit-risk assessment. These include logical soundness, comprehensiveness, 
acceptability of results, practicality and generativeness. 
 
As part of their benefit-risk methodology project, twenty-one approaches were 
reviewed, including three qualitative frameworks (BRAT, CMR framework and US 
FDA’s benefit-risk framework) and 18 quantitative models in the second work 
package (EMA, 2010). This was conducted with the above five criteria for a benefit-
risk assessment model. In response to the observation in the first work package, they 
attempted to redefine benefits as favourable effects, harms or risks as unfavourable 
effects and uncertainties as variations, bias, flaws and deficiencies of the above 
types of effects. With regards to the qualitative frameworks, these were still under 
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development at the time of the review and hence limited comments were made. It 
was highlighted however, that the uncertainties of benefits and risks, being of 
concern to regulators, should be addressed by these frameworks. The quantitative 
approaches were reviewed according to four broad categories based on their 
functions, namely simulation, models, statistics and measurements. Some of the 
approaches reviewed included the Markov processes (Sonnenberg et al., 1993), 
TURBO, Principles of Three, QALYs/ Disability adjusted life years (DALYs), Kaplan-
Meier estimators (Kaplan et al., 1958) and conjoint analysis (Johnson, 2006). They 
concluded that four approaches, namely the qualitative framework, MCDA, Bayesian 
statistics (O’Hagan et al., 2006; Ashby et al., 2000) and decision trees (Goodwin et 
al., 2009; Stonebraker et al., 2002), would be useful to regulators and can 
comprehensively quantify a benefit-risk balance. A qualitative framework would be 
required to support any quantitative model and may be used for simple decision-
making. Again, it was recommended that a combination of tools would be useful in 
selected situations involving magnitude, seriousness and uncertainty of the effects. 
With the findings and understanding of the potential of the MCDA in this area, EMA 
proposed their own benefit-risk framework which consists of eight steps, the 
PrOACT-URL (Table 1.1). This is meant to be a flexible framework that can 
accommodate the various scientific methodologies for assessing benefits and risks, 
as well as a graphical representation of the outcomes of assessment.  
 
The PrOACT-URL was subsequently applied to the third and fourth work packages. 
In the third work package (EMA, 2011d), the framework guided the review of selected 
quantitative approaches conducted retrospectively using the European Public 
Assessment Reports (EPAR). The products reviewed were Accomplia® 
(rimonabant), Cimzia® (certolizumab), Sutent® (sunitinib) and Tykerb® (lapatinib) 
using a combination of MCDA, probabilistic simulation (PSM), Markov model and 
decision tree. The use of the framework and the quantitative approaches allowed for 
different perspectives to be tested, reviewed the impact of uncertainties, as well as 
provided a structure to the review and communicated explicitly the objectives and 
trade-offs. However, this current method would be labour intensive and require the 
availability of suitable software to conduct the various analyses. Moreover, 
justifications for clinical judgment were not accounted for as the outcomes were to be 
quantified. 
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Table 1.1 The proposed qualitative framework from EMA – PrOACT-URL 
 Steps Actions 
1 Problem • Determine the nature of the problem and its context 
• Frame the problem 
2 Objectives • Establish objectives that indicate the overall purposes to be 
achieved 
• Identify criteria of favourable and unfavourable effects 
3 Alternatives • Identify the options to be evaluated against the criteria 
4 Consequences • Describe how the alternatives perform for each of the 
criteria, that is, the magnitudes of all effects and their 
desirability or severity and the incidence of all effects 
5 Trade-offs • Assess the balance between favourable and unfavourable 
effects 
6 Uncertainty • Assess the uncertainty associated with the favourable and 
unfavourable effects 
• Consider how the balance between favourable and 
unfavourable effects is affected by uncertainty 
7 Risk tolerance • Judge the relative importance of the decision makers’ risk 
attitude for this product and indicate how this affected the 
balance 
8 Linked 
decisions 
• Consider the consistency of this decision with similar past 
decisions, and assess whether taking this decision could 
impact future decisions 
 
The ability of the PrOACT-URL to accommodate a quantitative aspect of benefit-risk 
assessment shown in this work package was reported and published by Phillips 
(2011). The fourth work package (EMA, 2012) continued to support the findings in 
the third work package, the use of PrOACT-URL framework and the value of 
graphical displays. It was recommended that the effects table be used for simpler 
cases and a full MCDA approach be employed for contentious cases. The last work 
package would be the development of training materials which have not been 
published at the time of this research. On top of the work to identify benefit-risk 
methodologies, EMA has also extended its transparency movement to include 
publication and public access to clinical trial data (EMA, 2013b).  
 
Since 2009 the US FDA have taken initiatives to explore systematic approaches to 
assess and communicate benefits and risks, in tandem with the efforts taken at the 
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EU. The initiatives included the development of a framework to characterise and 
provide a structure for the benefit-risk assessment already existing in their decision-
making processes, as well as communicate the reasoning behind the decision to all 
stakeholders (FDA, 2012a). This led to the current 5–step benefit-risk framework 
which was put together after a pilot project in 2012. The five steps are related to the 
five key areas to be discussed in the assessment of the medicine, namely the 
analysis of the condition, the medical need for the product, clinical benefit, risk and 
risk management (FDA, 2013a). The strength of the evidence and its uncertainties 
would be considered during the assessment, with the reasons provided for the 
conclusion of each of the five areas. The outcomes of these five areas would then be 
cumulatively discussed leading to the overall benefit-risk conclusion. The framework 
would also look into current treatment options, a summary of the submitted evidence 
for the benefits and risks and risk management plans. With the development of this 
initial framework, the US FDA embarked on the five-year plan, starting 2013 till 2017, 
for a structured approach to benefit-risk assessment, which was part of the larger 
PDUFA V program. During this period they will further refine the framework and how 
this might be worked into their current clinical reviews to facilitate communication. 
Mullin of the US FDA, during a workshop conducted by CIRS (2011), commented 
that this structured framework had the potential to improve the predictability and 
consistency of decision-making as it is capable of clearly outlining both the available 
evidence and the uncertainties. It would also articulate the consideration and clinical 
judgement taken for the benefit-risk decision and hence improve the transparency of 
the decision-making process. 
 
The US FDA acknowledged that the existing programmes to facilitate patient 
representation may be inadequate and thus they are committed to a new initiative, 
Patient-Focused Drug Development. This aims to obtain the patients’ perspective on 
the medical condition and the currently available therapies for a set of disease areas 
and runs till 2017. For each disease area, FDA conducts a public meeting and invites 
participation from FDA staff, the relevant patient advocates and other interested 
stakeholders. Diseases covered thus far include chronic fatigue syndrome and 
myalgic encephalomyelitis (FDA, 2013b), human immunodeficiency virus (HIV) (FDA, 
2013c), lung cancer (FDA, 2013d) and narcolepsy (FDA, 2013e). Other diseases 
planned for 2014 and 2015 includes fibromyalgia and sickle cell disease. The US 
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FDA has also published its own user’s guide on communicating benefits and risks 
(FDA, 2011), which provides the expectations and standards of communicating risks. 
 
In the MHRA’s corporate plan for 2013-2018 (MHRA, 2013a), it was indicated that 
benefit-risk decisions should be made more informed by the experiences and 
perspectives of patients and views from other stakeholders. This is to be achieved 
through initiatives like more stakeholder partnerships to increase the understanding 
of benefits and risks of medicines and a better representation of patient and public 
views in regulatory decisions.  
 
Through their new initiatives for the next three years, TGA will be focusing on 
increasing transparency and engaging stakeholders with a new framework for 
communications which is committed to relaying the benefits versus risks approach in 
their regulation of medicines (TGA, 2013). This is to be achieved through information 
that is easily understood by patients and consumers and received and shared by 
healthcare professionals. TGA aims to provide accessible, clear and consistent 
relevant information through various multimedia platforms. In addition, consumers 
would be consulted for the labelling changes. The stakeholder engagement is also 
extended to the healthcare professionals, in improving the awareness and 
accessibility to relevant information. 
 
Pharmaceutical companies 
To a similar extent, the pharmaceutical industry has been also taking an initiative to 
address the need for an improved benefit–risk assessment by developing a 
structured, systematic, and transparent framework. Led by the Pharmaceutical 
Research and Manufacturers of America (PhRMA), the Benefit Risk Action Team 
(BRAT) Framework sought to incorporate all relevant aspects of benefits and risks 
and focused on both qualitative and quantitative analysis, for the purpose of 
communication between the companies and regulatory agencies. The framework 
aimed to advance the reproducibility, transparency and communication of the basis 
of the benefit–risk decisions (Coplan et al., 2011). This six-step framework (Table 
1.2) is a flexible structure which allows the use of appropriate scientific tools to 
analyse the outcomes. 
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In a workshop organised by CIRS (2011), Hughes from Pfizer reviewed the steps of 
the BRAT framework and the history of its development. The process of BRAT 
framework starts with defining the decision context (including the formulation, 
indication, patient population, comparators and decision perspective). Next, the 
benefit and risk outcomes are identified and selected, followed by the creation of an 
initial value tree which determines the preliminary set of outcome measures. In step 
three, source data are extracted to support outcome measures and input into 
summary tables. The framework is then customised and the value tree re-examined 
and revised to incorporate any additional clinical context. In step five, the outcome is 
assessed for its importance, with informal or formal weighting methodologies being 
employed to determine the relative importance of all outcomes. Finally, the key 
measures and data are summarised in a visual format to aid the interpretation and 
decision, information gaps are filled in and sensitivity analyses are conducted. 
 
Table 1.2 The Benefit-Risk Action Team (BRAT) Framework 
 Steps 
1 Define the decision context 
2 Identify outcomes 
3 Identify and extract source data 
4 Customise the framework 
5 Assess outcome importance 
6 Display and interpret key benefit-risk metrics 
 
In developing the framework, BRAT conducted interviews with 16 companies to build 
a baseline of industry perspectives on benefit-risk and benefit-risk assessment. 
These interviews showed that most companies engage with regulatory agencies in 
discussions of benefit-risk profiles, but only some do so consistently throughout the 
development of a medicine and few companies used explicit benefit-risk frameworks 
during US FDA and EMA approval discussions. With the challenges of interacting 
with regulatory agencies as well as internally, a common benefit-risk language and 
approach was proposed. The BRAT framework is designed to supplement rather 
than substitute for expert judgement and to facilitate a balanced approach. The 
triptans were used as an example to illustrate the applicability of the framework 
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(Levitan, 2011). The utility of BRAT was also studied in the background of the various 
frameworks by the regulatory agencies (Levitan B, 2012). The experience of using 
the BRAT framework as a retrospective review of Tysabri® (IMI PROTECT, 2012a 
and 2012b) illustrated the potential in benefit-risk assessment. 
 
To obtain real-world experience with the use of the BRAT framework, PhRMA 
commissioned the Soft Pilot programme. The goals for this programme were to gain 
PhRMA member companies’ experience with the framework process and tools. 
These experiences were used to further refine and develop the framework and to 
help facilitate increased use across the other member companies. To date, ten 
companies have enrolled and the pilot is currently in the implementation phase. The 
main aim of the programme is to refine the framework and also to gather additional 
information regarding the effectiveness and use of the framework and this is now the 
responsibility of CIRS since 2012. 
 
Regulatory collaborations 
The Innovative Medicines Initiative (IMI) commenced a project in September 2009, 
the Pharmacoepidemiological Research on Outcomes of Therapeutics by a 
European Consortium (PROTECT) (IMI PROTECT, 2010 and 2011a).  This is a 
collaborative effort between public bodies (including the EMA, MHRA, regulatory 
agencies of Denmark and Spain), academia and the pharmaceutical industry 
(collectively represented by the European Union and the European Federation of 
Pharmaceutical industries and Associations (EFPIA) which includes major 
companies such as GlaxoSmithKline, Bayer, AstraZeneca, Novartis and Pfizer). This 
consortium is led by the EMA and is to extend over a period of five years to achieve 
the objectives and is funded by the IMI and EFPIA among others. While PROTECT is 
primarily aimed at strengthening the safety and benefit-risk monitoring of medicinal 
products in Europe, the conduct of this project will also review and develop tools to 
improve the evaluation and communication of a product’s benefit-risk balance. This is 
to be achieved by various work packages, through the enhancement to the early 
detection of safety data and enabling of the integration and presentation of benefits 
and risks. Three work packages (second to fourth) focused on the safety signal 
detection and evaluation, as well as the opinions of users of traditional methods of 
data capturing, that would contribute to improving the profiling of epidemiological 
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risks. The assessment and communication of benefits and risks was studied in the 
fifth work package, while the sixth package looked into the validation of the 
methodologies identified in the fifth package. To complete the entire project, the last 
work package will be looking into training and education to ensure the successful 
implementation of the findings from PROTECT. 
 
The fifth work package related to the integration and communication of benefits and 
risks and was investigated in five separate steps (IMI PROTECT, 2011b and 2011c), 
including identification of framework, review of assessment methods and graphical 
representations, case studies and application across databases. A literature search 
was conducted to identify approaches and was inclusive of other existing reviews, 
both qualitative and quantitative methods and use in pharmacoepidemiology, clinical 
trials and health technology assessment (IMI PROTECT, 2013a). The approaches 
were reviewed and broadly classified into benefit-risk frameworks, metric indices (for 
threshold, trade-off and health utility), estimation techniques and utility survey 
techniques. To appraise these approaches, criteria used in the EMA’s Benefit-risk 
project were referenced. A final set of appraisal criteria was developed around four 
key dimensions, namely fundamental principle, features of respective approaches, 
visual presentation of models and lastly, assessibility and accessibility. These were 
meant to gauge the theoretical reasoning, capacity to deal with uncertainty, ease of 
use and availability of visualisation respectively.  
 
A framework for the evaluation of benefits and risks was required and the PROTECT 
project found that there were fundamentally two types, namely the non-quantitative or 
descriptive type and the quantitative or comprehensive type. The former group 
included the PrOACT-URL and BRAT, both of which were considered suitable for 
further testing. The PrOACT-URL was found to promote a systematic consideration 
of critical elements in decision-making and hence improves the transparency of the 
process. However it may not provide substantial value for communication. While 
BRAT could aid in the communications (including visualisation) of benefits and risks 
between regulators and companies, the recommended use of odds ratios may not be 
acceptable by the different stakeholders. Other descriptive frameworks were still 
under development among the various agencies and hence appraisal was not 
conducted for these. The UMBRA (CIRS) was noted to be a collative development 
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for international use. Among the descriptive frameworks appraised, it was assessed 
that both the PrOACT-URL and UMBRA could accommodate a wider scope of 
perspectives including the pharmaceutical companies, healthcare providers and 
regulatory agencies. Quantitative frameworks deemed appropriate for further study 
were the MCDA and its variant, the Stochastic Multi-criteria Acceptability Analysis 
(SMAA) (Tervonen et al., 2008; 2011). MCDA may be limited when preference 
information or consensus are not available and could not account for uncertainties, 
while the SMAA accounts for this through simulation. However, it was highlighted that 
MCDA is the only approach capable of incorporating multiple objectives 
simultaneously. The potential limitation to the use of SMAA is the requirement of 
extensive mathematical and computational knowledge which may not be widely 
available across the stakeholders. Both MCDA and SMAA were found to be able to 
accommodate the wide scope of perspectives from various stakeholders.  
 
The quantitative methodologies consisting of metric indices, estimation techniques 
and utility survey techniques were separately appraised. These tools were expected 
to be capable of estimating the magnitude and incidence of events related to the 
benefits and risks, from both patients’ and regulators’ perspective. These values 
should then be combined into a single quantitative measure for interpretation. It was 
believed that metric indices may be used under a framework or with other 
techniques, but not solely for benefit-risk decision-making as they lack the 
transparency and possess variable subjective issues. PROTECT recommended five 
metric indices for further studies, namely NNT/NNH, impact numbers (Attia et al., 
2002; Heller et al., 2002), QALY (Weinstein et al., 2009), Q-TWiST, INHB and 
Benefit-risk ratio (BRR) (Chuang-Stein et al., 2008; Korting et al., 1999). While many 
statistical concerns can be addressed by estimation techniques, the satisfactory 
contribution to decision-making may be dependent on concurrent use of various 
techniques and would require compliance to these techniques across regulatory 
practices to effectively increase transparency. PROTECT recommended probabilistic 
simulation method (PSM) and mixed treatment comparison (MTC) (Lumley, 2002; Lu 
et al., 2004) for further study. Utility survey techniques were included for review of 
benefit-risk assessment as they can afford robust value judgments. The discrete 
choice experiment (DCE) (Ryan et al., 2008) was proposed for further study. 
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Case studies were carried out in a retrospective manner as part of the fifth work 
package to review the application and integration of the selected 13 methodologies 
above. The information for case studies was obtained from clinical trials and publicly 
available assessment reports and these were used to document the benefits, risks 
and uncertainties together with the value judgments and assessment. Two waves of 
case studies were conducted. The first wave of case studies used Tysabri® 
(natalizumab)(IMI PROTECT, 2013b), Acomplia® (rimonabant)(2011d), Ketek® 
(telithromycin)(2012c) and Raptiva® (efalizumab)(2013c) for the above 
recommended tools. The second wave included rimonabant (IMI PROTECT, 2012d), 
rosiglitazone (2013d), natalizumab (2012e) and warfarin (2013e). It was meant to 
compare and benchmark the frameworks and quantitative tools through these 
retrospective exercises. 
 
Given the emphasis on graphical representation (or visualisation techniques) and 
communication of the outcomes of benefit-risk assessment, visualisation techniques 
were assessed for their suitability in achieving this goal for the 13 methodologies 
identified, with recommendations for each specific methodology. Each potential 
visualisation technique was appraised against a common set of criteria, namely the 
representation type, display design and elements of communication. The outcomes 
of the first part of the review (IMI PROTECT, 2013f) led PROTECT to recommend 
various techniques for the 13 methodologies, specifically the effects table for 
PrOACT-URL and forest plot and bar graph for BRAT. For both MCDA and SMAA, 
bar graph and forest plot were recommended. PROTECT commented that 
recommendations of visualisation techniques were limited to those typically already 
accompanying the methodologies as a result of the review and they were not able to 
explore potential innovations that may improve or be customised for the eventual 
user. Simpler tools may be preferred if complex visual presentations offer no clear 
advantages for the benefit-risk outcomes. For the second part of the review (IMI 
PROTECT, 2013g), PROTECT provided 17 high-level recommendations for the use 
of visualisations in benefit-risk assessment of medicines. These are meant to 
address the concerns regarding the general principles for visualisation, use in the 
different key stages of assessment and common benefit-risk questions. The Wicken’s 
Principles of Display Design (Wickens et al., 2004) was recommended to help 
facilitate user’s understanding, while the GSK Graphic Principles (CTSpedia, 2012a, 
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2012b) should be used to enhance data communication. Various recommendations 
were provided specifically for each process in the benefit-risk evaluation process, 
namely context and structuring the issue, data gathering and preparation, data 
analysis and exploration (statistical robustness and uncertainties).  A second wave of 
case studies was conducted to refine the methodologies as well as the application of 
visualisation techniques. 
 
The sixth work package of PROTECT (IMI PROTECT, 2012f) aimed to validate the 
transferability and feasibility of the identified tools in the preceding work packages to 
other data sources and patient population groups, in addition to using other data to 
investigate specific aspects of a safety or benefit-risk concern. It could be seen as an 
extension of the previous two waves of case studies in the fifth work package. Data 
sources used in this work package included national databases (General Practice 
Research Database, UK, GPRD), patient registries (Danish Psychiatric, Somatic 
Hospital Discharge & Mortality Registers, DKMA; Utrecht Patient Oriented Database, 
Netherlands, UPOD) and research databases (Pharmacoepidemiology General 
Research Extension, PGRx). The research goals were to address reproducibility with 
the same data source, external validity, impact of uncertainties, sensitivity and 
specificity, validation by clinical records and controlling for confounders. This work 
package started in September 2010, but a report on the findings was not available at 
the time of this research. 
 
The Centre for Innovation in Regulatory Science (CIRS) is an independent, not-for-
profit organisation with a focus on furthering regulatory sciences.  It provides a 
common and non-binding platform for various stakeholders such as the regulatory 
agencies and pharmaceutical companies to discuss and convene the development 
and future direction of regulatory science. Since the 2002, CIRS has been involved in 
the development of a framework for the assessment of benefits and risks of 
medicines, as well as including the role of patients in these processes.  
 
More than a decade ago, in two workshops attended by both regulatory agencies and 
pharmaceutical companies, the need to manage and communicate risks in the 
development of new medicines was discussed (CMR, 2002 and 2003). Methods for 
communicative risk information should consider the society’s changing views on 
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risks, so that regulatory science would not hinder the evolution of innovation. It was 
also identified that physicians, patients and consumers should be involved earlier in a 
communication strategy and not just the final marketing phase. The industry 
commented on the need for greater transparency among internal and external 
customers’ expectations and best practices for decision-making as some approaches 
to minimise the attrition of potential candidates for drug development. As shared from 
the European regulator’s viewpoint, the goals of communication should allow open 
and transparent information on the benefit and risk balance to be presented in a 
concise manner. Interactions within and among stakeholders, namely the industry, 
academia and regulators, had to be optimised as it was recognised that the various 
stakeholders held different skillsets essential for the development of successful 
strategies in risk management and communication. It was agreed that risk 
management plans should extend from discovery to the end of the product life cycle. 
The stakeholders also agreed that the communication tools should be improved and 
scientific discussion could be conducted between the agencies and companies 
earlier in the development of a medicine. Taskforces and workshops were deemed 
useful in pursuing the key goals above. Importantly, during these workshops, the 
stakeholders agreed that the information on risk should always be discussed in the 
context of the management of the medical condition to allow a balanced perspective. 
The risks of use should be interpreted in relation to the expected benefits. In 
facilitating this new perspective that involved assessing the balance between benefits 
and risks, CIRS studied the potential of the MCDA framework for this purpose (CRM, 
2004 and 2005). The framework was well received and it was proposed that it should 
be further validated through the various stakeholders, especially the incorporation of 
the views of patients. If the agencies would believe that the framework could improve 
communication, the companies would support its use and incorporation into the CTD 
dossier for regulatory submission. 
 
CIRS continued to investigate the potential use of a global benefit-risk framework 
through engaging both regulators and companies to provide the critical factors used 
in determining a benefit-risk balance and opinions on the  future direction forward for 
the framework (CMR, 2008). A framework, to be used globally, should contain the 
elements considered by both regulators and companies in assessing the benefit-risk 
balance. While quantitative methodologies might have its merits in ensuring 
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consistency, accountability and communication but it should not replace clinical 
judgment. A benefit-risk framework should be used as an aid in the process of 
decision-making. Emerging markets should be engaged early in the development of 
such frameworks so that the acceptance would be timely across agencies and 
companies around the world. The use of the framework should be applied at all 
stages of the product life cycle, including post-market risk management plans. To 
ensure the correct understanding of terms used in a framework and to put users on a 
common platform for discussion, a lexicon was proposed to be developed. In the 
subsequent workshop by CMR (2009), the lack of common definitions was believed 
to be a barrier to the communication of benefits and risks. Indeed it becomes 
necessary to acknowledge the differences and commonalities among the 
stakeholders and provide a common understanding of terms used through a lexicon if 
a universal framework is to be developed (CIRS, 2012b). It was also agreed among 
the regulators and companies that a benefit-risk framework would provide a structure 
for discussion and lead to greater transparency, a desired element in communication. 
Walker (CMR, 2009) presented a preliminary framework consisting of five steps, in 
which after data on the product’s safety and efficacy are identified, summary tables 
are constructed, a value tree of benefits and risks is developed, a prioritisation of the 
those values is made, a weight is assigned to the prioritised values and the benefit-
risk assessment is finalised using expert judgment. However, it was noted that the 
acceptance of weighting of benefit-risk parameters varied widely among agencies, 
which could be due to the differences in regional regulatory and cultural viewpoints 
(CIRS, 2012b). This framework was later refined to the 7-step process (CMR, 2010), 
based on further collaborative work (Mussen et al., 2009).  
 
During one of the workshops conducted to refine the benefit-risk framework, it was 
agreed among the regulatory agencies and pharmaceutical companies that tools 
such as a value tree and supportive data tables are necessary for a structured 
benefit-risk debate (CMR, 2010). Eichler from the EMA also commented that as 
methodology and presentation evolve from providing implicit to explicit value 
judgements and from being a reflection of regulators’ values to those of patients, the 
development of a toolkit for benefit-risk assessment will further enhance the 
predictability and auditability of regulatory decisions (CIRS, 2011). However, in order 
for the best practices to emerge and thus identify the appropriate tools, time should 
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be allowed for these to be developed, refined and validated for use. This would 
require commitment, resources and time from the stakeholders to establish the 
processes for the management and the archiving of information to support iterative 
improvements in techniques for benefit-risk assessments (CIRS, 2012b).  
 
In communicating benefit-risk decisions, visualisation tools help to focus the 
discussions on critical issues, identifying gaps and congruence of opinions for 
benefits and harms and providing a concise summary of the information needed to 
make the benefit-risk decision. MCDA may provide a framework that achieves the 
communication of a decision rationale. However, stakeholders like physicians, may 
require assistance to understand the underlying principles and methodology, while 
patients may benefit from a simplified set of results through the use of graphically 
displayed quantification of trade-offs (CIRS, 2011). Stakeholders should thus be 
introduced to novel visualisation tools in a methodical and educational manner, to 
allow them to familiarise themselves with the strengths and weaknesses of each 
approach. The familiar Forest plot was agreed by the agencies and companies to be 
a simple way to represent and visualise the results of a benefit-risk assessment 
(CMR, 2010). 
 
In a workshop that focused on developing a framework to improve the clarity of 
decision-making, it was agreed among the stakeholders who participated that for 
conditions involving subjective benefits and harms, patient input is invaluable in 
informing the thinking of decision makers such as regulators and researchers (CIRS, 
2011). Following this another workshop (CIRS, 2012b) was conducted to look into 
the patient’s role in benefit-risk assessment, during which Breckenridge from the  
MHRA commented that while there was significant progress in the work on the 
benefit-risk assessment of medicines over the past decade, much less attention was 
given to the contribution of the patient, who is the primary stakeholder. It should be 
highlighted that the views of patients and their caregivers on the potential risks and 
benefits may differ from those of the regulator, companies and healthcare technology 
agencies. Eichler from the EMA added that in order to bring patients and their 
preferences and values into the regulatory system, the EMA engaged patients in the 
regulation of medicine in Europe through the public hearing and representation on 
committees. Another method would be the systematic exploration of the input of 
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patients enrolled in clinical trials. Similarly, the US FDA through the PDUFA V 
initiatives started a series of patient meetings to understand medical needs and 
patients’ opinions in various medical conditions. Among the recommendations that 
surfaced from the 2012 workshop included the development of guidelines for the 
engagement of patients and their involvement throughout the life cycle of medicines. 
There is much to learn from the patients’ input from other sectors such as over-the-
counter medications or experiences on drugs that failed during development, both 
which are areas neglected for information collection. There should also be efforts to 
engage legislative bodies to review and eliminate potential legal barriers to patient 
involvement in benefit-risk decisions.  
 
Another recent CIRS workshop (CIRS, 2013a) conducted to assess the potential 
contribution of patients in the assessment of benefits and risks highlighted the 
various consortia involving patient organisations that were required to achieve the 
long-term goal of accelerating patients’ excess to innovative medicines through 
active participation and input of clinical data. Rockhold from GSK recommended a 
non-competitive approach to obtaining information about medicines and the 
perspectives of patients living with disease, as all stakeholders would benefit from 
the alignment of these inputs and methodologies. With the current approaches, 
benefit-risk decisions are made by clinicians and regulators who might not be trained 
specifically to investigate the impact of patients’ inputs. Johnson, Principal Economist 
from Research Triangle Institute, commented that patients rather than physicians or 
regulators are the best judge of their own welfare. He also reviewed the potential of 
three different methods for eliciting patients’ values and preferences: analytic 
hierarchy process, best-worst scaling and discrete-choice experiments, also known 
as conjoint analysis. 
 
McAuslane (2013a) presented the pharmaceutical companies’ hurdles to patient 
participation, which included the varying perspectives on the different methodologies 
and the uncertainty regarding how the input would be used and accepted. These may 
be solved by developing patient engagement guidelines and alignment on flexible 
methodologies for benefit-risk assessment. From the agencies’ perspective, the 
hurdles were finding representative, informed patients without unresolved conflicts of 
interest and methodological issues on how to accurately represent and extrapolate 
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the findings from the entire cohort to the population. Solutions proposed included 
guidelines to resolve potential conflict of interest and the direct engagement with 
patient groups. From the patient’s perspective, the major hurdle is the lack of 
understanding arising from the language and statistical methods used. Proposed 
solutions include the expansion of patient involvement and education. In addition, 
further recommendations were highlighted to improve the involvement of patients. 
These included using inputs from interviews to be conducted in Phase I and II studies 
to develop appropriate methodologies for confirmatory trials, incorporating the use of 
media technology to obtain and communicate information and conducting a wider 
reaching survey to ascertain the barriers to including patient information.  
 
An earlier workshop in 2012 revealed that companies’ involvement with patients may 
be construed as marketing influence and product advocacy (CIRS, 2012a). Thus 
rules of engagement must be established to avoid misunderstandings, which further 
support the need for such guidelines. The clinical development frequently relies on 
well-established efficacy endpoints (which may include traditional patient-reported 
outcomes), but these might not necessarily address the needs of the patients given 
the evolving context of medical care. By having patients’ input into the development 
and regulation of medicines, it will connect the use of the most clinically relevant 
patient-reported outcomes as part of clinical trial design. Patients should also be 
informed of the results of their input as they have contributed much time and effort to 
the research programmes and would benefit from an education regarding the 
inherent nature of uncertainty in such benefit-risk decisions.  While the value of 
patient input appears implicit, it has to be demonstrated to a wider audience through 
further research and communication.  
 
Certain principles were consistently mentioned through these workshops in a 
continued effort to development a framework for the assessment and communication 
of benefits and risks. This included the need to communicate the balance between 
benefits and risks, as the unopposed communication of risk without the benefits 
would not represent the appropriate context of the decision-making process (CMR, 
2009). The assessment of benefits and risks should involve all stakeholders and 
conducted throughout the product life cycle, as the updated information on evolving 
benefits and risks becomes available over time and use. As stakeholders approach 
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the benefit-risk assessment from various perspectives, differing opinions are 
expected and these should form the basis of discussion in addressing the multiple 
factors affecting the balance (CIRS, 2011). In developing a global framework, it was 
proposed that the framework should start as a qualitative one and eventually refined 
to be quantitative. This is in recognition of various quantitative tools which should be 
accommodated within a standard framework and aid in both the assessment and 
communication of benefits and risks (CMR, 2010). Uncertainty must be formally 
incorporated into a benefit-risk framework and applied across the entire decision-
making process and not be limited to statistical uncertainty or to a single step of the 
assessment (CIRS, 2012b). Regulatory decision-making should consider four crucial 
aspects, namely transparency, consistency, communication and definition of the 
treatment populations (CIRS, 2011). One of the challenges identified in making 
quality decisions include internal organisation processes such as the difficulty in 
applying valuing and weighting, communicating the problem statements and 
explaining uncertainties. Another challenge would be to apply the global framework 
to their current workflow, regardless of the individual jurisdictions and contexts. 
Participants at the workshop, however, agreed that the validated framework would 
accommodate individual circumstances and the various stages of the medicine’s life 
cycle (CIRS, 2012b).  
 
In the recent workshop to look into the role of frameworks in facilitating the provision 
of quality decisions, stakeholders again agreed that a decision framework is a 
“structured, flexible, systematic and scientific approach to organising, evaluating, 
quality assuring, summarising and re-assessing over time both the known and the 
unknown information and the subjective values and judgements that form the basis of 
the decision” (CIRS, 2013b). This will help provide quality and transparent decisions 
to be documented and communicated. Such frameworks should be applied at 
common time-points in the regulatory review process, namely at submission, all 
stages of evaluation, during the communication of deficiencies, responses, expert 
opinions, benefit-risk balances and the final regulatory decision for the product.  
 
The need for a universal benefit-risk assessment framework 
Leufkens et al., (2011) commenting on innovations in regulatory science, suggested 
that there are three dimensions in this area. Firstly, regulators should keep current 
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their understanding of the science and technologies and help in drug development 
and the advancement in innovation. Secondly, new standards and tools should be 
developed to evaluate and assess benefit-risk balance of medicines to facilitate a 
sound and transparent decision-making process. Lastly, the entire system should be 
monitored for its impact on patient safety, public health and meeting medical needs. 
Therefore it is likely that a new overarching framework would be required to 
encompass these new initiatives. 
 
From the above activities of the major regulatory agencies US FDA and EMA and the 
pharmaceutical industry, a framework is required to provide a systematic and 
structured approach to the assessment of benefits and risks with the greater 
involvement of the stakeholders for decision-making. The outcomes of this approach 
should support a transparent and consistent basis of decision-making and facilitate 
the communication of the benefit-risk decisions. It does however appear that effective 
communication is the focus of these initiatives, as ultimately a sound framework 
should enable the communication of the final benefit-risk decision. Indeed the failure 
to communicate will compromise all efforts to improve consistency, transparency and 
accountability to stakeholders. In a workshop to identify strategies for communicating 
benefits and risks, it was agreed that appropriate communication should be 
accommodated and made a feature within benefit-risk assessment frameworks 
(CMR, 2009). In fact, it was discussed more than a decade ago in a workshop for 
developing effective stakeholder communication the importance of involving 
physicians and patients early in the development of a new medicine and not wait until 
the product is approved for marketing (CMR, 2002). The interpretation of safety 
information needs to be made more transparent and information held by industry and 
regulators needs to be shared. Ideally this could be based on information used for 
the preparation of a submission document and provide information that is complete 
and understandable for the relevant benefit-risk decisions (Schmid E F et al, 2007). 
 
It can be deduced that though the stakeholders’ acknowledge that a framework will 
provide a structure and consistency in decision-making, their efforts in achieving this 
have largely been independent. As observed by EMA within the EU, there is no 
common framework being utilised and this would compromise the consistency of the 
assessment of benefits and risks and decision-making. Echoing this sentiment, there 
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is now a need to identify a common framework that can be used by both regulatory 
agencies and pharmaceutical companies to fulfil their pursuit in improving 
communication to stakeholders. These are in line with the discussions from a 
workshop on strategies for the benefit-risk assessment of medicines, where it was 
agreed that a framework should address the difficulty faced by agencies and 
companies in explaining the outcomes of the assessment (CMR, 2008). 
 
Mussen et al. (2009) had identified the use of MCDA in regulatory decision-making 
and this approach has been the principle foundation for existing frameworks, namely 
the EMA’s PrOACT-URL, the BRAT framework and the 7-step CIRS framework. 
While IMI PROTECT might have classified MCDA as a qualitative method, the steps 
of executing MCDA were based on the MCA, which are the qualitative and logical 
steps in decision-making. As such, it would be the tools used in MCDA that would 
confer a quantitative nature. By itself MCDA is a qualitative illustration of the thought 
processes that went into a decision. As evident in the journey of framework 
development thus far, a qualitative framework is seen as more desirable now as its 
flexibility can accommodate various benefit-risk assessment tools and visualisation 
techniques.  
 
While the MCDA approach has been embraced by many, in particular CIRS, the 
investigated use during its development was largely retrospectively based on 
selected case studies however its full utility and impact on regulatory processes 
could not be fully understood at that time. The EMA’s PrOACT-URL is now being 
implemented and also further supported by the IMI PROTECT initiatives, but its 
functionality is only being validated within the EU regions. Similarly, the US FDA’s 5-
step benefit-risk framework is still under development and largely within the context 
of the USA. The BRAT framework is piloted among the companies and hence its 
usefulness to regulators may not be fully illustrated. As observed above, the activities 
of developing and validating a benefit-risk framework is limited to individual 
jurisdictions and purposes. There is currently no single framework that is proposed 
for use by all stakeholders in making and communicating benefit-risk decisions. It is 
also apparent that the smaller agencies and emerging markets have largely been left 
out in these activities. For a framework that is designed for universal use, it would 
have to be applied and accepted by agencies, companies and other stakeholders in 
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all parts of the world. The current activities are exclusive and will not contribute to 
addressing this need. 
 
There are currently on-going projects utilising different scientific tools to find those 
best suited for benefit-risk assessment and for visualisation. The immediate need is 
to first identify a universal benefit-risk framework that can be used by all regulatory 
agencies and pharmaceutical companies based on the principles of benefit-risk 
assessment and enable the communication of the basis of the decision. By 
encompassing a qualitative and overarching character, it should accommodate the 
future tools required by individual stakeholders to conduct the benefit-risk 
assessment specific to each product and medical context. 
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Study aim 
This research aims to develop a universal framework for the assessment of benefits 
and risks of medicines by regulatory agencies and its role in communicating the 
benefit-risk decisions.  
 
Objectives 
The objectives for this research are to: 
• Review the current practices in benefit-risk assessment by agencies and 
companies and the needs and perception for a common framework 
• Review existing frameworks and propose a universal framework that would 
encompass the current frameworks and meet the needs of stakeholders 
• Validate the applicability of the universal framework by regulatory agencies in 
benefit-risk assessment which would increase the effectiveness and 
transparency of communication. 
• Explore the applicability of the universal framework in documenting and 
communicating benefit-risk decisions in the emerging markets 
• Explore the applicability of the universal framework in communicating benefit-
risk decisions in comparison with current publicly available assessment 
reports from major regulatory agencies 
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CHAPTER 2 
 
 
 
 
 
Study rationale and methodological framework 
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STUDY RATIONALE 
With the evolution of the assessment of efficacy and safety towards systematic 
explicit benefit-risk balance, both regulatory agencies and pharmaceutical companies 
have developed frameworks albeit each for their own jurisdiction and purpose. Given 
the individual efforts, this will perpetuate the problem of inconsistency in regulatory 
decision-making and the perceived lack of transparency in the processes. Hence, 
there is now a need to provide a universal framework that is able to meet the needs 
of the various stakeholders. Based on the background information reviewed thus far, 
it appears that a universal benefit-risk assessment framework should: 
• Encompass the existing frameworks used by the regulatory agencies and 
pharmaceutical companies  
• Align and support the current principles of the assessment of benefits and risks 
• Be flexible and accommodate the various scientific tools to assess different 
benefits and risks 
• Reflect the contribution of other stakeholders e.g. that of patients to the overall 
decision 
• Enhance transparency of the decision-making process 
• Aid communication of the benefit-risk balance and the basis of regulatory 
decision to stakeholders 
• Include visualisation or other graphic representation of the assessment outcomes 
 
METHODOLOGICAL FRAMEWORK 
Research design 
Research can be broadly classified into qualitative and quantitative designs. The 
latter are commonly employed in clinical studies, where the goal is likely singular. 
Analysis of the data will be conducted through predefined statistical methods to 
minimise the bias in interpretation of the outcomes. This is possible as the measures 
of the data are objective and quantifiable, allowing the application of statistical testing 
on the numerical outcomes. The purpose of quantitative design is usually to prove 
the acceptance of a hypothesis through the generation of statistical evidence to 
support the conclusion. For qualitative studies, the scope is wider and is likely used 
to generate collective opinions and directions for future quantitative studies. While 
basic descriptive statistics may be generated, the overall conclusion is obtained 
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through expert interpretation rather than statistical outcomes. However, the absence 
of statistical outcomes should not be seen as a limitation in the use of qualitative 
designs. Both quantitative and qualitative studies are conducted in a systematic 
manner to collect predefined data that is relevant to the study goals. In settings 
where opinions, comments and experience are explored to generate concepts that 
would guide future developments (Pope, 1995), qualitative designs should be 
considered. Pope illustrated the differences between quantitative and qualitative 
research (Figure 2.1).  
 
Figure 2.1 Differences between qualitative and quantitative research design* 
 
 
*adopted from Pope, 2005 
 
For the purpose of achieving the objectives for this research, it appears that 
qualitative designs would be more appropriate.  
 
Data source 
Literature searches strategy 
To provide a good overview of the current environment in regulatory assessment of 
benefits and risks, published literature should be systematically searched. Two 
established repository of reputable publications will be used, namely PubMed and 
ScienceDirect. The following keywords and terms are considered relevant in 
searching the literature: 
• Benefit 
• Risk 
• Benefit assessment 
• Risk assessment 
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• Benefit risk assessment 
• Benefit risk balance 
• Assessment framework 
 
To optimise the validity of the opinions from the publication, the period of search 
should be confined to within the last five years. However, it is expected that some 
older literature would provide vital fundamentals to the history relevant to this 
research and these should be included for reference. 
 
Main regulatory authorities’ websites 
Guidance documents for benefit-risk assessment from major regulatory agencies and 
international bodies should be reviewed to understand the underlying principles in the 
evaluation of medicines. This is important as any framework proposed should not 
deviate or challenge these fundamentals, but rather support the execution of the 
processes. The major reference regulatory agencies should include the EMA, US 
FDA and TGA while relevant international bodies would include the ICH and WHO. 
Likewise, the search for existing frameworks and publicly available assessment 
reports by these recognised bodies should be conducted, either through publications 
or their respective websites. 
 
DATA COLLECTION TECHNIQUES AND ANALYSIS 
Comparing existing frameworks 
The key goals of the comparison of the frameworks are to identify the similarities and 
differences.  Similarities will be carried over to the universal framework as these 
would facilitate the adoption of the new framework by the owners of the reference 
frameworks. The similarities will also be reviewed for their functionality and how 
these can be harmonised across the frameworks. The differences may potentially 
challenge the use of a universal framework and these will be assessed for the 
contribution to the overall decision-making process. Differences that are deemed 
relevant to benefit-risk assessment will be considered for the universal framework, 
while those differences found to be related for the purpose of fulfilling specific 
jurisdiction requirements may be omitted. Beyond the content of the framework, the 
flow of processes will also be compared. The ideal flow should correlate closely to 
the processes undertaken by a reviewer. 
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 Validating the proposed universal framework and templates 
To carry out the systematic collection of opinions and comments, study tools will be 
developed. Questionnaires, surveys and decision conferencing are common tools 
employed for such purpose. One established approach to develop a survey is the 
use of the Delphi method for structuring group communication process to ensure the 
effectiveness in allowing a group of individuals to solve a complex problem (Linstone 
et al., 2002). This will be further explored here. 
 
Delphi Technique 
Linstone et al expounded on the application of the Delphi process, which can be 
carried out either using the traditional "Delphi Exercise" or the newer “Delphi 
Conference” manner. The traditional approach requires the draft questionnaire to be 
sent via hardcopy documents to the respondent group for feedback on the proposed 
contents. With the inputs returned from the respondents, the questionnaire is revised 
and the group is again sought to review their original answers based on the new 
questionnaire. This approach is similar to a combination of a poll and a process to 
shift the need for a large communication to the smaller team developing the 
questionnaire. The newer "Delphi Conference" replaces the hardcopy exchanges 
with real-time communications afforded by the current technology and thus reduces 
the time to obtain the responses. Regardless of the approaches, there are four 
distinct phases. The first phase determines the subject for discussion and provides 
the initial content deemed relevant for the questionnaire.  The second phase aims to 
understand of how and where the group agrees or disagrees on the contents. 
Disagreements are then explored in the third phase to find out the underlying 
reasons for the differences and review them. The final phase includes the final review 
by the group when all previous responses are reviewed and the outcomes have been 
fed back for consideration. Okoli et al (2004) showed an alternative but similar way 
for executing the Delphi method (Figure 2.2) and also further explained on the 
process of selecting the panel of experts forming the respondent group. Simple 
statistical analysis of the responses can be carried out to assist in the analysis of the 
outcomes. 
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The use of the Delphi method is frequently employed for postgraduate and higher 
learning degrees (Skulmoski et al., 2007). It has been utilised widely in social 
sciences (Landeta, 2006) as well as in healthcare systems, such as the identification 
of characteristics for injury surveillance and long term prevention (Mitchell et al., 
2009) and a consensus statement among respiratory specialists on the health effect 
of asbestos (Banks et al., 2009). It is also considered a versatile tool and can be 
used in selecting and defining a further research topic (Okoli et al., 2004). 
 
Figure 2.2 One approach of carrying out the Delphi method* 
 
*adapted from Okoli, 2004 
 
Comparison of the Delphi Technique with other questionnaire techniques 
Okali et al (2004) also provided differences between a traditional survey against a 
questionnaire constructed via the Delphi method. Some surveys may require 
statistical tools to power the findings and thus require an appropriate sample size, the 
Delphi method does not require a statistical number of participants. However, the 
ideal number of members in a panel has been recommended to be 10 to 18. While a 
survey tends to extrapolate a conclusion based on a select group of individuals, the 
Delphi method can draw out expert opinions that are superior to the views of the 
individuals. As per the Delphi method, there is a follow-up to the data collected during 
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the process, leading to a richer amount of relevant data. This however is limited 
when conducting a traditional survey. 
 
Linstone et al (2002) also shared on the limitations of the Delphi method. One of 
these is discounting the future, since the subjective nature of the inputs tends to 
change over time and the applicability of the questionnaire would be affected. With 
the multiple of contributing opinions, there is a tendency to select a few and fit them 
into a familiar context. This behaviour is called the “simplification urge”. As such, the 
final questionnaire may not also represent holistically or entirely the actual situations. 
Another limitation is the illusory expertise, where the group, typically a panel of 
experts in the field, may not be the best at predicting the relevance of the contents. 
This may be due to the panel members being too specialised in a niche area, leading 
to a failure to understand the interactions of the entire system at large. Therefore, it is 
important that the panel selection is carried out effectively to best optimise the Delphi 
method, as the entire process is dependent on their inputs. Bolger et al (2011) 
investigated the impact of various factors related to the panel, including degree of 
confidence, expertise and majority positioning. It was found that majority opinion is 
the strongest influence and the conduct of Delphi method should aim to reduce this 
along the process. A recent more scientific method of weighing and pooling scientific 
advice, the Cooke method may be considered (Aspinall, 2010). Its goal is to quantify 
uncertainty and not eliminate this unavoidable concern from the decision-making 
process.  
 
Validity of questionnaire techniques 
The validity of the questionnaire will determine the robustness of the outcomes. A 
basic way of looking at validity would be the content validity, which is how well the 
item on the questionnaire can measure what it is intended to measure and 
possesses the appropriate level of emphasis and focus (Nunnally and Bernstein, 
1994). The importance of content validity should be emphasised as it forms the 
foundation of accurate measurement of the outcomes (Yaghmaie, 2003). It should be 
noted that in order to achieve content validity, there must be face validity. Face 
validity has been defined as the appropriateness of the items in relating to the goals 
of the questionnaire (Nunnally and Bernstein, 1994; Anastasi, 1988; Nevo, 1985). As 
for most research, the conclusions are generalised and extrapolated beyond the 
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original research. It is important that such claims are supported by causal 
relationships between the observations i.e. internal validity (Johnson, 1997). Indeed, 
the ultimate aim of a questionnaire is to achieve construct validity, where the logical 
relationship between the outcomes and the outcomes with the system is being 
established (Guyatt et al. 1993). 
 
Design conferencing 
Another method of systemically reviewing a group’s input is to conduct a decision 
conference (Phillips, 2006). The process starts with a discussion on the objectives 
(Figure 2.3). To achieve these objectives, the model that captures the key elements 
is required to resolve the issues. Discussions would involve personal judgments, 
intuitive opinions and feelings of unease. Exploring the observed difference may 
identify new insights that feed into improving the model. With the new inputs, the 
process is repeated again until the model reflects the new perspectives. Decision 
conferences help to generate a shared understanding of the issues, without requiring 
consensus about all issues. It can also develop a sense of common purpose, and 
find the best way forward in the midst of disagreements. Decision conferencing can 
be frequently employed during workshops in which many new initiatives can be 
generated. 
 
Figure 2.3 A decision conference process* 
 
*adopted from Phillips, 2006 
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The choice of methods for carrying out a study would be dependent on the 
availability of both time and experts. It is expected that both questionnaire techniques 
and decision conferencing will be the main tools employed for this study to achieve 
the objectives. 
 
STUDY PLAN AND DATA COLLECTION 
The conduct of this research will begin with a review of the current approaches used 
by the major stakeholders for benefit-risk assessment and regulatory decision-
making. The outcomes will provide inputs for the development of a universal 
framework and benefit-risk assessment template, which these would be tested out in 
various settings (Figure 2.4). 
 
Figure 2.4 The study flowchart 
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Evaluation of the current approaches to benefit-risk assessment of medicines 
by regulatory agencies and pharmaceutical companies 
This will be carried out by the administration of an assessment tool to regulatory 
agencies and pharmaceutical companies. The scope of this review is limited to these 
two main stakeholders. The introduction of other stakeholders at this stage may 
compromise the review as too many opinions and perspectives have to be 
accommodated. The assessment tool is expected to be a combination of a tick-box 
checklist and a free-text comments box. The Delphi method is not suitable as critical 
issues need to be identified through a general qualitative review first. 
 
Development of a framework, template and user manual for the benefit-risk 
assessment of medicines 
A comparison of the existing frameworks, especially among the major regulatory 
agencies, will be carried out to identify the common items and the difference. A 
universal framework will be proposed based on the findings of the comparison. It is 
expected that a documentation tool or template should be available for the 
implementation of such a framework. Guidance on the assessment of benefits and 
risks will be referenced to form the basis of this template. A pilot exercise to review 
its feasibility will be conducted among selected regulatory agencies. A retrospective 
study using an application of the agency’s choice on the proposed template should 
suffice for this preliminary investigation. Solicited comments on improving the 
template will contribute to the revision of the template. To aid the use of the template, 
a user manual will be developed to provide guidance and clarification. 
 
Evaluation of the Benefit-Risk Template by regulatory agencies – A prospective 
study 
The revised template from the pilot study will be further validated through the 
prospective application of the template for chosen submissions by the selected 
agencies. A study evaluation tool will be developed, as a tick-box checklist and free-
text comments box. The feedback will provide information on improving the template. 
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Evaluation of the Benefit-Risk Summary Template for communicating benefit-
risk decisions 
A simplified version of the template will be studied using a regulatory agency from the 
emerging market. This is to examine the feasibility of extending the use of the 
framework and template to the rest of the emerging markets, who are earlier 
identified as stakeholders pursuing the regulatory trends led by the major agencies. A 
study evaluation tool similar to the one used for the prospective study of the template 
will be administered, given that the similar study goals are applicable to both 
template and the summary template. 
 
Evaluation of regulatory agencies’ strategies for communicating benefit-risk 
decisions  
A comparison of the existing publicly available assessment reports will be conducted 
against the developed template. This is to assess the potential applicability of the 
template in communicating benefit-risk decisions. 
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INTRODUCTION 
The benefit-risk assessment of medicines is a critical process in regulatory decisions, 
resulting in their approval or rejection. Regulatory authorities bear the responsibility 
to ensure that the approved products demonstrate the efficacy and safety as shown 
in the clinical trial data submitted. However, such regulatory decisions are largely 
based on clinical judgment and the local medical context in each country. In a bid to 
minimise subjectivity for such important decisions, there have been attempts to utilise 
quantitative approaches in assessing benefits and risks of a medicine (EMA, 2009). 
As a result, pharmaceutical companies have also initiated the use of quantitative 
approaches in developing their products for submission to the regulatory authorities 
(Levitan et al, 2011). 
 
Guo et al (2010) reviewed the methodologies and identified 12 quantitative 
approaches such as multi-criteria decision analysis (MCDA), probabilistic simulation 
methods (PSM), Monte Carlo simulation (MCS), incremental net health benefit 
(INHB), minimum clinical efficacy (MCE), number needed to treat (NNT), number 
needed to harm (NNH), and quality-adjusted time without symptoms and toxicity (Q-
TWIST). They concluded that these quantitative methodologies should serve as 
supplementary tools, but not replace the decision-making process of clinicians or 
regulators. In the absence of a consensus among the agencies for a standard 
methodology, they recommended the use of multiple approaches across different 
clinical settings. 
 
During 2010, the European Medicines Agency (EMA, 2010) completed the second 
phase of their research into benefit-risk assessment, with the main objective of 
identifying suitable approaches that can be utilised within member states. Based on 
their first phase and experience, a list of criteria (logical soundness, 
comprehensiveness, acceptability of results, practicality and generativeness) for 
reviewing the methodologies was constructed. A list of qualitative and quantitative 
techniques, identified through literature search and experience, was reviewed against 
the criteria. When reviewing, these methodologies were also subjected to evaluators’ 
opinion of relevance. The conclusions of the second phase were that a combination 
of approaches may be useful in different clinical settings and an overarching 
qualitative framework will be required to effectively develop any quantitative 
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methodologies. Structured processes should be in place to improve transparency, 
audit trail, communication as well as the quality and speed of decision-making. 
 
The aims of this study were to solicit opinions from the major stakeholders (agencies 
and companies) regarding their knowledge and use of different qualitative and 
quantitative techniques in order to put the findings by Guo et al (2010) and EMA 
(2010) into an international context, as well as to elucidate any potential differences 
between agencies’ and companies’ expectations.  
 
OBJECTIVES 
The objectives of the study were to: 
• Identify agencies’ and companies’ current approaches to benefit-risk assessment 
• Establish the criteria for including a framework/model for benefit-risk assessment 
• Investigate agencies’/companies’ current views of the advantages and 
disadvantages of the various models/frameworks available or being developed 
• Identify both the internal and external barriers and possible solutions to 
incorporate a framework/model into medicines development and their regulatory 
review 
 
METHODS 
Development of the assessment tool 
Current knowledge suggested that regulatory agencies and pharmaceutical 
companies had in place a framework for the assessment of the benefits and risks of 
medicines. These frameworks can be broadly classified into 3 types, as seen in the 
Table 3.1. Of note, all final decisions incorporated expert judgment, thus emphasizing 
the role of the framework as a supporting tool and not as a replacement for decision-
making. 
 
In addition, current opinions on the advantages and barriers to implementing a 
universal framework were sought, and relevant factors for the review of a framework 
were investigated. Seven factors (Table 3.2) were proposed for this study and these 
had been identified from those utilised by the EMA (2010) study.  
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Table 3.1 Definitions of systems 
System Definition 
Qualitative The system is a purely qualitative framework based on internal 
experts or management making a “gut decision” on the benefit-risk 
profile of each product and providing a conclusion. The final 
decision will be exercised based on Expert Judgment.  
Semi-quantitative The system is semi quantitative in that it has a structured (written) 
framework or standard operating procedure for data collection and 
analysis. The conclusion is based on the result of the outcomes of 
the internal system, as well as contributing opinions. The final 
decision will be exercised based on Expert Judgment.  
Quantitative The system is a fully quantitative model which includes a benefit-
risk balance for a new medicine, and is applied across study data 
and contributing opinions. The conclusion is based on the 
cumulative outcome from this single system. The final decision will 
be exercised based on Expert Judgment.  
 
Table 3.2 Definition of factors for reviewing of frameworks 
1. Logical soundness  Provides an approach that is sound and allows decisions that are coherent and aids rational thinking  
2. Comprehensiveness 
 Provides an approach that handles all forms of data 
(including qualitative and quantitative, subjective and 
objective information) and allows for multiple criteria 
3. Acceptability of 
results 
 Provides an approach that checks for inconsistencies in 
data and judgment and a realistic approach to the 
evaluation of benefits and risks 
4. Practicality  Provides an approach with minimum burden on resources and ease of use 
5. Specificity and 
sensitivity 
 Provides a statistical perspective underpinning the 
reliability of the decision 
6. Presentation 
(visualisation) 
 Provides outcomes in an easily understandable format 
such as charts and plots 
7. Scope  Provides a consistent approach throughout drug development and post-approval monitoring 
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It was presumed that agencies and companies would have different opinions and 
experiences and it would be meaningful to study these differences and their potential 
impact on the development and implementation of a universal framework. Therefore, 
the study decided to stratify the data pertaining to agencies and companies. 
 
Study participants 
The participants were those holding senior positions and involved in benefit-risk 
assessment and decision-making. To improve the representation, participants from 
various sized organisations and geographical locales were invited.  
 
Data collection 
The assessment tool was finalised into a questionnaire consisting of 13 questions. 
Out of these, the following 4 questions required the participant to rate or rank a list of 
statements found within each question: 
• Perceived advantages of the benefit-risk framework 
• Barriers to implementing a formal benefit-risk framework 
• Perception of the need for an appropriate benefit-risk framework 
• Factors for reviewing benefit-risk frameworks  
 
Eight questions were included using checkboxes for information collection:  
• The current system employed by the organisation for the benefit-risk assessment 
of a new medicine during review (qualitative, semi-quantitative, or quantitative) 
• The use of values, weights, and selected parameters during assessment of 
benefits and risks 
• Satisfaction with current system 
• Reasons for not using a semi-quantitative or quantitative system 
• Plans to implement a semi-quantitative or quantitative system 
• Construction of the benefit-risk framework 
• Opinions of various models and approaches 
• Development of visualisation tools for communicating benefit-risk balance 
 
An open ended question was also used to solicit the potential hurdles and solutions, 
to be provided in a free-text manner. Most of the questions had an open field for 
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comments, allowing the participants to provide any issues of concern or relevant 
points that were not addressed by the questionnaire. The study tool can be seen in 
Figure 3.1. 
 
All participants were required to indicate if they were from regulatory authorities 
(“agencies”) or pharmaceutical companies (“companies”). The questionnaires were 
sent via email directly to the participants. Completed responses were received via 
email, as instructed to the participants. 
 
Data processing and analysis 
All responses were stratified into 2 groups, the agencies and the companies, allowing 
comparisons between these two stakeholders. 
 
Some items that required categorical inputs in the questionnaire received very low 
responses. To allow meaningful interpretation of the results, these low responses 
were combined with others into logical categories. Variables of similar opinions were 
also grouped, as seen in the table below. 
 
Table 3.3 Grouping of categorical variables 
Categorical variables Logical groups for interpretation 
Yes, No, Sometimes Yes, Sometimes No 
Strongly agree, agree, 
indifferent, disagree, 
strongly disagree 
Strongly agree, agree Indifferent, disagree, 
strongly disagree 
High, Medium, Low, Not 
applicable 
High Medium, Low, Not 
applicable 
 
All other data were expressed as percentage over number of responders for that 
item, and ranking was applied when necessary. Free-text comments were collated 
and presented in appropriate categories. 
 
This was designed as an exploratory study and the outcomes were interpreted to 
provide qualitative inferences relating to the objectives. No statistical analyses were 
planned or conducted. 
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Figure 3.1 Study tool 
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RESULTS  
For the purpose of clarity the results will be presented in three parts: 
• Part I - Current systems for benefit-risk assessment during development and 
review;  
• Part II - Criteria identified for the development of a universal benefit-risk 
assessment framework; and 
• Part III – Barriers and solutions to implementing benefit-risk assessment 
frameworks 
 
Demographic Characteristics of the Study Participants 
A total of 38 questionnaires were sent out to 24 pharmaceutical companies and 14 
regulatory agencies. Eleven out of 14 (79%) agencies responded. These agencies 
included the European Medicines Agency (EMA), national agencies from the 
European member states, Medicines and Healthcare products Regulatory Agency of 
UK (MHRA), the US Food and Drug Administration of (US FDA), Therapeutic Goods 
Administration of Australia (TGA), Health Canada, SwissMedic and the Health 
Sciences Authority of Singapore (HSA). Among the companies, 20 out of 24 (83%) 
responded. These companies comprised of both small and large organisations. The 
overall responders formed a diverse group with representation from developed and 
developing nations. 
 
Part I – Current Systems of Benefit-risk Assessment during Development and 
Review 
Usage of qualitative and semi-quantitative systems 
No responders indicated that they used a fully quantitative system. Among the 
agencies, there were similar numbers using qualitative and semi-quantitative 
systems (five versus six agencies respectively). A similar trend was observed among 
the companies when making a decision to submit an application, with ten companies 
using qualitative systems and nine using semi-quantitative systems. However, during 
the companies’ development of a medicine, more used qualitative systems than 
semi-quantitative systems (13 versus seven companies respectively). Generally, it 
was observed that the companies utilised qualitative systems more frequently than 
the agencies.  
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Use of values, weights and selected assessment parameters 
Six agencies and nine companies who were currently using semi-quantitative 
systems responded and similar trends were observed between the two. Combining 
the two response options of “Yes” and “Sometimes”, it demonstrated that two thirds 
of responders assigned values and one third assigned weights for benefit and risk 
parameters (Figure 3.2). There was no observed correlation between responders 
who provided value inputs and those who applied weighting. This suggests weighting 
of parameters was not commonly utilised in the assessment of benefits and risks. 
 
Figure 3.2 Percentage of responders applying values and weights to benefit 
and risk parameters 
 
 
 
Among these agencies, the majority used number-needed-to-treat (NNT) and 
number-needed-to-harm (NNH), while the companies tended to include other 
parameters (Figure 3.3). Nonetheless, NNT and NNH were the commonly utilised 
parameters in semi-quantitative systems for assessing benefits and risks between 
the agencies and companies.  
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Other parameters indicated by responders were Markov modelling, Pharmaceutical 
Research and Manufacturers of America Benefit-Risk Action Team (PhRMA BRAT) 
framework, probabilistic sensitivity analysis and sales statistics. 
 
Figure 3.3 Percentage of responders applying selected methodologies 
 
 
Experiences with various systems and approaches 
To obtain the participants’ experience with some commonly used systems and 
approaches (collectively known as methodologies), a list of 17 methodologies (Table 
3.4) was presented to the participants in the study. Ten agencies and 19 companies 
responded. 
 
The most common methodologies used by the agencies included the qualitative 
approach and NNT/NNH (Table 3.5). The agencies had minimal or no experience 
with a discrete event approach, system dynamics, stated preferences, conjoint 
analysis, Bayesian belief network and contingent valuation. In comparison, 
companies showed a similar trend to the agencies for the methodologies frequently 
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(agencies 11% versus companies 56%) and conjoint analysis (agencies 10% versus 
companies 61%); companies had markedly more experience with these two 
methodologies. 
 
Table 3.4 List of 17 methodologies presented in study 
 Qualitative approach  Decision trees and 
influence/relevance diagrams 
 KM estimators 
 Discrete event approach  Evidence based benefit-risk 
model 
 NNT/NNH 
 Probabilistic simulation  Incremental net health 
benefits 
 Conjoint analysis 
 System dynamics  Markov processes  Contingent valuation 
 Bayesian belief 
networks 
 MCDA  Stated preferences 
 Bayesian statistics  QALY/DALY  
 
 
Table 3.5 Top five methodologies currently used by agencies and companies 
Ranking 
Percentage of responders 
Agencies % Companies % 
1 Qualitative approach 67 Qualitative approach 83 
2 NNT/NNH 67 KM estimators 56 
3 Evidence based benefit-risk model 56 
Decision trees and 
influence/relevance diagrams 53 
4 Decision trees and influence/relevance diagrams 50 
Evidence based benefit-risk 
model 47 
5 KM estimators 40 NNT/NNH 44 
 
The top methodologies considered useful and relevant for agencies and companies 
are Bayesian statistics and MCDA. It was observed that the three main 
methodologies used by agencies, namely qualitative approach, NNT/NNH and 
evidence based benefit-risk model, did not rank highly for usefulness and relevance 
(Table 3.5 and 3.6). The companies’ responses were more evenly distributed across 
the methodologies compared with the agencies. Although Bayesian statistics and 
MCDA were ranked top methodologies by agencies and companies in terms of 
usefulness and relevance; their current usage was low to none.  
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Table 3.6 Comparison of rankings between top methodologies considered useful and relevant with those currently 
used 
Agencies Companies 
Methodology 
Useful and relevant Currently in use 
Methodology 
Useful and relevant Currently in use 
% of 
responders Rank 
% of 
responders Rank 
% of 
responders Rank 
% of 
responders Rank 
Bayesian 
statistics 40 1 30 7 MCDA 47 1 12 13 
MCDA 40 1 0 15 Bayesian Statistics 44 2 28 8 
Probabilistic 
simulation 30 2 10 10 
Qualitative 
approach 44 2 83 1 
Decision trees 
and influence/ 
relevance 
diagrams 
30 2 50 4 NNT/NNH 44 2 44 5 
Markov 
processes 30 2 0 14 QALY/DALY 44 2 33 6 
     
Incremental net 
health benefits 44 
2 28 7 
     Conjoint analysis 44 
2 28 9 
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In general, both agencies and companies had most experience with and usage of the 
qualitative approach, but viewed this methodology not as relevant and useful. In 
contrast, Bayesian statistics and MCDA were not widely used but deemed to be the 
most useful and relevant. Hence, future frameworks should consider the inclusion of 
these two methodologies. 
 
Development of visualisation tools for communication of benefit-risk balance 
None of the nine agencies who responded had developed any visualization tools for 
such purposes. It was observed that for the 19 companies who responded and 
developed visualization tools, it was more for internal communication, and 
infrequently for communications to health professionals and patients (Figure 3.4). 
 
Figure 3.4 Companies’ responses to the use of visualization tools to 
communicate benefit-risk balance 
 
 
Plans for implementing a semi-quantitative or quantitative system 
Five agencies and 11 companies responded, and no responders indicated plans to 
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the companies (Figure 3.5).  
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 Figure 3.5 Indication of plans to implement a semi-quantitative or quantitative 
system 
  
 
Part II – Criteria Identified for Development of a Universal Benefit-risk 
Assessment Framework 
Perception of the need for an appropriate benefit-risk framework 
The results were collated from the responses to 13 statements in the study regarding 
the perception of the need for an appropriate framework. Eleven agencies and 20 
companies responded and these responses were reviewed and presented as three 
categories namely utility and scope, purpose and direction for developing a benefit-risk 
framework. 
 
Utility and Scope of a benefit-risk framework 
Most agencies felt that a benefit-risk framework should be used by both agencies and 
companies, across divisions of a regulatory agency, and be applied from drug 
development to post-approval changes (Figure 3.6). Responses from the companies 
had a similar trend. 
 
Fewer agencies believed that the framework, if developed for registration of 
medicines, should be utilised across agencies worldwide. However, the majority of 
companies would prefer this to be so. It was also observed that more companies than 
agencies wanted the framework to be applicable to heath technologies agencies 
(HTA). 
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Figure 3.6 Responses to perceived utility and scope of a benefit-risk framework 
 
The general consensus was for a benefit-risk framework to be utilised by both 
agencies and companies and for the entire life cycle of a medicine.  
 
Purpose of a benefit-risk framework 
There was a good level of agreement between the agencies and companies for the 
purposes of a framework. Both groups felt that a benefit-risk framework would 
enhance the quality of communication and enable the assessment of benefit-risk 
management plans (Figure 3.7). 
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Similarly, both agencies and companies did not feel the need to have a framework 
that translates benefit-risk balance into absolute numeric terms and measures 
sensitivity to various other parameters. This closely mirrored the observations that no 
responders currently utilise a fully quantitative system and the inconsistent use of 
values and weights for benefit-risk parameters. 
 
Figure 3.7 Responses to perceived purposes of a benefit-risk framework 
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from agencies, companies, academia and other stakeholders) to guide the direction 
and application of the framework and to involve these relevant stakeholders in 
developing and validating the framework. These outcomes were agreed by both 
agencies and companies. Differences in opinions could be observed in the 
preference for a quantitative approach, and the need to develop specific frameworks 
for different therapeutic areas. 
 
Perceived advantages of benefit-risk framework 
This study evaluated the perceived advantages of a framework through nine 
statements. All responders, 11 agencies and 20 companies, provided responses to 
this section. The main advantages of a benefit-risk framework, as perceived by 
agencies, were in providing documentation for a structured discussion, acting as a 
tool for communication among peers within the organization and communicating 
between the organization and stakeholders (Figure 3.9). The main advantages, 
indicated by companies, were to enhance transparency and accountability and 
communicate between the organization and stakeholders.  
 
A major discrepancy between the agencies’ and companies’ responses was in 
having the framework as a training tool with more than half of the agencies believing 
this advantage was significant, but not with the companies. Among the responders, 
all the listed advantages were considered significant. Between agencies and 
companies, there was a general agreement that the advantages of a framework 
included proper documentation and enhancement of communications (including 
transparency and accountabililty of decisions).  The advantage of streamlining of 
current work did not appear to be a high priority. Additional comments received from 
these responders included the advantages of focusing on both benefits and risks of a 
medicine as well as providing a tool for decision-making in urgent situations. 
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Figure 3.8 Responses to the perceived directions in developing a benefit-risk framework 
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Figure 3.9 Responses indicating the perceived advantages of a benefit-risk framework 
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Factors for reviewing benefit-risk frameworks 
The major factors for reviewing a benefit-risk framework were logical soundness, 
acceptability of results and practicality. These results were similar for both agencies 
and companies (Figure 3.10).  
 
Figure 3.10 Responses indicating the relevance of factors for reviewing a 
benefit-risk framework 
 
 
In general, all the listed factors could be considered relevant in reviewing a benefit-
risk framework for appropriateness. Additional comments provided by responders 
were to include factors like transparency of the methodology and provision of an 
audit trail from evaluation to decision. 
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Criteria in constructing benefit-risk balance 
The criteria used for constructing a benefit-risk balance were similar between the 
agencies and companies. The more frequently used criteria were the description of 
alternative therapies or interventions, the identification of outstanding issues and 
potential post-market commitments (Figure 3.11). In addition, other criteria included 
the direct comparisons of the absolute gains or harms in terms of lives saved, lost, or 
specific clinical events. Five out of 11 agencies (45%) and three out of 20 companies 
(15%) calculated the benefit-risk balance for each major subpopulation. Similarly 
there was a difference with respect to the acceptable level of risk with regards to 
clinical benefit (36% of agencies compared with 16% of companies) and the 
evolution of benefit-risk balance over time (36% of agencies compared with versus 
20% of companies). The remaining criteria, namely consideration for different 
regulatory options for approval and calculation of the uncertainties for benefit and risk 
were used in similar frequencies by agencies and companies.  
 
In considering criteria important to construct a benefit-risk balance, there was 
agreement between the agencies and companies to include the calculation of 
uncertainties on benefits and risks, direct comparison of absolute gains or harms, 
calculation of acceptable risk with regards to clinical benefits, the description of 
alternative therapies or interventions and the identification of outstanding issues and 
potential post-market commitments (Figure 3.12). With the exception of the 
calculation of acceptable risk with regards to clinical benefits, the rest were currently 
used in similar frequencies by agencies and companies. In general, these five criteria 
should be considered in the development of a benefit-risk framework. 
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Figure 3.11 Comparison between agencies and companies for criteria currently 
used in constructing benefit-risk balance 
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Figure 3.12 Comparison between agencies and companies for criteria 
considered important to be included in constructing benefit-risk balance 
 
 
There was a difference between agencies and companies with respect to the criteria 
as to whether the benefit-risk framework could be of value for regulatory approval 
options. Half the companies reported that this criterion was important, whereas in 
contrast the agencies considered it to be of no value.  Other differences were also 
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observed for two other criteria namely evolution and sensitivity of benefit-risk balance 
over time and calculation of benefit-risk balance for each major patient 
subpopulation, with more companies considering them important to be included. 
 
Part III – Barriers and Solutions to Implementing Benefit-risk Assessment 
Frameworks 
Agencies’ and companies’ satisfaction with existing benefit-risk assessment 
system 
The majority of the agencies and companies (10 out of 15) who were currently using 
semi-quantitative systems were not satisfied. The reasons for this were that their 
current semi-quantitative systems required additional training, had poor acceptance 
by staff and were not validated. In addition, there were concerns about the uptake of 
certain methodologies by the stakeholders with some agencies preferring different 
models and some not requesting any formal approaches at all. The methodology 
should be structured and standardised and be applied through product development 
to submission for registration. 
 
Reasons for not using semi-quantitative or quantitative systems 
Four agencies and eleven companies who were currently using qualitative systems 
responded. The major reasons, among the agencies, were the lack of a scientifically 
validated framework and a universal framework (Figure 3.13). However, for the 
companies, the lack of a universal framework and the semi-quantitative or 
quantitative system not being required for current processes in the organizations, 
were the reasons given.  
 
For six of the seven reasons for not implementing semi-quantitative or quantitative 
systems, there was a consistent trend by both agencies and companies with the 
agencies attaching more importance with the exception of one reason, namely “not 
being required for current processes” in the organizations (Figure 3.13). The most 
important reasons indicated by both agencies and companies were the lack of a 
common framework and a scientifically validated framework. Further, the area of 
closest agreement was in respect of the lack of knowledge of benefit-risk framework. 
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Figure 3.13 Comparison between agencies and companies for not 
implementing semi-quantitative and quantitative systems 
 
 
Barriers to implementing a semi-quantitative or quantitative benefit-risk 
framework 
The barriers that were most commonly observed among the agencies included the 
lack of an accepted framework, resource limitations, change in work processes and 
the lack of a scientifically validated framework (Figure 3.14). For the companies, the 
major barriers were the lack of an accepted and scientifically validated framework. 
The lack of an accepted and validated framework expressed by both agencies and 
companies as significant barriers to implementing a framework correlated with the 
findings for reasons for not using a semi-quantitative or quantitative framework. 
Close to half of the agencies and companies rated support from senior management 
as low in significance or not applicable.  
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Figure 3.14 Comparison between agencies and companies for barriers to 
implementing a semi-quantitative or quantitative benefit-risk framework 
 
 
Hurdles and possible solutions to implementing a benefit-risk framework 
Ten agencies and 20 companies provided free-text comments regarding potential 
hurdles to implementing a benefit-risk framework and the possible solutions. These 
comments were reviewed and categorised accordingly.  
 
The major potential hurdles were the lack of consensus and various considerations 
for implementing and developing a common framework (Table 3.7). These results 
correlated with the reasons for not implementing a semi-quantitative and quantitative 
framework and barriers to implementation (Figure 3.13 and 3.14). 
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Table 3.7 Major hurdles to implementing a benefit-risk framework 
1. Lack of consensus 
• Absence of a global and common framework meeting the needs of both 
agencies and companies  
• Absence of clear directions on the purpose and utility of a common 
framework in assessing benefits and risks 
• Absence of buy-in from major regulatory agencies for a single common 
framework 
2. Considerations before implementing a common framework 
• Need to account for differences in legal, cultural and medical practices 
• Need to consider the requirements for manpower, skills, training and 
changes in work processes  
• Need to consider the communication of relevance and the need for a 
common framework, involving a change management within an 
organisation 
3. Considerations in developing a common framework 
• Need for validation using real-world examples, accounting for 
uncertainty, consistency and communication of decisions 
• Need for a flexible framework, incorporating various methods 
• Need for framework to be comprehensive, quickly usable and easily 
understood 
 
The majority of the proposed solutions pertained to coordination of activities related 
to the development and implementation, as well as the communication of these 
activities (Table 3.8). The comments also reported on the need to provide a toolbox 
of methodologies for use under this framework. The proposed solutions aligned well 
with the main perceived directions in developing a framework (Figure 3.8). 
 
The proposal to form a committee to oversee the progress of the development and 
implementation will help to obtain consensus across the stakeholders, communicate 
the purpose and utility of the common framework and initiate validation studies. The 
toolbox will provide flexibility to account for the differences in legal, cultural and 
medical practices, as well as preferences for selected methodologies. Guidance on 
the use of the common framework will alleviate the strain on training and changes in 
work processes. In general, the proposed solutions appeared effective in resolving 
the identified hurdles. 
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 Table 3.8 Main proposed solutions to overcome hurdles 
1. Coordination and communication 
• Form a committee or working group comprising stakeholders to oversee 
the development and implementation of the framework 
• Put up a guidance at international level e.g. International Conference on 
Harmonisation (ICH) 
• Advise change management of organisations, ensure and promote the 
continued use of the framework 
• Initiate pilot studies for validation, setting of standards and lead scientific 
discussions 
2. Toolbox of benefit-risk methodologies 
• Obtain consensus for toolbox of methodologies for assessing benefits 
and risks, (including at least one for testing sensitivity), allowing flexible 
for different situations and with the option to add relevant methodologies 
along the way 
3. Resources for implementing a common framework 
• Provide training via workshops and simple protocol/guidance 
 
DISCUSSION 
Benefit-risk assessments and decisions for approving medicines rely on scientific 
capabilities and clinical judgment. These decisions should be monitored during the 
life cycle of a medicine from drug development to post-marketing. Many stakeholders 
are involved in the management of the life cycle of a medicine including 
pharmaceutical companies, regulatory agencies, health technology assessment 
agencies, physicians and patients. Information should be flowing effectively from one 
stakeholder to another and from one phase to another, emphasizing the importance 
of appropriate communication. Effective communication is facilitated by appropriate 
documentation and the information to be transferred in a manner that can be 
accurately understood by stakeholders (EMA, 2008). 
 
The study showed that qualitative systems were employed by both agencies and 
companies, which may undermine communication as there is unlikely to be an 
appropriate structure for documentation and communication on the basis of the 
decisions. Among those using semi-quantitative systems, values and weightings 
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were generally not applied. Valuing the options can be used to highlight the relative 
differences between investigated product and comparator, and hence assist in 
deciding the clinical relevance of the medicine in managing the condition. Placing 
weights on the different benefits and risks to allow a clarification of relative 
importance of each parameter in the context of the decision to be made is critical. 
Without the use of values and weights it may be difficult to articulate the basis of the 
decision. A well-documented and logical flow of thought processes will form a 
platform for transparent discussion amongst stakeholders especially in situations of 
differing opinions. 
 
Visualisation tools display the outcomes of benefits and risks in a clear and simple 
manner for ease of interpretation and understanding. This may be significant for 
physicians and patients who do not have access or the expertise to evaluate the vast 
amount of data in clinical study reports. However, this study revealed that only 
companies develop these tools and this was mainly for internal communication. It 
appears that more initiatives can be taken to enhance the appropriate flow of critical 
information at a level that can be easily interpreted by different stakeholders. 
 
In the absence of fully quantitative systems, values, weights and visualisation tools, it 
remains a significant challenge to optimise the communication of benefit-risk 
decisions to all stakeholders. This current situation places a burden on regulatory 
authorities to provide transparent and consistent decisions that other stakeholders 
are seeking to determine their accountability. The proposed framework should 
provide a formal structure for documenting logical thought processes leading to the 
final decision and thereby fulfilling the need for transparency. Thus, communication 
will be clear and effective. This is important in the healthcare context whereby 
appropriate communication across stakeholders is pivotal to making informed 
decisions.  
 
The robustness of benefit-risk assessment lies in the scientific capabilities and 
clinical judgment and it is fundamental that the science used to back the decisions 
should be optimised. It is apparent that both agencies and companies are aware of 
better scientific methodologies that may improve the quality of their assessment of 
benefits and risks, as revealed by the disparity between those methodologies 
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currently used and those considered relevant. Therefore, current methodologies 
employed by agencies and companies may not be able to provide the best 
assessment of benefits and risks of medicines. This may have led to inconsistent 
assessments for the same medicine. Consequently, the intention to be transparent 
about the processes of decision-making may be hampered by this deficiency not 
being rectified. As healthcare sciences advance rapidly, there must be an alignment 
to develop tools that are capable of assessing the benefits and risks correctly. 
Further studies should be conducted in this area to identify the required 
methodologies for inclusion into the proposed overarching framework. 
 
The outcome of benefit-risk assessment should contribute to the availability and 
utility of a medicine. Patients are the eventual recipients of this decision on benefits 
and risks, but their views are often not incorporated in the development (Hareendran 
et al, 2012) and review of the medicine. Though there are current tools like patient 
reported outcomes, there is currently no recommended approach to this. In the 
absence of patients’ perspectives, a medicine may be approved but poorly utilised or 
is not made available in ignorance of what ultimately matters most to the patients.  
 
Health technology assessment agencies (HTA) play a key role in deciding the 
availability of the medicine. They may consider other factors like cost effectiveness, 
value and the availability of other therapeutic options in making their decisions. 
However, there is little information on their requirements and methods of 
assessment. In view of these potential differences (Eichler, 2012a), regulatory 
agencies, pharmaceutical companies and HTAs should focus on communication, 
which enables them to emphasize contentious issues. In this way, the potential 
differences in expectations can be better managed and a consistent message can be 
available to the patients. A universal framework will help to achieve this. The lack of 
communication may result in the delay of a medicine being made available or the 
lack of payor coverage leading to fewer therapeutic options for patients. Future 
studies should consider collecting information on the current status of how 
assessments are carried out by the HTAs, and how these differences can be 
resolved across the various stakeholders. 
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Regulatory agencies are charged with approving medicines that are shown to be 
safe, efficacious and meeting the medical needs of the intended population. They are 
accountable for their decisions backed by the assessment of scientific evidence. The 
agencies have a tendency to focus on scientific aspects, as evidenced in their 
preference to adopt semi-quantitative systems. It is also justified that each agency 
makes decisions suitable for their own jurisdiction, as determined by individual 
legislation, disease demographics, medical practices and culture. The agencies are 
expected to then account to the public for their decisions through appropriate 
communication, while taking caution not to impose additional liabilities on 
themselves. Therefore, the main concerns for agencies appear to be enhancing 
scientific capabilities. It is observed that agencies have little experience with the 
various tools currently available in assessing benefits and risks and effectively 
communicating these decisions to their local population. It is thus observed that 
fewer agencies felt the need to have a framework to be used internationally. 
 
Pharmaceutical companies are driven by the objective to market a medicine by 
demonstrating to the agencies and HTAs that the medicine is proven to be safe and 
effective. Their challenge is to provide a similar set of clinical data to meet the 
varying regulatory requirements of different countries. Despite similar clinical data, 
companies could receive diverse opinions and regulatory decisions from the different 
countries resulting in a lack of predictability for the companies. To address this need, 
the companies would be seeking a universal framework for transparent 
communication between the agency and the company which would ease the sharing 
of information across agencies and reduce the resources required to meet varying 
regulatory requirements. 
 
Patients’ perspectives have already been identified as a fundamental consideration in 
assessing the benefits and risks of medicines (EMA, 2008). However, approaches to 
represent and collect objective information are still being explored. The US FDA is 
embarking on PDUFA V (FDA, 2012a) and identifying diseases whereby patients’ 
perspectives would have a significant impact on regulatory decision-making. 
 
There are currently many available methodologies to assess medicines though none 
have been established as a standard as there are varying perspectives in assessing 
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the benefits and risks. To reach a consensus for standard tools, it requires them to 
be validated across different users and situations. This can take a considerable time 
and is unlikely to be fruitful, given that the science behind the tools continues to 
advance as we validate their use. Hence, to facilitate identifying the methodologies 
for use under the proposed framework, it would be prudent to understand the 
characteristics of an acceptable universal framework. These can be found from the 
factors for reviewing a framework namely logical soundness, acceptability of results, 
practicality, presentation/visualisation, scope, comprehensiveness, sensitivity and 
specificity. Any methodologies for inclusion into a framework should enhance the 
quality of the above factors which have been agreed by both agencies and 
companies. 
 
There seems to be conflicting approaches regarding the speed with which to bring 
about changes to the current benefit-risk assessment systems within the agencies 
and the companies. Therefore there is an urgent need for the stakeholders 
concerned to come together to agree on the way forward for a universal benefit-risk 
framework and the timetable for its implementation.  
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SUMMARY 
• Evidence to date showed that there is no consensus for a universal benefit-risk 
assessment framework. 
• This study aimed to explore the current views, potential differences and future 
directions in benefit-risk assessment between agencies and companies. 
• Eleven agencies (79% response rate) and 20 companies (83% response rate) 
responded and was found that none uses a full quantitative system while among 
the companies, more were using a qualitative system. 
• There were discrepancies between the methodologies currently in use by the 
responders and those that were deemed useful and relevant. 
• From the results, it appears that a benefit-risk framework, if implemented, should 
be able to be utilised by both agencies and companies, through relevant divisions 
of a regulatory agency, and its scope to include the entire life cycle of a product.  
• It was reported by both agencies and companies that there is a common need for 
the provision of a framework that can be used for benefit-risk management plans 
throughout the life cycle of a product.  
• There is a need to involve relevant stakeholders in the development, validation 
and application of an appropriate benefit-risk framework. 
• Major barriers, as expressed by both stakeholders, are resource limitations, the 
lack of knowledge/expertise, a scientifically validated and accepted/recognised 
framework. 
• It is reported that while the stakeholders are looking forward to a change, the 
system is likely to be an overarching, semi-quantitative framework that 
incorporates a toolbox of various assessment methodologies.  
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CHAPTER 4  
  
 
 
 
 
Development of benefit-risk assessment 
support system (BRASS) - a framework, 
template and user manual for the benefit-risk 
assessment of medicines 
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INTRODUCTION 
Currently there is a need to understand why different regulatory agencies come to 
different outcomes despite having the same data submitted for their assessment. 
This has led to an increasing pressure on agencies to improve transparency and 
accountability and establish appropriate document governance for their decision-
making processes. A universal framework (CMR, 2008) would be of value and should 
be applicable to both pharmaceutical companies and regulatory agencies resulting in 
a standardised framework for benefit-risk assessment to support transparency in 
decision-making. 
 
A survey conducted within pharmaceutical companies and regulatory agencies 
showed that the main hurdle to establishing a universal framework was the lack of an 
accepted, validated and international model. It is therefore vital to establish a 
universal framework with the participation of major regulatory agencies to ensure the 
possible uptake of the same framework by other regulators across the world. One of 
the challenges is to harmonize the different requirements of such a framework for the 
assessment of benefits and risks of medicines which could be applied across 
different jurisdictions and scenarios. 
 
At a time of constrained resources, shared and joint reviews are a possible way 
forward and this led to the formation of the Consortium, consisting of four similar-
sized agencies (SwissMedic, Therapeutic Goods Administration (TGA), Singapore’s 
Health Sciences Authority (HSA) and Health Canada). The four agencies had a plan 
to initiate work sharing whereby a harmonised benefit-risk assessment template 
would be required. In order to achieve this, it was important to review the existing 
frameworks and select one for further development.  
 
OBJECTIVES 
This study had the following objectives, namely to develop: 
1. A universal framework for benefit-risk assessment of medicines to achieve a  
systematic approach to benefit-risk decision-making 
2. A benefit-risk template to document benefit-risk decision-making using the 
benefit-risk framework principles 
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3. A user manual for regulatory assessors to guide the use of the benefit-risk 
template 
 
METHODS 
In order to develop and propose a universal framework that facilitated decision-
making, the expectations and requirements of such a framework were obtained 
through a review of published literature and reports from relevant workshops. 
Opinions were then collated and organised to provide a list of requirements for a 
universal framework for the benefit-risk assessment of medicines. 
 
Existing frameworks for the assessment of benefits and risks of medicines were 
reviewed. The selected frameworks were assessed against the list of criteria which 
included logical soundness, comprehensiveness, acceptability of results, practicality, 
specificity and sensitivity, presentation (visualisation) and scope. Finally, the selected 
framework was evaluated by comparing the components with those of existing 
frameworks to determine if it included the essential elements for a universal 
framework.  
 
Benefit-risk decisions need to be communicated in an effective and systematic 
manner, allowing appropriate understanding of the information by the stakeholders. A 
template should be an aid for documenting the processes leading to the construction 
of a benefit-risk balance and the eventual basis that would support the decision. A 
search was conducted for guidances used by regulatory agencies in order to identify 
those elements considered essential to the assessment of benefits and risks of a 
medicine. The EMA guidance document of 2008 was utilised in developing an 
appropriate BR template. These elements were then transformed into a template that 
allowed documentation and editing. This initial developmental template was then 
reviewed against the universal framework so that it could support the principles 
outlined in the overarching universal framework.  
 
The initial template was assessed by the Consortium who evaluated its use in a 
feasibility study and the template was amended and finalised based on the feedback 
from the Consortium. Comments from the reviewers of the template highlighted the 
need for a user manual. It was found that the usefulness of the template would be 
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dependent on an understanding of the terms and requirements of the input fields and 
compliance in completing the template. The Consortium identified areas in the 
template that would require clarification or additional explanation. These provided the 
critical elements in producing the user manual to guide users in completing the 
template. The initial user manual was further revised by the Consortium resulting in 
the final version. 
 
RESULTS 
The results are presented in three parts, namely: 
• Part I – Development of the universal framework 
• Part II – Development of the benefit-risk template 
• Part III – Development of the user manual 
 
Part I – Development of the universal framework 
Requirements of a universal framework 
The EMA Benefit-Risk Methodology Project (EMA, 2009) was aimed at the 
development and testing of tools and processes for balancing multiple benefits and 
risks, which could be used as an aid to informed, science-based regulatory decisions 
about medicinal products. This project consisted of five consecutive work packages. 
The second work package (EMA, 2010) examined the applicability of three qualitative 
frameworks, namely the Pharmaceutical Research and Manufacturers of America 
(PhRMA) benefit-risk assessment team framework (BRAT framework), the seven-
step framework developed by the Centre for Innovation in Regulatory Science 
(CIRS), and the benefit-risk framework developed by the US FDA, and the 18 
quantitative approaches for assessing the benefit-risk balance.  
 
It was found that clinical judgment remained a critical role in regulatory decision-
making and models could assist but not replace the complex process of constructing 
a benefit-risk balance and incorporating uncertainties into the final decision. In the 
EMA’s evaluation of quantitative approaches, it was concluded that any quantitative 
method or approach would require a qualitative framework within which the model 
could be effectively developed. Combinations of approaches could prove useful in 
situations that required a review of the contributions by the magnitude of favourable 
effects, seriousness of unfavourable effects, uncertainties, transitions in health states 
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and the time spent in each state and trade-offs between effects. Therefore, an 
overarching benefit-risk assessment framework with the capacity to incorporate 
various quantitative methods would be ideal. 
 
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
Risk-benefit Management Working Group conducted a study (Guo et al., 2010) to 
review and compare published quantitative benefit-risk assessment methodologies 
employed by regulatory agencies and/or the pharmaceutical industry in the hope that 
comparisons may help disclose unique characteristics of the techniques that may be 
more applicable to a specific drug evaluation scenario or a specific therapeutic 
indication. It was found that each quantitative method had its unique advantages and 
disadvantages based on data requirements and statistical properties. Numerous 
methodologies have been proposed, but there were a limited number of empirical 
applications of these techniques and there was no consensus among regulators for 
defining a clear gold standard. When evaluating any new health-care technology, 
Guo et al (2010) recommended the use of multiple benefit-risk assessment 
approaches across different therapeutic indications and treatment populations to 
construct the risk–benefit profile. This was similar to the EMA opinion regarding the 
need to vary the tools available for effective benefit-risk assessment, which should be 
governed under an overarching framework. 
 
In the report of methods for benefit and harm assessment in systematic reviews by 
the Agency for Healthcare Research and Quality (Boyd et al, 2012), some principles 
for a review protocol development were highlighted. Firstly, the key potential benefits 
and harms should be identified. Then the approaches used in the reporting of the 
benefit and harm outcomes should be indicated, including the assumptions 
undertaken for the approaches described e.g. number needed to treat (NNT) and 
number needed to harm (NNH). This would help to understand the appropriateness 
and rationale for the approaches selected. Preferences (including patients’ 
preferences) should also be considered in the assessment and sensitivity analyses 
conducted to determine the impact of varying preferences. In delivering the overall 
benefit harm assessment, a qualitative or quantitative approach should be clearly 
stated. 
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Mussen et al (2009) conducted a literature review of tools for the assessment of 
medicines and argued that the development of a new model ought to achieve the 
following objectives: 
1. Framework should match current practices of regulatory agencies for benefit-
risk assessment, in order that the framework can be used in the scope of 
those practices 
2. Framework should be able to take into account the data in a marketing 
authorisation application and the scientific data otherwise available to 
regulatory agencies 
3. Framework should not require additional analyses or re-analyses of source 
clinical data, or additional clinical meta-analyses 
4. Use of framework for initial registration and post-approval re-assessment of 
existing medicines 
5. Framework should be applicable to all kinds of medicines, including vaccines 
and non-prescription medicines 
6. Framework should be considered a tool for regulatory agencies and 
pharmaceutical companies for assessing benefit-risk balance of medicines, 
but not substitute decision-making 
7. Framework should be validated 
 
A study was conducted to explore the current status and the need for a universal 
benefit-risk framework for medicines in regulatory agencies and pharmaceutical 
companies (Chapter 3). It was found that for the utility and scope of a universal 
benefit-risk assessment framework, most agencies and companies believed that a 
benefit-risk framework should be applied throughout the life cycle of the medicine 
with the emphasis on applicability to product registration, health technology 
assessment agencies and across the life cycle of a product (Table 4.1). The general 
consensus was that a benefit-risk framework should be utilised by both agencies and 
companies. Both agencies and companies also believed that a universal framework 
would enhance the quality of communication and enable the assessment of benefit-
risk management plans. The advantages of a universal framework were that it would 
provide documentation for a structured discussion, act as a tool for communication 
among peers within the organization and enable communication between the 
organization and stakeholders. There was a general agreement that these 
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advantages would include appropriate documentation and enhancement of 
communication together with transparency and accountabililty of decisions. 
 
Table 4.1 Requirements of a universal benefit-risk framework 
Utility and Scope of a universal framework 
• Need for a universal benefit-risk assessment framework 
• Importance of a universal benefit-risk framework developed for registration 
purposes 
• Importance of a universal benefit-risk framework applied throughout life cycle 
of a medicine 
• Applicability of a universal benefit-risk framework to health technology 
assessment agencies 
• Utility of a universal benefit-risk assessment framework 
Purposes of a universal framework 
• Application of a universal benefit-risk framework to benefit-risk management 
plans 
• Transparency and consistency of decision-making 
• Communication of decision 
 
Chapter 3 also identified the criteria from both agencies and companies for reviewing 
a benefit-risk framework (Table 4.2). These would be used to assess the suitability of 
frameworks in consideration for further development into a universal framework. The 
findings from EMA and Guo et al (2010) for an overarching framework allowing 
various assessment tools can be subsumed under the criterion 
“Comprehensiveness”.  
 
Identification of a suitable framework 
There were five frameworks identified that are currently used for the assessment of 
the benefits and risks of medicines (Table 4.3). Of these, two were used by 
regulatory agencies and another two by pharmaceutical companies. The 7-step 
framework by CIRS had been reviewed by both the major stakeholders, namely 
regulatory agencies and pharmaceutical companies. None were currently used as a 
universal framework. 
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Table 4.2 Criteria influencing the quality of a universal benefit-risk framework 
1. Logical soundness 
 Provides an approach that is sound and 
allows decisions that are coherent and aids 
rational thinking  
2. Comprehensiveness 
 Provides an approach that handles all forms 
of data (including qualitative and 
quantitative, subjective and objective 
information) and allows for multiple criteria 
3. Acceptability of results 
 Provides an approach that checks for 
inconsistencies in data and judgment and a 
realistic approach to the evaluation of 
benefits and risks 
4. Practicality  Provides an approach with minimum burden on resources and ease of use 
5. Specificity and sensitivity  Provides a statistical perspective underpinning the reliability of the decision 
6. Presentation 
(visualisation) 
 Provides outcomes in an easily 
understandable format such as charts and 
plots 
7. Scope 
 Provides a consistent approach throughout 
drug development and post-approval 
monitoring 
 
Table 4.3 Frameworks currently used for the assessment of benefits and risks 
of medicines 
Source CIRS  EMA US FDA PhRMA Novo Nordisk 
Name of 
framework 
7-step 
framework 
8-step 
PrOACT-URL 
5-step Benefit-
risk 
Framework 
6-step BRAT 
framework 
8-step BRAIN 
framework 
Basis of 
framework 
MCDA MCDA  MCDA MCDA 
Reviewed 
by 
Regulatory 
agencies and 
pharmaceutical 
companies 
EU regulatory 
agencies 
US regulatory 
agency 
Pharmaceutical 
companies 
Pharmaceutical 
companies 
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Multi-criteria decision analysis (MCDA) was the platform on which other frameworks 
were based and it was also confirmed as a useful relevant methodology (Chapter 3). 
MCDA is a process described in the Multi-Criteria Analysis (MCA) manual (Dodgson 
et al, 2009) which aims to explore the individual contributing aspects of the decision-
making process before collating the outcomes to form the basis of the decision. 
There are three key phases of the MCDA process. The problem is first identified and 
structured and secondly the decision-maker’s preferences are taken into account. 
Lastly, action plans are developed. The steps in executing these three key phases 
can be found in Table 4.4.  
 
An important feature of the MCDA model is the ability to carry out sensitivity analyses 
on the results by varying any of the weights and scores to assess the impact on the 
overall benefit-risk balance. The MCDA model generates two assessments of the 
data, with the first being the overall value (cumulative outcomes after scoring and 
weighting) and the second a sensitivity analysis (through adjusting the scores and 
weights). The criteria to be taken into account in determining the outcome for the 
assessment were grouped as ‘benefits’ and ‘risks’. The criteria for risks included not 
only the incidence of adverse events and drug-related reactions, but also unobserved 
and potential risks based on knowledge of factors including related products and the 
mechanism of action.  
 
Each criterion would then be assigned a score and given a weight according to its 
relative importance to the benefit-risk decision. Weighted scores were then 
calculated at each level in the hierarchy which enabled an overall weighted score to 
be calculated for each of the options. The process of ‘scoring’ would be based 
predominantly on measurable data such as the clinical trial endpoints and incidence 
of adverse events, measured as percentages.  The process of ‘weighting’ the criteria 
was where experience and judgement were built into the methodology. The 
assignment of weight to a criterion was normally based on a combination of factors 
on which a value judgement would be made. 
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Table 4.4 Steps in Multi-criteria Decision Analysis (MCDA) 
 Steps Actions 
1 Establish the decision 
context 
• Establish aims of the MCDA; identify decision 
makers and other key players 
• Design the socio-technical system for 
conducting the MCDA 
• Consider the context of the appraisal 
2 Identify the options to be 
appraised 
 
3 Identify objectives and 
criteria 
• Identify criteria for assessing the 
consequences of each option 
• Organise the criteria by clustering them under 
high-level and lower-level objectives in a 
hierarchy 
4 Scoring – Assess the 
expected performance of 
each option against the 
criteria, then assess the 
value associated with the 
consequences of each 
option for each criterion 
• Describe the consequences of the options 
• Score the options on the criteria 
• Check the consistency of the scores on each 
criterion 
5 Weighting – Assign 
weights for each of the 
criteria to reflect their 
relative importance to the 
decision 
 
6 Combine the weights and 
scores for each option to 
derive an overall value 
• Calculate the overall weighted scores at each 
level in the hierarchy 
• Calculate the overall weighted scores 
7 Examine the results  
8 Sensitivity analysis • Conduct a sensitivity analysis: do other 
preferences or weights affect the overall 
ordering of the options? 
• Look at the advantage and disadvantage of the 
selected options, and compare pairs of options 
• Create possible new options that might be 
better than those originally considered 
• Repeat the above steps until a “requisite” 
model is obtained 
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MCDA is believed to have the following advantages as it: 
• Takes explicit account of multiple and conflicting criteria 
• Helps to structure the problem 
• Helps decision-makers learn about the problem, their own and others’ values 
and judgment and through structuring and presenting the information, 
identifies a preferred course of action 
• Serves to complement and challenge intuition, but does not seek to replace 
intuitive judgment or experience 
• Leads to better considered, justified and explainable decisions and provides 
an audit trail 
• Demonstrates that decisions are conceptually simple and transparent 
 
In addition in support of a universal benefit-risk framework, the MCDA model is not 
limited by type of data and is used for approval or post-marketing and with all types 
of medicines. It makes use of available data without the need to conduct further 
analyses and does not aim to replace decision-making, but provides clarity with 
respect to the basis of the decision made. Scoring, weighting and sensitivity analyses 
fulfil the requirements for a universal framework that could check for inconsistencies 
in the data (acceptability of results) as well as specificity and sensitivity. 
 
MCDA, in providing a structured flow of information leading to a decision, is a tool for 
communicating a transparent and consistent decision. It also appears not be limited 
in its scope and can be applied to benefit-risk management plans and be used by 
health technology assessment agencies. 
 
The factors influencing the quality of a universal benefit-risk framework were 
reviewed against the MCDA approach and the steps in executing this model. The 
structure of MCDA, in presenting and organising information, provides logical 
soundness and since it uses available data, it would be a comprehensive and 
practical framework not limited by the scope of application in approval and post-
marketing scenarios. However MCDA does not provide any form of visualisation that 
could enhance the ease of understanding the outcomes. It could help enhance the 
consistency, objectivity and transparency of the decision-making process for benefit-
92 
 
risk assessments by providing a structured and systematic approach and appropriate 
documentation for tracking the process and providing greater accountability. It also 
facilitates the reviewing of past decisions and experiences to ensure the consistency 
of regulatory decisions on marketing authorisation applications. Through this, a better 
understanding could be achieved of the contexts as to why different agencies could 
reach different conclusions on the basis of the same data as well as imparting 
objectivity to the regulatory process. 
 
It thus appeared that frameworks using the MCDA approach could be considered 
appropriate for further development into a universal framework. The CIRS 7-step 
framework was chosen as the model for further development into a universal 
framework due to its independent development and its exposure to both regulatory 
agencies and pharmaceutical companies.  
 
Development of the Framework 
The CIRS 7-step framework, based on the 3 key phases of MCDA, was reviewed to 
identify areas of improvement. The processes of this 7-step framework are described 
in Figure 4.1. Step 1, namely “decision context”, is the identification and structuring of 
the problem, while steps 2 to 5 are the development of decision-maker preferences 
i.e. criteria for benefits and risks. Step 7 is “Expert judgment” and correlated to the 
final key phase of MCDA, in providing an action plan leading to a decision. It should 
be noted that Step 6 “Visual presentation” was added to fulfil the requirements as 
identified earlier for a universal framework. 
 
Although the CIRS 7-step framework had been reviewed by both major stakeholders, 
it had not been applied in the real world situation. Noting that groups of the four other 
frameworks were currently used individually by the respective developers 
harmonisation of the essential elements was conducted to impart a character of 
universal utility to the CIRS framework. This would help incorporate the existing work 
processes of the various stakeholders around the world and make the potential 
uptake of the universal framework more appropriate.  
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Figure 4.1 The initial 7-step Framework for the assessment of benefits and 
risks of medicines 
 
 
The US FDA used a framework (Table 4.5) that would accurately and concisely 
describe benefit and risk considerations to help assessors apply a structured 
approach in regulatory decision-making (CIRS, 2011). An important consideration is 
the context of the decision, an understanding of the condition treated and the unmet 
medical need. A more systematic and open discussion with informed patients could 
provide valuable insights in a given disease and the potential gaps or limitations in 
available therapies. There are now ongoing projects to develop and implement a plan 
to integrate a benefit-risk framework in the drug review process during PDUFA V 
(FDA, 2012a).  
 
The European Medicines Agency (EMA) used a set of guiding principles (Figure 4.2) 
in decision-making for medicines (EMA, 2011d, 2012). It commenced by examining 
the challenge or decision to be made and the objectives, considering the options, 
alternatives and trade-offs before a decision or action would be decided. 
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Table 4.5 US FDA’s 5-step approach to assessment of benefits and risks 
Consideration Evidence and Uncertainties Conclusions and Reasons 
Analysis of Condition Summary of evidence: Conclusions (implications for 
decision): 
Unmet Medical Need Summary of evidence: Conclusions (implications for 
decision): 
Clinical Benefit Summary of evidence: Conclusions (implications for 
decision): 
Risk Summary of evidence: Conclusions (implications for 
decision): 
Risk Management Summary of evidence: Conclusions (implications for 
decision): 
Mullin T (CDER): 16-7June2011 CIRS Workshop, Visualising benefit-risk: The key to developing a 
framework that informs stakeholder perspective and clarity of decision-making Washington DC.   
 
Figure 4.2 The guiding principles used by EMA in assessment of benefits and 
risks of medicines 
 
 
The PrOACT-URL (Table 4.6) was developed on the basis of the above guiding 
principles to further illustrate the considerations undertaken in making the decision on 
the benefits and risks of the medicines. This 8-step framework shown was based on 
a generic framework for decision-making (Hammond et al, 1999).  
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Table 4.6 EMA’s Approach: 8-step PrOACT-URL 
 Steps Actions 
1 Problem • Determine the nature of the 
problem and its context 
• Frame the problem 
At this point, only issues 
concerning the 
favourable and 
unfavourable effects, 
and their balance, have 
been considered 
2 Objectives • Establish objectives that 
indicate the overall purposes to 
be achieved 
• Identify criteria of favourable 
and unfavourable effects 
3 Alternatives • Identify the options to be 
evaluated against the criteria 
4 Consequences • Describe how the alternative 
perform for each of the criteria, 
that is, the magnitudes of all 
effects and their desirability or 
severity and the incidence of all 
effects 
5 Trade-offs • Assess the balance between 
favourable and unfavourable 
effects 
6 Uncertainty • Assess the uncertainty 
associated with the favourable 
and unfavourable effects 
• Consider how the balance 
between favourable and 
unfavourable effects is affected 
by uncertainty 
These three steps are 
relevant in considering 
how the benefit-risk 
balance is affected by 
taking account of 
uncertainties 
7 Risk tolerance • Judge the relative importance 
of the decision makers’ risk 
attitude for this product and 
indicate how this affected the 
balance reported in step 5 
8 Linked 
decisions 
• Consider the consistency of this 
decision with similar past 
decisions, and assess whether 
taking this decision could 
impact future decisions 
 
The Benefit Risk Action Team (BRAT) under the auspices of the Pharmaceutical 
Research and Manufacturers of America (PhRMA) developed a 6-step framework 
(Noel et al, 2012; Coplan et al, 2011). The BRAT Framework (Table 4.7) is a set of 
flexible processes and tools that provides a structured approach to pharmaceutical 
benefit–risk decision-making in drug development and in the post-approval setting. It 
consists of six steps that produce representations of key trade-offs, with appropriate 
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documentation of the rationale for decisions and the assumptions made in their 
development. 
 
Table 4.7 PhRMA’s Benefit-risk Action Team (BRAT) Framework 
 Steps Actions 
1 Define the 
decision context 
• Define drug, dose, formulation, indication, patient 
population, comparator(s), time horizon for outcomes, 
perspective of the decision makers (regulator, sponsor, 
patient, or physician) 
2 Identify 
outcomes 
• Select all important outcomes and create the initial value 
tree 
• Define a preliminary set of outcomes measures/endpoints 
for each outcome 
• Document rationale for outcomes included/excluded 
3 Identify and 
extract source 
data 
• Determine and document all data sources (e.g. clinical 
trials, observational studies) 
• Extract all relevant data for the data source table, 
including detailed references and any annotations, to help 
the subsequent interpretations create summary measures 
4 Customise the 
framework 
• Modify the value tree on the basis of further review of the 
data and clinical expertise 
• Refine the outcomes measures/endpoints 
• May include tuning of outcomes not considered relevant 
to a particular benefit-risk assessment or that vary in 
relevance by stakeholder 
5 Assess outcome 
importance 
• Apply or assess any ranking or weighting of outcome 
importance to decision makers or other stakeholders 
6 Display and 
interpret key 
benefit-risk 
metrics 
• Summarise source data in tabular and graphical displays 
to aid review and interpretation 
• Challenge summary metrics, review source data and 
identify and fill any information gaps 
• Interpret summary information 
 
This framework was developed to address the differences in information on benefits 
and risks between regulatory agencies and companies to communicate these views 
to patients and healthcare professionals and results in the transparency of the 
decision-making process. The BRAT Framework is guided by a number of principles: 
a systematic approach to defining the decision context and outcomes needed, the 
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documentation of all key underlying assumptions, including the rationale for the 
exclusion of particular outcomes or data sources from the assessment, the 
transparency of the sources/information underlying all the measures appearing in the 
summary, the flexibility to accommodate differing technical benefit–risk 
methodologies and perspectives and the use of clear and flexible visual displays to 
simplify understanding and communicate complex trade-offs.  
 
The last framework reviewed was developed by Novo Nordisk and is an interactive 
process based on the experience gained from working with several different 
medicines. This process can extract information from clinical trials, which are 
otherwise not captured by statistics. The method, called the Benefit Risk Assessment 
in New and old drugs (BRAIN, Figure 4.3), consists of eight steps (CMR, 2010). 
 
Figure 4.3 The BRAIN framework by Novo Nordisk 
 
 
 
In profiling the decision context, the aims, goals, expectations and relevant 
information to support the benefit-risk assessment are identified. For defining the 
disease profile, this includes the identification of benefit and risk criteria that 
characterise the disease. For the most important criteria selected within the given 
decision context, justifications are provided and the decisions can be tracked. 
Weighting and scoring are then applied to these criteria and an evaluation of the 
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evidence is conducted by assessing the strength of the evidence. Weighted scores 
are computed by multiplying the weights and scores and these are visualised through 
a Tornado-like diagram. An overall conclusion and recommendation is then provided 
with any uncertainties and its impact described. Unexpected issues are included and 
strategies for further studies are also presented.  
 
The steps of the various frameworks are tabulated and common process elements 
identified. It was found that at a higher level of categorisation of the tasks involved, 
four common core elements (Table 4.8) were identified:  
a. Framing the decision 
b. Identifying benefits and risks 
c. Assessing the benefits and risks 
d. Interpretation and recommendation 
 
As there were no observed differences among the frameworks, a harmonised 
framework could possibly be constructed to incorporate all the elements included in 
the other frameworks. It appeared that the CIRS 7-step framework closely 
represented the common essential activities and this was selected for revision. It was 
thus amended to reflect the core elements above and provide a unified standardised 
framework that would meet the requirements of the US FDA, EMA, the two 
frameworks developed by the industry (BRAT and BRAIN). The final universal 
benefit-risk framework (Figure 4.4) consisted of eight steps and the processes were 
essentially unchanged, with the addition of “Evaluating uncertainty” now as a specific 
step in the process.  
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Table 4.8 Comparisons of existing benefit-risk assessment frameworks 
Frameworks reviewed Core elements 
Framing the 
decision 
Identifying benefits and 
risks 
Assessing benefits and 
risks 
Interpretation and outcome 
US FDA Analysis of conditions 
and unmet medical 
needs 
Clinical benefits, risks Evidence and uncertainties   Conclusions and 
reasons, risk 
management plans 
EMA PrOACT-URL Nature and framing of 
the problem 
Objectives, favourable and 
unfavourable effects 
Alternatives 
regarding 
options to be 
evaluated and 
the 
consequences 
Trade-offs and 
benefit-risk 
balance 
Evaluating 
uncertainty 
Effects table 
and risk 
tolerance 
Consistency of 
decisions (linked 
decisions) 
The BRAT framework Define decision context Identify 
outcomes, 
extract source 
data: build value 
tree 
Customise 
framework: 
refine value tree 
Assess relative importance of 
different outcomes: weighting or 
ranking, other stakeholders 
Evaluating 
uncertainty 
Display and 
interpret key 
benefit-risk 
metrics and 
validate 
results 
Decision and 
communication of 
benefit-risk 
assessment 
Novo Nordisk BRAIN Decision context Disease profile Weighting Scoring Evidence 
evaluation 
Weighted 
scores 
Presentation Overall conclusion 
CIRS 7-step 
framework 
Decision context Building the 
value tree for all 
benefits and 
risks 
Rational for 
which benefits 
and risks to be 
included for 
benefit-risk 
assessment 
Weighting of 
benefits and 
risks 
Valuing or 
scoring of 
options 
 Visualisation Expert  judgment 
and risk 
management 
Universal benefit-risk 
framework 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 
Decision context Building the 
value tree 
Customising the 
value tree 
Weighting of 
benefits and 
risks 
Scoring the 
options 
Evaluating 
uncertainties 
Concise 
presentation 
of results 
(visualisation) 
Expert judgment 
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 Figure 4.4 The final 8-step universal benefit-risk framework for the assessment 
of benefits and risks of medicines 
 
 
 
This final universal benefit-risk assessment framework was developed with elements 
common to other existing frameworks and used by the two major regulatory agencies 
and the pharmaceutical companies. It is an overarching, internationally acceptable 
and standardised benefit-risk framework that will serve as the on-going platform for 
discussions around the development of novel, dynamic methodological tools to 
address the diverse needs of benefit-risk assessment throughout a product’s lifecycle 
by diverse stakeholders. 
 
The development of this version of the universal benefit-risk framework enhances the 
objectivity and transparency of the decision-making process by providing a structured 
and systematic approach that could be adopted by both regulatory agencies and 
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pharmaceutical companies. The process of decision-making would also now be both 
auditable and provide greater accountability. 
  
Part II - Development of the Benefit-Risk Template 
The importance of communication between companies and agencies is frequently 
highlighted. There is also a need for a better understanding of why different agencies 
come to different conclusions when faced with essentially the same application data. 
Improved transparency is required as both companies and agencies hold different 
skillsets and interpret efficacy and safety information differently. There is further 
pressure on agencies to increase transparency and accountability and to establish an 
appropriate documentation system for the basis of their decisions. It was therefore 
important to have a document that enables the effective communication of benefit-
risk information amongst stakeholders in addition to having a universal framework for 
the assessment of benefits and risks. The communication of risks without the 
communication of benefits may serve to undermine public discourse and for this 
purpose, a template was proposed to be used in accordance with the principles 
outlined in the universal framework. 
 
The Centre for Innovation in Regulatory Science had identified the need for a 
template to be used in conjunction with their 7-step framework for the assessment of 
benefits and risks. They searched for a guidance document for the assessment of 
benefits and risks of medicines, which led to the identification of the published 
reflection paper by EMA (EMA, 2008). In the absence of the principles and 
methodologies for benefit-risk assessment from other major regulatory authorities, 
there would be issues of consistency, transparency and communication of the 
outcomes of assessment and the basis of decisions. Hence EMA undertook the task 
of revising the CHMP assessment report templates and incorporating a structured list 
of benefit and risk criteria. 
 
In order to recognise demonstrated benefits, important results should be critically 
assessed and the unresolved issues or uncertainties be identified (Table 4.9). For the 
assessment of safety (Table 4.10), important non-clinical and clinical findings should 
be discussed with the background of potential pharmacokinetic and pharmaco 
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dynamic interactions, the potential for overdose or for abuse, as well as the misuse 
and off-label use of the medicine. The extent of the contribution to the risk should 
also be stated. 
 
Table 4.9 EMA criteria for assessing efficacy 
1. Efficacy (primary endpoint) versus comparator and its clinical relevance  
2. Magnitude of treatment effect  
3. Clinical relevance of the primary endpoints 
4. Statistical significance of the efficacy results 
5. Representiveness of the studied population for the population targeted in the label  
6. Discussion of dose  
7. Evidence for the efficacy in relative subgroups 
8. Design conduct and statistical adequacy of the trial 
9. Confirmation of treatment effect by results of non-primary endpoints 
10. Validation of scales and outcome measures 
11. Patient preferred outcomes  
12. Confirmation of efficacy by results of relevant non-pivotal trials and extensions 
13. Anticipated patient compliance (and patient convenience) 
14. Clustering (consistency) of results of the pivotal trials 
 
Table 4.10 EMA criteria for assessing harms 
1. Overall incidence of adverse effects (from clinical trials)  
2. Overall incidence of serious adverse effects (from clinical trials 
3. Discontinuation rate due to adverse effects (from clinical trials) 
4. Incidence, seriousness and duration of specific adverse effects (from clinical trials and post-
marketing surveillance)  
5. Interaction with other drugs and food  
6. Safety in subgroups (e.g. race and sex) 
7. Potential for off label use leading to safety hazards 
8. Potential for non-demonstrated additional risk due to limitations of clinical trials and/or short market 
exposure. 
9. Potential for non-demonstrated additional risk due to safety issues observed in pre-clinical safety 
studies but not in humans 
10. Potential for non-demonstrated additional risk due to safety issues observed with other medicines 
of the same pharmacological class 
 
In determining the benefit-risk balance (Table 4.11), EMA decided that this should be 
put in perspective regarding alternative therapies or interventions (where possible 
and relevant) and to conclude as to whether the benefit-risk balance is positive in the 
specified target population. The evaluation of the balance should also take into 
account the observed benefits and harms as well as the uncertainties and risks. The 
perspectives of different stakeholders should be taken into account in the 
assessment of the benefit-risk balance, in particular the perspectives of patients and 
prescribing physicians. 
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 Table 4.11 Criteria for assessing benefit-risk balance 
• Amount of evidence to characterise the benefit-risk balance: 
o Availability of comparative data and their limitations and potential deficiencies 
• Interpret key benefits and risks 
o from perspectives of different stakeholders, including patients and treating physicians 
• Level of risk acceptability 
o corresponding to the perceived degree of clinical benefit in the specific context 
• Relating the benefits to the risks when possible:  
o Using logical comparisons e.g. potential lives saved as a result of treatment 
compared to potential lives lost as a result of adverse reactions 
• Factors affecting the benefit-risk balance: 
o Situations that may alter the current balance e.g. different patient or disease 
characteristics 
• Sensitivity of the benefit-risk balance:  
o Discussion of the potential changes to the balance if the fundamental assumptions 
are to be amended 
• Other appropriate discussions:  
o Effectiveness of proposed treatment compared to available options 
o For negative benefit-risk balance, describe the potential harm incurred upon exposure 
for the claimed indication 
o Evolution of benefit-risk balance over time 
o Outstanding issues, submission or reports to address identified issues 
o Evaluation of pharmacovigilance plan, risk mitigation plan or other post-marketing 
commitments including need for further studies 
o Opinions from scientific experts, patients, consumers or advocates and other 
stakeholders in the benefit-risk assessments 
• Conclusion on the benefit-risk being positive or not for every claimed indication. 
*adapted from EMA reflection paper 
 
A workshop was conducted by CIRS to seek opinions on the use of the EMA’s 
criteria in the reflection paper and these were deemed appropriate in the absence of 
other authoritative guidance. Therefore, a developmental version of the template 
based on the criteria from the EMA reflection paper was produced by CIRS.  
 
The developmental version was in Microsoft Word format and was tested for 
functionality by the Consortium. This was carried out as a retrospective feasibility 
study between two pairs of agencies, with each pair testing the template on a 
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common product. Major amendments to the developmental version included the 
addition of an overall summary, inclusion of summaries of relevant non-clinical, 
quality and clinical findings and changes to the presentation of study results. Other 
changes were made at the suggestion of the Consortium to improve user 
experiences and included functional tabs at the top of each page and an active 
content page that linked directly to the corresponding sections of the template.  
 
The second version of the template was again subjected to evaluation by the 
Consortium. It was in an active PDF format to facilitate the user experience. This 
phase was conducted as a retrospective exercise using a product submitted for 
review to all four partner agencies. A new section 6 for visualisation was included at 
the suggestion of the Consortium, which would further align the template with the 
universal framework. There were no other major changes, and amendments were 
made to improve user experience (functional icons to print, email and view the 
template). Hence the final version of the template consisted of two sections, namely 
the “Proforma” and “Benefit-risk summary” (Table 4.12). The final template, namely 
the Benefit-Risk Template or BR Template, is attached as Appendix I. 
 
The potential use of the BR Template was reviewed as to whether this would be able 
to fulfil the core elements of the universal framework, namely framing the decision 
(section 1), identifying the benefits and risks (section 2 and 3), assessing benefits 
and risks (section 4), interpretation (section 5) and recommendations (section 6). In 
relating to the universal framework, this template fully supports these requirements 
(Table 4.13). 
 
Part III – Development of the user manual 
The need for a user manual and its contents was identified as a result of feedback 
from the Consortium users who evaluated the BR Template. The user manual 
consists of two sections, namely a glossary and the instructions for completing the 
template. Amendments were made (Table 4.14) based on the comments received 
after the circulation of the draft user manual to the Consortium and the final user 
manual is attached as Appendix II. 
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Table 4.12 Components of the Benefit-Risk Template for the assessment of 
benefits and risks of medicine 
Proforma Section 
Proforma section 1: Background 
Proforma section 2:  Overall summaries for 
o Quality 
o Non-clinical 
o Human pharmacology 
o Clinical 
Proforma section 3:  Identified benefits and risks together with the main 
reason for inclusion or exclusion 
Proforma section 4:  Benefits and risks – study information 
Proforma section 5: Benefit-risk summary table and expert judgement 
including weighting and valuing 
Proforma section 6: Visualisation 
Proforma section 7:         Benefit-risk conclusions 
Benefit-risk Summary Section 
Summary 1: Benefit-risk conclusion 
Summary 2: Decision context 
Summary 3: Identified benefits and risks 
Summary 4: Benefit-risk: Weighting and valuing 
Summary 5: Benefit-risk management. 
 
Table 4.13 The BR Template supporting the universal framework 
 Core elements 
Framing the 
decision 
Identifying benefits 
and risks 
Assessing benefits and risks Interpretation and 
outcome 
Universal 
benefit-risk 
framework 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 
Decision 
context 
Building 
the 
value 
tree 
Customising 
the value 
tree 
Weighting 
of benefits 
and risks 
Scoring 
the 
options 
Evaluating 
uncertainties 
Concise 
presentation of 
results 
(visualisation) 
Expert 
judgment 
Template: 
Proforma 
section 
Section 1: 
Background 
Section 3: Identified 
benefits and risks 
Section 4: Benefits and risks – study 
information 
Section 5: Benefit-risk 
summary table and expert 
judgment including 
weighting and valuing 
Section 2: 
Overall 
summaries 
 Section 5: Benefit-risk summary table 
and expert judgment including 
weighting and valuing 
Section 6: Visualisation 
Section 7: Benefit-risk 
conclusions 
Template: 
Summary 
section 
   Benefit-risk summary 
section 
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Table 4.14 History of changes leading to the final list of definitions for commonly used terms 
Term Draft Definition Revised Definition Comments 
Adverse event  An effect seen to be disadvantageous 
or worsening the current state of 
health, observed during the clinical 
studies 
Also known as Adverse experience, it is any untoward medical 
occurrence in a patient or clinical investigation subject administered 
a pharmaceutical product and which does not necessarily have to 
have a causal relationship with this treatment. 
Adapted from 
ICH Harmonised 
Tripartite 
Guideline. E2A 
Adverse 
reaction/effect 
An effect seen to be disadvantageous 
or worsening the current state of 
health, potentially or confirmed to be 
from the exposure to the Product 
during the clinical studies 
In the pre-approval setting when the therapeutic dose(s) may not be 
established, it is all noxious and unintended responses to a 
medicinal product related to any dose should be considered adverse 
drug reactions. 
For marketed medicinal products, it refers to a response to a drug 
which is noxious and unintended and which occurs at doses 
normally used in man for prophylaxis, diagnosis, or therapy of 
disease or for modification of physiological function. 
Adapted from 
ICH Harmonised 
Tripartite 
Guideline. E2A 
Comparator - An investigational or marketed product (i.e. active control) used as 
a reference in a clinical trial. 
 
Risk Also known as harm, a potential 
unfavourable effect alluding to 
adverse reactions/effects resulting 
from exposure to the Product 
Also known as harm, an unfavourable effect or adverse 
reactions/effects on patients’ health, public health or the 
environment resulting from exposure to the Product 
Adapted from 
European 
Medicines 
Agency (EMA). 
Seriousness (of 
adverse 
event/reaction/effect) 
- A serious adverse event (experience) or reaction is any untoward 
medical occurrence that at any dose:  
• results in death,  
• is life-threatening (at risk of death at the time of the event) 
• requires inpatient hospitalisation or prolongation of existing 
hospitalisation,  
• results in persistent or significant disability/incapacity, or  
is a congenital anomaly/birth defect. 
Adapted from 
ICH Harmonised 
Tripartite 
Guideline. E2A 
Severity (of adverse 
event/reaction/effect) 
- The intensity of a specific adverse event which may or may not be 
of medical significance or seriousness, which is defined by a set of 
criteria. 
Adapted from 
ICH Harmonised 
Tripartite 
Guideline. E2A 
Submission An application sent for review to the 
regulatory authorities by the 
Company, for the market authorization 
of the claim indications of the Product 
An application sent for review to the regulatory authorities by the 
Company, for the market authorization of the proposed indications 
of the Product 
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DISCUSSION 
The development of the universal framework for the assessment of the benefits and 
risks of medicines was an outcome of reviewing existing frameworks as used by 
regulatory agencies and pharmaceutical companies. Through standardisation, the 
essential components of each framework were preserved and this would facilitate the 
uptake of the universal framework. Whilst the experience with the existing 
frameworks was confined to each region or company, this universal framework aims 
to remove this restriction and be a common global template. As concluded by Noel et 
al (2012), there is a need for a standardised approach that is broadly accepted and 
utilised by regulators.  The universal framework was developed with the inputs from 
various regulators and companies, while the use of the template and user manual 
were reviewed by the four agencies (Consortium) spanning the globe. Thus the 
Benefit-Risk Assessment Support System (BRASS) now stands as the complete 
package for the assessment of benefits and risks of medicines during the regulatory 
review. 
 
The main aim of BRASS is to enhance the transparency of decision-making through 
comprehensive documentation and a universal framework for assessing medicinal 
products, allowing the audit of the decision-making process. However, caution must 
be applied to the degree of transparency. Differing jurisdictions may not allow the 
same degree of transparency as this is not supported by the individual country’s 
legislation. Such openness may also subject the companies and agencies to 
immediate public scrutiny of their governance and competence, which therefore must 
be in place before any attempt to fully publicise their decision-making processes. 
Indeed, such differences in jurisdictions may also hamper the implementation of a 
universal framework.  
 
It is ideal to be able to incorporate all stakeholders’ perspectives into the framework. 
However, it should be recognised that due caution is required to retrieve relevant 
comments that would contribute to the assessment of benefit-risk balance. Patients, 
advocacies and representatives may be often biased in the interest of their pursuit. 
Similarly, physicians may only be able to provide a perspective relevant to their 
practice. The framework and template on their own are not able to discern the 
intrinsic significance of the values provided and require the regulators to be able to 
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apply clinical judgment at the conclusion of the assessment. Clinical judgment is a 
cumulation of education and experience which might not be achieved by BRASS.  
 
This universal framework for the assessment of benefits and risks has yet to address 
the notion of evolving the model towards a quantitative methodology (Phillips et al, 
2011). The exercise of assigning relative importance can be carried out using valuing 
and weighting, which imparts a fundamental objective and transparent perspective 
for decision-making (Walker et al, 2011). However, the concept behind this exercise 
is not apparent to most (Mt-Isa et al, 2011). The BRASS package now consists of a 
framework that is flexible and is able to accommodate various existing methodologies 
utilised by companies and agencies. This alludes to the current situation where there 
is no agreement on the methodologies considered acceptable or commonly applied 
in assessment. More research is required to further the understanding and 
application of weightings and identification and consensus of assessment 
methodologies.  
 
The Consortium thus far has had the most experience in evaluating the template. 
Though they could understand the potential advantages of implementing BRASS, 
there are barriers to achieving this. The implementation may result in a major change 
in work processes and retraining of personnel, which the agencies might not be able 
to accommodate. It appears that there may be differing opinions between higher 
management and staff personnel, resulting in a disagreement on the need and 
approach to implement this framework. As various agencies have diverse agendas 
and priorities, to implement BRASS globally may be challenged by a long timeline as 
each make arrangements at different rates to accommodate this framework. The 
members of the Consortium were also challenged to decide if the template should 
replace their current report templates or to be incorporated into existing ones. 
 
The BRASS package is only as relevant as the science behind its development. It is 
essential that continued work be provided to ensure the relevance and currency of 
the concept and tools as well as meeting the expectations of the stakeholders. This 
will require the continuous involvement of the stakeholders and efforts must be 
maintained to retain their on-going contributions. Hence, BRASS should be seen as 
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the initiation of a universal framework, to which companies and agencies would 
convene for further development and implementation. 
 
CONCLUSION 
The development of the Benefit-Risk Assessment Support System confers a 
universal applicability and the current package enhances the transparency of 
decision-making through improving its consistency and objectivity. Greater 
accountability and governance is also achieved through a structured documentation 
offered by the benefit-risk template. Finally it facilitates the review of past decisions 
within an organisation and also among different organisations, helping to understand 
the rationale for any observed differences in regulatory outcomes.  
 
SUMMARY 
• Comparison of the existing benefit-risk assessment frameworks identified 
common elements and no differences 
• A universal framework is now developed to encompass the existing frameworks 
• A template for documenting the benefit-risk decision and its accompanying user 
manual has also been developed. 
• A pilot study was conducted with four regulatory agencies to investigate the 
feasibility of the framework, template and user manual. 
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CHAPTER 5 
 
 
 
 
 
Evaluation of the benefit-risk template by 
regulatory agencies – A prospective study 
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INTRODUCTION 
The current climate in regulatory science seeks transparency of decision-making and 
communication to stakeholders for accountability. The results from Chapter 3 showed 
that both regulatory agencies and pharmaceutical companies believe that a benefit–
risk framework would enhance the quality (transparency and consistency) of 
decision-making, provide documentation for a systematic, structured discussion and 
act as a tool for communication. A tool was thus developed (Chapter 4) with inputs 
from the Consortium (consisting of TGA, Health Canada, SwissMedic and HSA) and 
the resulting universal Benefit-Risk (BR) Template was designed to enhance 
communication and documentation of benefit-risk decisions. This study aims to 
review the potential value of the BR Template for regulatory agencies.  
 
OBJECTIVES 
The objectives are to: 
• Examine the value of the BR Template for documenting the benefit-risk 
assessment decision of new active substances during the review process,  
• Evaluate the BR Template as a tool to communicate the benefit-risk decision to 
other stakeholders in a systematic, structured manner, 
• Determine if the BR Summary section of the BR Template is adequate as a 
stand-alone tool to communicate a benefit-risk decision to stakeholders  
 
METHODS 
TGA, Health Canada and HSA agreed to participate in this prospective study which 
was conducted as non-comparative evaluation. The study package, consisting of the 
BR Template (which included the Benefit-risk Summary section) and User Manual 
described in Chapter 4 were sent to the three agencies. The reviewers in the 
respective agencies selected a product undergoing active evaluation, and completed 
their own assessment report as well as the BR Template. Following this process, the 
reviewers were sent a study evaluation tool (Figure 5.1), which they completed and 
returned.  
 
 112 
The study evaluation tool was developed as a questionnaire consisting of 56 
questions divided into four sections, namely user-friendliness, documentation, 
applicability and general comments.  There were three systems of rating: 
• Excellent, Good, Fair and Poor (comments to be provided for ratings of “Fair” and 
“Poor”) 
• Fit for purpose, Fit for purpose with modifications required, Not fit for purpose 
(comments to be provided for the latter two choices) 
• Yes and No (comments to be provided for rating “No”) 
 
Most of the questions had an open field for comments, allowing the participants to 
provide any issues of concern or relevant points that were not addressed by the 
questionnaire. The questionnaires were sent via email directly to the participants. 
Completed responses were received via email, as instructed to the participants. All 
responses were collated into a single group and outcomes were presented according 
to their respective sections in the study evaluation tool. All data were expressed as 
direct ratings provided by the responders. Free-text comments were collated and 
presented in appropriate categories. 
 
This was designed as an exploratory study and the outcomes were interpreted to 
provide qualitative inferences relating to the objectives. No statistical analyses were 
planned or conducted. 
 
RESULTS 
The outcomes will be presented in four parts: 
• Part I – User-friendliness of the BR Template 
• Part II – Appropriateness (fit for purpose) of the documentation 
• Part III – Applicability of the BR Template 
• Part IV – Usefulness of the BR Template 
 
None of the agencies used visualisations and hence no outcomes were documented 
for these items in the survey tools. 
 113 
  
 
 
 
 
 
 
 
 
 
Figure 5.1 The study evaluation tool 
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Part I – User-friendliness of the BR Template 
The BR template has three features that assist the user in locating selected pages 
within the document, namely the tabs at the top of each page, the “Go to page” 
button and the page thumbnails (Figure 5.2).  
 
Figure 5.2 Navigation functions of the BR Template 
 
 
Click on thumbnail 
icon for the desired 
page 
Click on button 
for the desired 
section 
Click on tab for 
the desired 
section 
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The thumbnails were not used while the tabs and “Go to page” buttons were rated 
either good or excellent (Table 5.1). The agencies suggested that the use of 
bookmarks for the sections and subsections would be preferable, as well as a search 
function for identifying key words within the document. 
 
Table 5.1 Practicality of the navigation functions 
Agency Tabs at top of page "Go to page" button page thumbnails 
TGA Excellent Excellent Did not use 
Health 
Canada 
Good Good Did not use 
HSA Good Good Did not use 
 
In addition to navigation features, the BR Template incorporates four functions to 
print, email, view the form (Figure 5.3) and auto-populate information for fields 
requiring the same inputs (Figure 5.4).  
 
Figure 5.3 Document support functions of the BR Template 
 
 
Figure 5.4 Auto-populate function of the BR Template 
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Conclusion on the usefulness of the print, email and view functions were not provided 
as TGA did not use the former two functions, Health Canada experienced a technical 
issue that prevented them from getting back to the document after using these three 
functions while HSA rated these support functions as good. However, the auto-
population function was considered useful by all, being rated as good or fair (Table 
5.2). 
 
Table 5.2 Usefulness of the document support functions 
Agency Print function Email function 
View full form 
function 
Auto-populate 
function 
TGA Did not use Did not use Excellent Good 
Health 
Canada 
Poor Poor Poor Fair 
HSA  Good Good  Good  Good  
 
The User Manual was provided as a guide to help the reviewer in completing the BR 
Template and included a glossary of commonly used terms. TGA and HSA rated the 
manual as good or fair in terms of clarity, comprehensiveness and applicability (Table 
5.3). Overall, the agencies believed more details are needed e.g. case studies and 
examples to improve the usefulness of the User Manual. Health Canada would like to 
have more guidance regarding the intention of the BR Template, level of details of 
the outcomes and the type of information required. HSA commented on the need for 
examples to show how weighting and valuing may be carried out as this concept is 
new to the agency. 
 
Table 5.3 Appropriateness of the User Manual 
Agency Clarity of instructions Comprehensiveness Applicability 
TGA Good Fair Good 
Health 
Canada 
Poor Poor (Not reported) 
HSA  Good Good  Good  
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Other comments received on enhancing the technical aspects of the template 
include: 
• Allow changes in fonts (e.g., size, underlining, italicizing), use of bulleted listings 
within text boxes, use of the tab key within a cell in the tables 
• Allow for the use of the tools for commenting and marking-up (highlighting and 
cross-out functions) in Adobe Acrobat Professional as these would be  useful for 
supervisors or managers recommending revisions to the document 
• Ensure that the text copied and pasted from a Word document retains the 
original formatting (underlining, italicizing, symbols) 
 
Part II – Appropriateness (fit for purpose) of the documentation 
The BR Template incorporates five conclusions that are considered important in 
making a benefit-risk decision, namely the background (decision context) and quality, 
non-clinical, human pharmacology and clinical conclusions. Of the five, the agencies 
believed the clinical conclusion is fit for this purpose (Table 5.4). For the remaining 
four, the template could allow for more details as the actual benefit-risk assessment 
was carried out in much greater depth and the sections may not accommodate such 
a level of information.  
 
Table 5.4 Documentation of relevant information supporting the benefit-risk 
decision 
Agency 
Background 
information  
Quality 
conclusion 
Non-
clinical 
conclusion  
Human 
pharmacology 
conclusion  
Clinical 
conclusion  
TGA Fit for purpose 
Modifications 
required 
Modifications 
required 
Modifications 
required 
Fit for purpose 
Health 
Canada 
Fit for purpose 
Modifications 
required 
Modifications 
required 
Modifications 
required 
Fit for purpose 
HSA 
 Modifications 
required 
Fit for 
purpose  
Fit for 
purpose 
Fit for purpose Fit for purpose 
 
Health Canada commented that these were the only sections to discuss the 
contributions from quality, non-clinical and human pharmacology in the entire 
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template whereas the rest of the template is dedicated to clinical benefits and risks. 
However, Health Canada believed that if the intention of the BR Template was to 
feature only a high-level summary of the significant findings, then it would suffice. It 
was mentioned that a considerable amount of evaluation was conducted for those 
aspects for a new active substance and that this section would not be able to 
accommodate these findings. Without allowing the reviewer to provide details on the 
relevant studies, it would be difficult to explain the relevance of the reported issues 
and concerns. For completeness, TGA recommended the inclusion of sub-headings 
for pharmacokinetics, pharmacodynamics and drug interactions to further guide the 
reviewer. HSA preferred the background information to allow a discussion on related 
applications and products that may contribute to decision-making. 
 
It should be noted that the BR Template was designed to present and communicate 
only the significant findings that would affect the benefit-risk decision and that the 
corresponding details would be expected to be available from the original 
assessment report for the product. 
 
The template was seen by the agencies as being able to document benefits and risks 
identified by sponsors and the reasons for including or excluding them (Table 5.5).  
 
Table 5.5 Documentation of benefits and risks 
 Benefits Risks 
Agency 
Reasons 
for 
inclusion 
or 
exclusion 
of all 
benefits 
Relevant 
benefits as 
identified by 
sponsor 
Selected list 
of benefits to 
be included 
in the benefit-
risk 
assessment 
Reasons 
for 
inclusion 
or 
exclusion 
of all risks 
Relevant 
risks as 
identified 
by 
sponsor 
Selected list of 
risks to be 
included in the 
benefit-risk 
assessment 
TGA Fit for 
purpose 
Fit for purpose Fit for purpose 
Fit for 
purpose 
Not fit for 
purpose 
Fit for purpose 
Health 
Canada 
Fit for 
purpose 
Modifications 
required 
Not fit 
Fit for 
purpose 
Not fit for 
purpose 
Fit for purpose 
HSA 
Fit for 
purpose 
Fit for purpose Fit for purpose Fit for 
purpose 
Fit for 
purpose 
Fit for purpose 
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However, several concerns were raised for the listing of selected benefits by 
agencies to be included for benefit-risk assessment although TGA and HSA thought 
this section fit for purpose. It appeared to Health Canada that only benefits supported 
by statistics from clinical studies were allowed, as only the selected benefits would be 
discussed in further details in the template. Health Canada thought that only those 
benefits that were supported by a primary endpoint of the clinical studies should be 
considered. Thus, for benefits that were not quantifiable, such as advantages in the 
route of administration and dosing regimen, these could not be represented although 
they are taken into account by the reviewer.  
 
While the BR Template mostly accommodates the input of outcomes of clinical 
studies (which are the basis of the majority of product applications), other relevant 
benefits, either not quantifiable or intangible, may be further discussed in the 
template. In documenting the study outcomes, the BR Template allows for the factual 
representation of the values from the clinical studies with no bias towards positive or 
negative data. 
 
Although Health Canada stated that it was not clear if negative outcomes should be 
documented during this listing exercise, it should be clarified that this section was 
meant to highlight the benefits on which the benefit-risk assessment would be 
focused. The negative outcomes for these benefits would have been apparent in the 
section for study outcomes and during further concluding discussions.  
 
With regards to risk, both TGA and Health Canada believed that the template would 
not be able to effectively document all the risks identified by sponsors (Table 5.5) as 
they generally play down the risks. Unless the sponsor was specifically requested to 
provide a list of risks or potential risks, this section would not be reliable and 
therefore less useful.  
 
As only the selected risks are further discussed in details in the template, Health 
Canada believe that there are safety concerns that are taken into consideration but 
may not be documented. The scenarios may include those AEs for which a strong 
causality was not proved or where there was not a documented incidence of the 
defined AE in the clinical studies. The current set-up in the BR Template documents 
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only AEs with incidence rates and hence for those AEs not based on this 
measurement (for example significant changes in blood components), these could 
not be captured. In addition, Health Canada also sought for greater clarity in the 
definition of risks, in terms of nomenclature or categorisation. It was however noted 
that HSA found the template adequate in all aspects of documenting benefits and 
risks. 
 
For selected benefits and risks, the BR Template allowed the assignment of weights 
(relative importance) and values to demonstrate the contributing factors to the 
benefit-risk balance. Divergent views were received on the effectiveness of such 
documentation (Table 5.6). TGA believed that as long as the reviewer understood the 
concept of weighting, the template would fulfil this purpose. Health Canada rated the 
template as being “not fit” for purpose in this aspect and commented that it was 
unclear regarding the need to indicate the relative importance of benefits and risks, 
since those of little significance need not be discussed. Moreover, this exercise of 
providing values was replicated in another section when presenting study outcomes. 
  
Table 5.6 Documentation of weights and values 
Agency 
Contribution of 
weighting/relative 
importance of 
benefits  
Contribution of 
values of 
benefits from 
the studies 
Contribution of 
weighting/relative 
importance of risks  
Contribution of 
values of risks 
from the studies  
TGA 
Modifications 
required 
Fit for purpose 
Modifications 
required 
Fit for purpose 
Health 
Canada 
Not fit for purpose 
Not fit for 
purpose 
Not fit for purpose Not fit for purpose 
HSA Fit for purpose Fit for purpose Fit for purpose Fit for purpose 
 
While Health Canada thought this entire section for documenting weights and values 
was redundant, it should be highlighted that the BR Template referenced the 
principles of assessing benefits, risks and benefit-risk balance from the published 
reflection paper by EMA (EMA, 2008). Therefore, it has been designed specifically to 
document the considerations taken by the reviewer or regulatory agency for the 
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benefit-risk decision. If there is an explicit listing and the priorities identified for each 
of the benefits and risks, then there is the possibility of greater transparency in the 
exchange of information leading to improved communication. However, HSA 
believed that the BR Template was able to sufficiently document the contribution of 
both weights and values for benefits and risks.  
 
In documenting study outcomes, both TGA and HSA commented that the template 
would require modification before it would be fit for this purpose (Table 5.7). Health 
Canada indicated that since only numerical values are required, the completion of 
these tables would not effectively document conclusions. In addition, when the 
reviewer was requested to record the presence of benefits in patients receiving a 
placebo, Health Canada noted that this would be difficult since there was no 
opportunity to define when the benefits are present in the placebo group. HSA 
questioned whether the presence of benefits was dependent on statistical 
significance, clinical relevance or a combination of both. In addition, for situations 
where there is only one study, no comparisons can be drawn and hence it cannot be 
concluded if the benefit is present or absent. For such cases, HSA recommended to 
include a new option of “Not conclusive”. TGA would like to document the differences 
in benefits seen when the product is compared to other approved medicines. This 
would also be meaningful for other stakeholders who can make better informed 
decisions based on this information. In documenting compliance rates, TGA also 
suggested that completion rates and withdrawals should be provided.  
 
In documenting information relevant to benefits, Health Canada recommended the 
inclusion of subgroup analyses, which although often exploratory, can provide 
supporting information in terms of showing the benefit in relevant subgroups. 
Similarly, the inclusion of patient reported outcomes might also contribute in a limited 
way to the overall assessment of benefits. HSA commented that a new option of “Not 
applicable” be provided for situations where there is only one study and no other 
contributing information. Overall, the template can adequately document relevant 
information relating to benefits with the minor amendments as highlighted above by 
the agencies. 
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Table 5.7 Documentation of study outcomes, safety information and overall conclusion 
 BR Template 
Benefit-risk 
Summary 
Agency 
Outcomes and 
conclusions of 
studies 
Contribution of 
other 
information 
relevant to 
benefits 
Overall 
summary of 
incidence of 
adverse 
events/effects 
Overall 
incidence of 
adverse 
effects 
Information 
relevant to 
identified risks 
Contribution 
of 
uncertainties 
relevant to 
the benefits 
and risks 
Relevant 
information to 
draw conclusion 
regarding the 
recommendation 
Benefit-risk 
summary 
presented 
information in a 
structured 
systematic 
manner that led to 
benefit-risk 
decision 
TGA 
Modifications 
required 
Fit Fit 
Modifications 
required 
Fit Fit 
Modifications 
required 
Not fit 
Health 
Canada 
Not fit 
Modifications 
required 
Not fit Not fit 
Modifications 
required 
Fit Not fit Not fit 
HSA 
Modifications 
required 
Modifications 
required 
 Fit 
Modifications 
required 
Not fit Fit 
Modifications 
required 
Fit 
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Health Canada recommended the inclusion of overall summary tables for serious 
AEs and AEs leading to discontinuation and to allow for the option of summarizing 
such information as text. HSA preferred the flexibility of being able to upload different 
common formats in addition to those currently allowed.  As the summary was based 
on the overall safety data, any potential differences that occurred in individual studies 
would not be documented, but would likely be considered in the overall benefit-risk 
assessment. Likewise, the input of values of AEs without other relevant information 
reduced the importance of this documentation, especially for deaths, where a 
discussion on the causes and temporal relationship would usually be carried out. It 
also appeared that the BR Template did not clarify the details to be provided, as 
there would be meaningful and deeper discussion on the comparisons of the type 
and frequencies of reported AEs, which would also include an evaluation of 
information at individual patient level. In the BR Template, the term “Adverse events” 
was used and the general discussion on safety information led Health Canada to the 
opinion that an examination of the safety impact was irrespective of drug exposure. It 
would be more meaningful and important to assess adverse reactions for causality 
and association. HSA felt that amidst the numerous details that would be required in 
the template, there was a lack of focus and it would be difficult to understand the 
contribution in justifying the final benefit-risk decision. 
 
All the agencies thought that the BR Template can effectively document uncertainties 
relating to the benefits and risks, but also agreed that currently the template is not 
suitable for documenting the relevant information leading to a conclusion or a 
recommendation. TGA commented on their lack of experience in the weighting and 
valuing and the assimilation of such outcomes into the benefit-risk conclusion. They 
thought that a quantitative approach of allocating of score or rank to the final 
outcome as part of the template would be expected, which may also include affirming 
these decisions as favourable or unfavourable, or a statement on the evidential 
strength of the final benefit-risk outcome. HSA, on the other hand, believed that the 
summary section is suitable for this purpose. 
 
In the development of the BR Template, the current environment and practice of 
regulatory agencies were taken into consideration. As most were still employing a 
qualitative or semi-quantitative approach in their assessment of benefits and risks, 
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the BR Template was designed to accommodate this approach but not the 
quantitative exercise of allocating a final score to the outcomes.  
 
Health Canada alluded to the fact that there were other factors like practice 
guidelines, legislation and precedents which should be taken into consideration, but 
the BR Template appeared not to capture these contributing factors. Other identified 
factors would include the benefits and risks associated with a proposed route of 
administration or dosing regimen, judgement calls and decisions from other 
regulatory agencies. However, the BR Template, in the sections for the concluding 
discussion, allow for the input of other significant factors otherwise not presented in 
the earlier parts of the template. Health Canada also highlighted an important point 
that there was less emphasis on the final recommended indication than the proposed 
indication and that there was no specific section to discuss the reasons for any 
amendments to the proposed indication, dosing or critical changes to the package 
inserts. This opinion was similarly shared by HSA. 
 
Both TGA and Health Canada agreed that the Benefit-risk Summary section was not 
suitable in presenting information in a structured systematic manner that led to a 
benefit-risk decision. As for the entire BR Template, TGA noted that a conclusive 
statement on the outcome of the review of weights and values should be included in 
the Benefit-risk Summary section which would drive the recommendation to accept or 
reject the proposed application. No reasons were provided by Health Canada for 
their negative opinion. These views are aligned to the ratings of both TGA and Health 
Canada regarding their unwillingness to share the BR Template and Benefit-risk 
Summary section with other stakeholders. 
 
Part III – Applicability of BR Template 
Divergent views were received on the usefulness of the BR Template (Table 5.8). 
Both TGA and HSA have generally positive opinion of the applicability of the BR 
Template. TGA believed the template had good utility to document the benefits and 
risks, but more details would be required to further support the conclusions. Health 
Canada rated the template as “not fit” for this purpose as it was not able to capture all 
of the factors in regulatory decision-making. Their reasons that the BR Template was 
not suitable for documenting relevant information have been discussed above. 
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Table 5.8 Applicability of the BR Template 
Agency Contributing to 
regulatory 
decision-making 
Ensuring 
consistency in 
standard of 
assessing 
benefits and 
risks of 
medicines 
Enhancing the 
transparency of 
decision-making 
Promoting 
effective 
communication 
to stakeholders 
Achieving 
consistency of 
decisions 
between 
regulatory 
agencies 
An advantage 
over the current 
systems in the 
organisation 
TGA Fair Good Good Good Good Excellent 
Health 
Canada 
Poor Poor Poor Poor Poor Poor 
HSA  Good Good  Good  Good  Fair  Fair  
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Therefore, Health Canada could not confirm its contribution to decision-making and 
standards in assessing benefits, risks and uncertainties. However, Health Canada 
noted that the BR Template was able to achieve consistency in assessing benefits 
and risks and was able to document this information. 
 
Regarding the ability of the BR Template to improve transparency and 
communication, Health Canada stated that the template was neither able to capture 
critical thinking, nor other significant contributing factors such as the additional 
analyses that the reviewers requested from sponsors. It is therefore believed that if 
clarification were to be provided on the existing availability of appropriate sections in 
the BR Template to discuss these other contributing factors, Health Canada may 
accept the template as having adequate applicability. 
 
It was also not clear to Health Canada how the template would contribute to 
achieving consistency in decisions between regulatory agencies, when the decision 
could be affected by other factors such as the subjective interpretation by a reviewer, 
precedent decisions made for medicines in the same therapeutic class and clinical 
practices. Similarly, HSA clarified that, with the understanding that regulatory 
decisions were dependent on individual jurisdictions, the template would suffice if the 
intention is to compare the basis of the decision between agencies. Although Health 
Canada commented that they did not find that the template had an advantage over 
their current system, they noted the value of the BR Template over their Summary 
Basis of Decision (SBD) regarding the inclusion of a section dedicated to discussing 
uncertainties, as this was noted to improve transparency. HSA mentioned that most 
of the information required was already in the existing evaluation report, leading to 
duplication of work. Moreover, the BR Template could not replace the existing 
assessment report as detailed information on the studies would need to be 
documented. 
 
Both TGA and Health Canada agencies expressed their willingness only to share the 
completed BR Summary Template under the covering of confidentiality and 
memorandums of understanding with the receiving stakeholders. As such, their 
current circumstances do not allow them to share the completed BR Template (Table 
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5.9). HSA would be willing to share with other stakeholders except patients and the 
media, as they believed that the contents might be too technical in nature to allow a 
meaningful and clear understanding. 
 
Table 5.9 Willingness to share the entire BR Template with various 
stakeholders 
Agency Healthcare 
professionals 
Health 
technologies 
assessment 
agencies 
(HTA) 
Patients/ 
patient 
advocacy 
groups 
Other 
regulatory 
agencies 
Media/ 
public 
domain 
Academia 
TGA No No No No No No 
Health 
Canada 
No Yes 
(Not 
reported) 
Yes 
(Not 
reported) 
(Not 
reported) 
HSA  Yes Yes  No  Yes  No  Yes  
 
 
For the same reason regarding the template, both TGA and Health Canada could not 
share the completed Benefit-risk Summary section (Table 5.10). Given the correct 
circumstances, TGA would consider sharing with healthcare professionals, HTA 
agencies, other regulators and academia if the additional details to support the 
benefits and risks could be provided in the summary. In addition, they commented 
that patients and media might benefit from this summary as it would be easier for 
them to understand. However, HSA again would exclude sharing with patients and 
the media as the contents might be too technical. 
 
Although, Health Canada believed the current summary would not be suitable for 
sharing, they commented that the Benefit-risk Summary section was more complete 
than their current report format (Summary Basis of Decision). Again, they mentioned 
that the Benefit-risk Summary section did not capture the significant contributing 
factors which were previously mentioned as the reasons not sharing the BR 
Template.  
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Table 5.10 Willingness to share the BR Summary section with various 
stakeholders 
Agency Healthcare 
professionals 
Health 
technologies 
assessment 
agencies 
(HTA) 
Patients/ 
patient 
advocacy 
groups 
Other 
regulatory 
agencies 
Media/ 
public 
domain 
Academia 
TGA No No No No No No 
Health 
Canada 
No No No No No No 
HSA  Yes Yes  No  Yes  No  Yes  
 
Part IV – Usefulness of the BR Template 
All the agencies rated the BR template as fair or good with regard to ensuring 
consistency in decision-making through improving regulatory memory. In addition, it 
can act as an audit tool and contribute to post-marketing activities (Table 5.11).  
 
Table 5.11 Usefulness of BR Template in ensuring consistency, auditing and in 
post-marketing activities 
Agency Improving regulatory 
memory and enabling 
documentation of 
previous decisions to 
ensure consistency in 
decision-making 
Contributing as an 
audit tool 
Contributing to post-
marketing activities 
TGA Good Fair Fair 
Health 
Canada 
Fair Good Good 
HSA  Good Good  Fair 
 
Health Canada believed that the BR Template could ensure consistency, though their 
existing documents achieve the same function. If several agencies were to use the 
same BR Template, it would then be useful in determining the inconsistencies 
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between these agencies. While the table on benefits, risks and uncertainties might be 
able to highlight differences, it would allow a discussion of the reasons if relative 
importance or weights had been applied to enable a benefit-risk decision. 
 
TGA found the BR Template useful for audit as it provided a consistent format 
although the lack of details about the studies might hamper the auditing process. 
Health Canada similarly noted that the uniformity of content would be useful for 
auditing their reviewers if they had consistently used the template appropriately, 
although again their existing documents might achieve the same purpose. 
 
TGA concluded that while the BR Template had limited information on post-marketing 
issues, it would be useful for post-licensing reviewers to obtain an overview of the 
risks of the product. Similarly, Health Canada noted that the tables of risks might be 
useful for a follow-up post-marketing activity and could also be used as a reference 
for any risk management plans that were in place for the product.  The convenience 
of quickly accessing this information in the BR Template using the navigation 
functions was noted.  
 
HSA commented that the template could serve to document the baseline of the 
benefit-risk assessment of the product at approval. It would be good if the template 
could be used in the management of the benefit-risk profile of the product throughout 
the life cycle. However, the template would need to be amended significantly to allow 
for capture of post-marketing information as such information usually does not come 
from prospective clinical trials. 
 
DISCUSSION 
The outcome of this study has provided many valuable inputs regarding the areas for 
improvement to the BR Template and User Manual. In examining the value of the 
template in documenting benefit-risk decisions, it was found that with suitable 
clarification provided to the agencies, the BR Template should be able to fulfil this 
role adequately. This is supported by the observation that all the three agencies 
found the BR Template able to ensure consistency in the decision-making processes 
through its systematic approach in documentation. The clarifications required, should 
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consist of a clear objective and the intended functions of the BR Template, which 
primarily is to document and communicate significant findings and benefit-risk 
conclusions in a logical systematic manner.  
 
Similarly, with the appropriate modifications suggested by the agencies, the 
applicability of the BR Template, with its contribution to regulatory decision-making 
and consistency in the assessment of benefits and risks, would be improved. The 
template, however, at the time of development, was not intended to replace the 
existing assessment reports used by the individual agencies but act as a tool for their 
consideration. This could have led to the views of a negative impact on work 
processes, increasing workload and worsening timelines.  
 
The approach of using weights and values is new to many stakeholders and not 
frequently practised explicitly but rather implicitly as part of their current assessment 
processes. Therefore, adequate academic and scientific support should be provided 
in order to update and align the understanding and application of this approach. As 
the use of weights and values is a core component of the BR Template, the failure to 
understand this approach will directly compromise its effectiveness. It is, however, of 
interest that TGA was open to this new approach, Health Canada foresees the 
favourable utility of weights and values in discussing benefit-risk decisions and HSA 
considers the current template as being suitable for this purpose. 
 
Looking at the outcomes and comments received for increasing transparent and 
effective communications and the willingness to share the template, it can be 
concluded that there is a general positive acceptance of these aspects in the light of 
the required revisions to be made to the BR Template. Although, many of the 
outcomes appear to be negative, these are supported by constructive inputs to 
improve the template in achieving its function to facilitate communication. Indeed, all 
three agencies agreed that the section on discussing uncertainties improves 
transparency in communication. TGA and HSA believed that the template does 
present an advantage over their current systems, with both TGA and Health Canada 
having observed the value of the template as a convenient and accessible source of 
safety information for post-marketing communication purposes. 
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It is observed that the reluctance to share the BR Template is largely due to existing 
legislation and confidentiality clauses for regulatory processes. Hence, it would be a 
safe assumption, that under relevant memorandums of understanding or future 
enforcement of legislation for documented transparency, these participating agencies 
are likely to share both the BR Template and Summary.   
 
Although the rating of the willingness to share the Benefit-risk Summary section were 
not positive, these opinions were based on TGA’s and Health Canada’s observations 
that the BR Template on the whole could not capture some of the relevant 
information to support the decisions on the benefits, risks and the benefit-risk 
balance. As the contents of the Benefit-risk Summary section were auto-populated 
from the main BR Template, it is expected that the changes suggested by the 
agencies would improve the documentation function of the BR Template. The 
Benefit-risk Summary section would then be able to fulfil its role adequately. Suitable 
amendments to the contents may then be carried out to cater for the needs of the 
stakeholders based on their level of understanding, as suggested by HSA.  
 
Arising from this study, the following clarifications are suggested as it is important to 
understand that: 
• The intention of the BR Template was to highlight significant findings for quality,  
non-clinical and human pharmacology conclusions and further details could be 
obtained from the actual assessment report 
• The design of the BR Template was to document and communicate the decisions 
during assessment that lead to the final benefit-risk decision 
• How the application of weights and values would contribute to communicating 
decisions 
• The appropriate sections were to document discussion and concerns arising from 
local clinical practice and guidelines, legislation, precedent decisions for other 
approved products, advantages of proposed route of administration or dosing 
regimen, expert opinions and judgement.  
• The consistency in regulatory decisions is not a direct goal of the BR Template, 
but that this is a valuable aspect for emerging markets to benchmark their 
standards 
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The User Manual is an essential tool in ensuring the appropriate use of the BR 
Template and may be used as a vehicle to convey the above clarifications. In 
addition, the following suggestions were collated from this study, namely to: 
• Incorporate bookmarks to facilitate navigation of the document 
• Include a search function for keywords to help reviewers identify specific 
locations within the document 
• Investigate the potential technical issues with the document support functions 
• Provide case studies and examples to better illustrate the use of the BR 
Template 
 
This study has also identified some deficiencies of the BR Template which will 
require attention so that the template can effectively fulfil its objectives which are to: 
• Clarify the definitions of AE, risks and the level of details required 
• Allow a discussion of the AEs in the section on safety information as well as the 
causes of SAEs and deaths and their contribution to the benefit-risk decision 
• Clarify the definition of benefits in patients who received placebos 
• Clarify the intention of the provision of study information if it is to document study 
details or to show the overall contribution of the identified benefits 
• Allow a discussion of the comparison of benefits and benefit-risk balance with 
other approved products 
• Provide a section on reasons for any changes to the proposed indication 
• Allow a conclusive statement in the Benefit-risk Summary section on the outcome 
of weights and values to support the decision and 
• Allow the provision of more details to support decisions on benefits and risks in 
the Benefit-risk Summary section 
 
It is acknowledged that the three participating agencies, given their similarity in 
capacities and regulatory history, may not always represent other mature, 
established regulatory agencies or agencies in the emerging markets. Moreover, the 
opinions provided for this study from the three agencies are not collated from all 
reviewers and there may be concerns over the bias of a single reviewer representing 
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their agency. However, the study was completed under the supervision of the 
management in each agency and hence the outcomes are unlikely to be 
misrepresented. 
 
With the recommendations provided to enhance the BR Template and User Manual, 
the next revision is expected to meet the current expectations of these participating 
agencies. The new BR Template could then be reviewed by other regulatory 
agencies to assess its potential role as a universal standard for documentation and 
communication of benefit-risk decisions. With regard to product life cycle 
management, this BR Template should be evaluated with pharmaceutical companies 
to assess its role as part of the submission dossier to the regulatory agencies. This 
should also be carried out with HTA agencies and patient advocacy groups to 
evaluate the effectiveness of the communication and accuracy of the messaging from 
the BR Template. 
 
As the BR Template was developed using the criteria for the assessment of benefits, 
risks and benefit-risk balance as derived from the regulatory authority EMA, the 
template itself can be seen as guidance to the standards in benefit-risk assessment. 
There should be further studies to assess the use of the BR Template in helping 
emerging markets in their pursuit of improving their regulatory standards. In support 
of the regulatory agencies of the emerging markets, understanding the basis of the 
decisions of other agencies will be useful as these decisions from major regulatory 
agencies are often of value to these emerging markets. Although, there may be 
publicly available assessment reports, these may contain a significant amount of 
information to review that would require both time and scientific capabilities that are 
not available. Hence, it is now a suitable opportunity to investigate the use of the 
Benefit-risk Summary section for smaller agencies, in an effective stand-alone 
format, so that they can complete, understand and exchange such information with 
other similar sized agencies. 
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SUMMARY 
• This study has identified changes required to the BR Template and User Manual 
to help achieve its objective in documenting and communicating benefit-risk 
decisions 
• Most of the clarifications required are relevant to the intention of the BR Template 
but further guidance in documentation, especially weights and values, is required 
• A major deficiency of the BR Template includes more detailed discussion on 
safety information 
• The User Manual should be enhanced to provide the required clarifications and 
provide examples to illustrate the use of the BR Template 
• The potential of the Benefit-risk Summary section should be further investigated 
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CHAPTER 6 
 
 
 
 
 
Evaluation of the benefit-risk summary 
template for communicating benefit-risk 
decisions 
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INTRODUCTION 
The assessment of benefits and risks of medicinal products for regulatory approval 
remains largely a qualitative exercise, although there are on-going initiatives to 
introduce a quantitative approach into the review process. Given the current setting, it 
is important that both the processes and the benefit-risk decisions are transparent 
and communicated to stakeholders for accountability. Hence there is a need to find 
appropriate tools to enhance communication in a manner that it would uphold 
transparency, consistency and standards.  
 
Previous studies (Chapters 3 and 4) showed that the need for effective 
communication can be carried out through a benefit-risk framework supported by a 
documentation tool. The UMBRA Template was designed to enhance the 
communication of decisions in support of the 8-step framework for the assessment of 
benefits and risks. However, this template was based on the EMA guidance and the 
details required may be challenging for emerging regulatory agencies that are 
currently building up their scientific capabilities and regulatory processes.  
 
The potential use of the BR Summary Template as a stand-alone in the emerging 
markets was proposed for the purpose of documenting, understanding and 
exchanging information on benefit-risk decision with other similar sized agencies 
(Chapter 5). Therefore, this study aims to review the usefulness of the BR Summary 
Template (a collation of relevant conclusions leading to the final benefit-risk decision) 
in communicating benefit-risk decisions by the Health Sciences Authority (HSA) of 
Singapore. 
 
OBJECTIVES 
The objectives of this study were to: 
• Determine the practicality of documenting benefit-risk assessment for abridged 
applications in HSA using the BR Summary Template 
• Examine the potential of the BR Summary Template for communicating benefit-
risk balance and conclusions to stakeholders 
• Assess the effectiveness of the User Manual in guiding a reviewer to complete the 
BR Summary Template 
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METHODS 
This research was conducted as a retrospective and non-comparative study. The 
study protocol (Appendix III) was made available to all the participants of this study. 
 
The UMBRA BR Template was reviewed and the Benefit-risk Summary section 
extracted to produce the BR Summary Template (Appendix IV). Both the User 
Manual and the study evaluation tool (as described in Chapter 5) for the BR 
Template were changed accordingly to support the BR Summary Template. The 
study package, namely the study protocol, BR Summary Template, revised User 
Manual (Appendix V) and the revised study evaluation tool (Appendix VI), were sent 
to 16 clinical reviewers in HSA (Therapeutic Products Branch) involved in the 
assessment of benefit-risk balance and the registration of medicines. The reviewers 
were asked to identify an appropriate product application based on the following 
criteria:  
- New Drug application which requires a benefit-risk evaluation 
- An abridged review, applicable to products having obtained a marketing 
approval in at least one country 
- Regulatory decision (having received marketing approval or confirmed benefit-
risk decision) obtained within the last three months  
 
The reviewers transferred the relevant information required for the BR Summary 
Template from the completed clinical assessment reports (as per current processes 
in HSA) with the support of the User Manual. Following this transfer, the reviewers 
completed the study evaluation tool.  
All responses were collated into a single group and the outcomes were presented 
according to their respective sections in the study evaluation tool. All data were 
expressed as percentage over number of responders for that item. Free-text 
comments were collated and presented in appropriate categories when necessary. 
 
This was designed as an exploratory study and the outcomes were interpreted to 
provide qualitative inferences relating to the objectives. No statistical analyses were 
planned or conducted. 
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 RESULTS 
A total of twelve responses (75%) were received by August 2013.  Of the four who 
did not respond, one was transferred to another unit, two did not have applications 
that met the criteria and the remaining one did not respond. Most (75%) of the 
responders had between one to five years of working experience in the agency, with 
one having less than a year and two having more than five years. As the reports were 
written independently, the responses actually represented the evaluation of ten 
different products reviewed via the abridged route.  
 
The outcomes will be presented in four parts: 
• Part I – User-friendliness of the BR Summary Template 
• Part II – Appropriateness (fit for purpose) of the documentation 
• Part III – Applicability of the BR Summary Template 
• Part IV – Suggested amendments to the BR Summary Template 
 
Part I - User-friendliness of the BR Summary Template 
The template has two functions to help users navigate the document, namely the “Go 
to page” button and page thumbnails to locate a specific page (Figure 6.1). These 
are aimed at reducing the effort required to move between different sections.  
 
The “Go to page” button appeared to be the more useful, as 83% of reviewers rated it 
either good or excellent (Figure 6.2). For the page thumbnails, 58% indicated it as fair 
or it was not used as it was commented that the thumbnail icons were too small to 
decipher the contents and bookmarks might have been more effective, although 
none rated the BR Summary Template as not user-friendly. There was a suggestion 
to include a “Back” button to the content page or another primary page.  
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Figure 6.1 Navigation functions of the BR Summary Template 
 
 
 
 
 
 
 
 
 
Click on button 
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Click on thumbnail 
icon for the desired 
page 
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Figure 6.2 Practicality of the navigation functions 
 
 
The User Manual was provided to guide the reviewer on the steps to complete the 
template, as well as to clarify the common terms used in the template. The majority of 
the responders (between 75% and 100%) rated the clarity, comprehensiveness and 
applicability of the User Manual as “good” (Figure 6.3).  
 
None rated the manual as poor in any of the three parameters. Comments received 
included the consideration to provide examples or a case study in the manual to 
better illustrate the use of the template. An inexperienced reviewer might find the 
manual insufficiently comprehensive. Even though the User Manual provided 
instructions with regard to assigning relative importance to benefit and risk 
parameters, the lack of experience by the reviewers prevented them from effectively 
completing the BR Summary Template in this aspect.   
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Figure 6.3 Appropriateness of the User Manual 
 
 
Part II – Appropriateness (fit for purpose) of the documentation 
The appropriateness of a template is dependent on its capability to present the 
processes leading to the final benefit-risk conclusion in a structured and systematic 
manner. In documenting the various conclusions, the BR Summary Template was 
largely thought to be fit for purpose (92% to 100%, Figure 6.4).  
 
One modification suggested was to clarify the difference between the clinical 
conclusion section and the overall conclusion for benefit-risk balance, as it might 
appear redundant if misunderstood. The other modification was to make available 
more guidance on writing the non-clinical conclusion as some reviewers were not 
familiar with providing details for this section. 
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 Figure 6.4 Documentation of relevant information supporting the benefit-risk 
decision 
 
 
In documenting the benefits and risks for the product being evaluated, 92% to 100% 
of the responders believed the template is able to achieve the purpose (Figure 6.5). 
For documenting relevant benefits and risks as identified by the sponsor, one 
responder was unsure as to the usefulness of this as the reviewer would eventually 
indicate the benefits and risks that are to be included for assessment and hence 
rated these two parameters as not fit for purpose. However, the reasons for listing 
benefits identified by the sponsor and the reasons for inclusion or exclusion by the 
reviewer is both for transparency and to provide more fully the rationale for the 
benefit-risk decision. Another responder felt that there must be greater clarity in 
defining risks in the template as those considered critical to the benefit-risk 
assessment and as a result rated the documentation of inclusion or exclusion of all 
risks as being not fit for purpose.  
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Figure 6.5 Documentation of benefits and risks 
 
 
The exercise of indicating relative importance and numerical values in the identified 
benefits and risks is aimed at improving the articulation of the basis of the benefit-risk 
decision. While the majority of the responders believed it was fit for purpose, 25% to 
33% of the responders felt that the template required modifications or was not fit for 
purpose (Figure 6.6). The reasons and comments are listed in Table 6.1 and can be 
seen as proposed amendments to the template to improve documentation of weights 
and values. It can be concluded that the lack of understanding of weighting and 
valuing in general is the root cause of the above observation. 
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Figure 6.6 Documentation of weights and values 
 
 
Table 6.1 Amendments required to improve the documentation of weights and 
values 
Modifications required 
• Clarification on how to assign weights 
• Provide more instructions on how to complete these sections on weighting and valuing 
• Recommend a consistent approach for weighting through a drop-down list of either numerical 
ranking or qualitative descriptors 
• Recommend a free text box for cases whereby the weightings are not clear-cut 
• Clarify if the weightings are to add up to 100% for both the benefits and risks, or are they to be 
considered separately for each component 
• Provide some examples to illustrate the intention of the sections 
Reasons not being fit for purpose 
• Not sure how to complete these sections 
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Overall, the BR Summary Template appeared to be able to document study 
outcomes and relevant benefit-risk information leading to a regulatory 
recommendation, with 83% to 92% of responders agreeing on this (Figure 6.7).  
 
Figure 6.7 Documentation of study outcomes, safety information and overall 
conclusion 
 
 
With regards to documenting study outcomes, one responder recommended 
modification to allow for applications based on bibliographic submission or published 
literature. Another responder who rated the template “not fit” for presenting study 
outcomes commented that this section did not contribute to the overall benefit-risk 
assessment. As for the template being useful in presenting information leading to a 
regulatory recommendation, one responder indicated that more clarification on 
weighting should be provided in order to achieve this purpose. 
 
As for presenting an overall summary of the adverse events or effects, half of the 
responders felt that either a modification was required, or the template was “not fit” 
for this purpose. The amendments required are listed in Table 6.2 and are largely 
technical in nature to accommodate other formats for uploading safety information.  
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Table 6.2 Amendments required to improve the documentation of overall 
summary of adverse events and effects 
Modifications required Reasons being not fit for purpose 
• Allow text format, PDF snapshots or 
other common formats besides the 
picture formats 
• This section does not serve the overall 
benefit-risk assessment 
• Further categorisation to listing of 
common treatment-emergent AEs, 
serious AEs, death, discontinuations, 
etc 
• Difficulties in attaching the PDF file 
 • As the studies had different safety 
endpoints, there was no pooled 
summary 
 
Part III - Applicability of the BR Summary Template 
The primary goal of the BR Summary Template is to communicate regulatory 
decision-making either internally or to external stakeholders. All the responders found 
the template effective in promoting communication to stakeholders (Figure 6.8), and 
83% of responders believed it could help achieve consistency of decisions between 
regulatory agencies. However, one responder commented that with the different 
weightings applied, consistency in regulatory decisions across agencies cannot be 
achieved. 
 
Four responders felt that the template did not confer any additional advantage over 
the current processes in the organisation. For new users, this approach generally 
appears more difficult to use than HSA’s current report template as the current 
system is more efficient and reaches the same conclusion. Incidentally, the BR 
Summary Template is a repeat of a section of the existing HSA’s current report 
template. Moreover, the BR Summary Template was formatted as a PDF which 
makes the use and uploading of information more tedious compared with the existing 
Word document. 
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Figure 6.8 Applicability of BR Summary Template 
 
 
When the responders were asked if they were willing to share the completed BR 
Summary Template, 92% were willing to do so with healthcare professionals and 
other regulatory agencies (Figure 6.9). One responder indicated “Not applicable” for 
health technologies assessment agencies (HTA) since this jurisdiction is not current 
in Singapore. One responder commented that the template could not adequately 
describe the benefit-risk findings. Reservations in sharing with patients, patient 
advocacy groups, media and in public domains included the use of technical terms 
and medical jargon being unsuitable for lay persons, which may lead to confusion 
and misinterpretation. This could invite unnecessary criticism and one responder 
suggested that only selected sections be made available to such stakeholders. 
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Figure 6.9 Willingness to share the BR Summary Template with various 
stakeholders 
 
 
Part IV – Suggested amendments to the BR Summary Template 
One reviewer suggested combining the identification of benefits and risks with the 
exercise of assigning weights and values to avoid repetition. However, this 
suggestion could be accommodated by auto-populating the benefits and risks in 
Section 3 into Section 6. More guidance could be given on listing the reasons for 
inclusion or exclusion of benefits, like local disease burden (medical need), available 
alternatives, strength of evidence, clinical relevance and convenience to patients. For 
completeness, one reviewer recommended adding another section to indicate if the 
benefit-risk balance is positive or negative, before being asked to provide reasons for 
a negative benefit-risk balance. While this study was conducted for new active 
substances, one reviewer recommended that the template could be amended to 
accommodate clinical variations. 
 
DISCUSSION 
The findings of this study showed that the successful implementation of a new 
process or tool in an established regulatory agency is dependent on the fundamental 
understanding of the principles behind the template.  The concept of weighting or 
assigning relative importance and valuing is a technique that is relatively new to both 
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HSA and other regulatory agencies (Chapter 3). However, weighting and valuing is 
seen as an explicit presentation of the subjective interpretation of a set of clinical 
information. This exercise aimed to enhance the transparency of decision-making by 
making it clear that the priorities placed on a set of benefits and risks ultimately affect 
the resulting benefit-risk balance. Without an understanding of the rationale behind 
weighting and valuing, some reviewers could not appreciate its contribution to 
effective documentation and communication. 
 
As for all new initiatives, an implementation strategy or change management 
programme should be drawn up. This would consist of dialogues with senior 
management, a dedicated training plan and the use of training tools. It is expected 
that senior management should be made aware of the potential advantages of the 
BR Summary Template and are agreeable to implementing this across the relevant 
departments in the agency. A top-down approach might be required to ensure the 
appropriate implementation of this template, as this may be helpful in situations 
where reviewers are unable to comprehend its role and advantages in the entire 
process. However, the end-users or reviewers should also clearly understand the 
usefulness of the template, its role in the current processes and the impact on 
existing workflow so as to ensure maximum compliance. This could be achieved 
through a standard training programme which would include a driver from senior 
management. In addition, it should include leaders among the users who would be 
trained as pioneers for the successful implementation of the BR Summary Template. 
As is evident from this study, the User Manual proved to be a valuable tool, however 
amendments would be required to enhance its effectiveness.  
 
The current BR Summary Template would require a revision to the technical 
capabilities and an improvement for the documentation of safety information and 
adverse events. The User Manual should be revised to include examples and case 
studies to better illustrate the use of the template. It appears that the capacity of the 
BR Summary Template to effectively communicate a benefit-risk decision has been 
clearly exhibited, as supported by the reviewers who were willing to share this 
template with stakeholders. However, this should go hand–in–hand with the legal 
framework to give the agency the mandate to implement it. Without the assurance of 
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legal protection and support of management, reviewers would be unlikely to release 
such reports, especially to stakeholders who are lay persons.  
 
The reviewers in this study indicated their willingness to share the completed BR 
Summary Template for a specific product with other regulatory agencies where there 
is a memorandum of understanding. It is also appropriate to examine the utility of this 
template as a means of transferring knowledge and communicating the basis of a 
decision. For major regulatory agencies it may be a requirement to provide details of 
the evaluation to achieve a level of transparency stipulated by the jurisdiction. 
However, this study, even in the absence of these details, has demonstrated that the 
BR Summary Template is an effective tool to communicate benefit-risk decisions. 
Therefore it may be considered as a basic report template for agencies that are in 
transition to build up their evaluation capabilities. Thus this would be an ideal tool for 
communicating benefit-risk decisions to emerging regulatory agencies, since the 
components of the template address the basic needs of a sound and scientific 
discussion. 
 
From another perspective, established agencies may find that the BR Summary 
Template replicates existing publicly available reports and is thus judged by some to 
be redundant. Attempts to use IT to auto-populate existing information from current 
reports should be undertaken to improve on this aspect. Through this study and 
Chapter 3, it can be seen that weighting and valuing are not consistently applied but 
the relevance of such an exercise in effective communication is accepted. Again, it is 
important to educate regulators on the use of weights and values as they form a key 
component with regard to communicating decisions in a transparent manner. It is 
only through a global understanding of the need for a common template that 
consistency in evaluating benefits and risks can be achieved. 
 
The outcome of this case study, involving reviewers within the Health Sciences 
Authority as representative of the emerging markets in the region, has demonstrated 
that the principles of the BR Summary Template are applicable to other jurisdictions 
or similar agencies. This is indeed encouraging in the current climate, where the 
debate surrounding the benefit-risk assessment of medicines is on the top of many 
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regulatory agencies’ agenda. Thus the promising features of the BR Summary 
Template will, no doubt, contribute to such on-going discussion.  
 
SUMMARY 
• The BR Summary Template is adequate to document benefits, risks, relevant 
summaries and conclusions 
• A revision of the BR Summary Template should include technical improvements 
and more details for safety information 
• The User Manual and navigation functions are useful to guide the reviewer in 
completing the template 
• More guidance should be provided for weighting and valuing, as well as the use 
of examples and case studies, in the User Manual 
• The BR Summary Template can be a useful tool for communicating benefit-risk 
decisions to a variety of stakeholders 
• The principles behind the template may be useful for guiding the benefit-risk 
assessment of medicines 
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INTRODUCTION 
The evolution in the requirements for assessing the benefits and risks of medicinal 
products has resulted in changes in the evaluation processes. Beyond the separate 
assessment of benefits and risks, the emphasis is now on the balance between the 
two, having to justify the potential harms in view of the efficacy claims. In a changing 
society where the demand is for transparency of such decision-making processes, 
there is a now a major challenge to adequately communicate the relevant information 
to stakeholders. The articulation of benefit-risk decisions remains both a 
responsibility as well as an opportunity. 
 
The European Medicines Agency (EMA) and the US FDA have provided guidances 
on the assessment of medicines. EMA provided a reflection paper on the assessment 
of benefits and risks of medicines (EMA, 2008), while US FDA (as part of the PDUFA 
V) has implemented a benefit-risk framework to allow the appropriate discussion on 
the considerations taken into account for a regulatory decision (FDA, 2012). While 
these may enhance the benefit-risk evaluation of a product, there is currently no 
standard template for the documentation and communication of the evaluation 
outcomes and benefit-risk decisions. Individual agencies have their own internal 
evaluation report templates and also those for publicly available assessment reports. 
Consequently, stakeholders seeking information on the assessment of a product may 
be presented with similar information in different formats.  
 
The results from a study on BR frameworks (Chapter 3) showed that both regulatory 
agencies and pharmaceutical companies believe that a benefit–risk framework would 
enhance the quality (transparency and consistency) of communication and should 
provide documentation for a structured discussion, acting as a tool for communication 
among peers within the organisation and between the organisation and stakeholders. 
The 8-step universal benefit-risk framework, UMBRA (Chapter 4), was therefore  
proposed and this framework encompasses the principles of existing frameworks by 
other major regulatory agencies such as the US FDA (FDA 2013) and EMA (EMA, 
2010) (Table 7.1). A documentation tool was also developed to support this 
framework and formed part of the Benefit-risk Assessment Support System (BRASS, 
Chapter 4).  
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Table 7.1 Comparisons of US FDA and EMA benefit-risk assessment frameworks with the Universal Benefit-Risk 
Framework 
Frameworks 
reviewed 
Core elements 
Framing the 
decision 
Identifying benefits and 
risks 
Assessing benefits and 
risks 
Interpretation and outcome 
US FDA Analysis of 
conditions and 
unmet medical 
needs 
Clinical benefits, risks Evidence and uncertainties   Conclusions and 
reasons, risk 
management 
plans 
EMA PrOACT-URL Nature and 
framing of the 
problem 
Objectives, favourable and 
unfavourable effects 
Alternatives 
regarding options 
to be evaluated 
and the 
consequences 
Trade-offs and 
benefit-risk 
balance 
Evaluating 
uncertainty 
Effects table 
and risk 
tolerance 
Consistency of 
decisions (linked 
decisions) 
Universal Benefit-
risk framework 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 
Decision context Building the 
value tree 
Customising 
the value tree 
Weighting 
(relative 
importance) of 
benefits and risks 
Scoring the 
options 
Evaluating 
uncertainties 
Concise 
presentation of 
results 
(visualisation) 
Expert judgment 
and 
Communications 
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This BR Template was designed to enhance effective documentation and 
communication of decisions and was used as the basis of comparison in this study. 
The outcomes from three agencies (TGA, Health Canada and HSA) showed that the 
BR Template is useful for documenting and communicating a benefit-risk decision 
(Chapter 5), while the BR Summary Template was investigated and similarly found to 
be adequate for the above purposes (Chapter 6). It is noted that there are currently 
publicly available assessment reports from the major regulatory agencies. This study 
aims to review these publicly available assessment reports to see if they adequately 
fulfil the functions found in the BR Template and BR Summary Template. 
 
OBJECTIVES 
The objectives of this study were to: 
• Compare the format of the US FDA’s, EMA’s, HC’s and TGA’s publicly available 
assessment reports with the BR Template and BR Summary Template 
• Evaluate whether these four regulatory agencies have an effective approach for 
communicating benefit-risk decisions to all stakeholders 
• Examine the utility of the BR Summary Template for communicating benefit-risk 
decisions by the US FDA and EMA using a case study. 
 
METHODS 
In order to establish the utility of the BR Template, four major reference agencies 
were selected, namely US FDA, EMA, Health Canada, and TGA. The criteria for 
choosing these reference agencies was based on a positive history of established 
regulatory processes, global recognition of regulatory standards and the public 
availability of assessment reports. Therefore, for the purpose of comparison in this 
study, the following report formats of the four reference agencies were used: 
• US FDA – Medical Review and the Risk Benefit Assessment 
• EMA – European Public Assessment Report (EPAR) and the Executive Summary 
• Health Canada – Summary Basis of Decision (SBD) 
• TGA – Australian Public Assessment Report (AusPAR) 
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The above mentioned report formats were expected to be common in their function to 
the BR Template, which is to document and communicate the information supporting 
benefit-risk decisions and regulatory outcomes. Report format templates were 
retrieved online for each agency. In the absence of an official document that 
explained the structure of the format, a recent publicly available assessment report 
would be used to review the contents of the report or support the understanding of 
the format.  Comparison of the report formats from the four reference agencies was 
conducted by reviewing the section headings of the report against those of the BR 
Template and BR Summary Template. Where there was a summary in the reference 
agency’s format, this would be directly compared with the BR Summary Template 
and the findings were tabulated and presented.  
 
Furthermore, to illustrate the use of the BR Summary Template, a case study was 
conducted using a recent US FDA Medical Review (FDA, 2012b) and EPAR (EMA, 
2013c) for the same product. Zaltrap® (aflibercept) was chosen as it was approved 
around the same time by both agencies (03 August 2012 for US FDA and 01 
February 2013 for EMA). Importantly, the US FDA Medical Review was written 
according to the new 5-step benefit-risk framework that features the Risk Benefit 
Assessment. These two respective summaries were transferred into the BR 
Summary Template and the omissions reviewed.  
 
RESULTS 
The outcomes will be presented in four parts: 
• Part I – Formats of the four reference agencies’ publicly available report templates 
• Part II – Comparison of the four reference agencies’ report templates with the BR 
Template 
• Part III – Comparison of the four reference agencies’ report templates with the BR 
Summary Template 
• Part IV – Case study of US FDA’s and EMA’s summary reports on Zaltrap® 
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Part I - Formats of reference agencies’ publicly available report templates 
US FDA’s Medical Review 
The US FDA Medical Review consists of nine sections (Table 7.2), with the opening 
section presenting the recommendations and Risk Benefit Assessment (based on the 
5-step benefit-risk framework). The remaining sections present the details of the 
assessment supporting the recommendations. It is known that the public available 
reports from US FDA are a redacted subset of the complete evaluation data. The 
original dataset will include discussions of queries and responses by the sponsor with 
the US FDA. 
 
EMA’s EPAR 
The EPAR consists of an Executive Summary and four sections (Table 7.3). The 
publicly available EPAR is extracted from the complete assessment report which 
would have included responses and justifications to EMA for queries raised. Agency-
specific requirements are those relating to submission information and regulatory 
processes.  
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Table 7.2 Format of US FDA Medical Review 
US FDA’s Medical Review 
Section Content 
1 Recommendations/ Risk benefit assessment 
2 Introduction and regulatory background 
 Product information 
 Tables of currently available treatment for 
proposed indications 
 Availability of proposed active ingredient in US 
 Important safety issues with consideration to 
related drugs 
 Summary of pre-submission regulatory activity 
related to submission 
 Other relevant background information 
3 Ethics and good clinical practices 
 Submission quality and integrity 
 Compliance with GCP 
 Financial disclosures 
4 Significant efficacy/safety issues related to other 
review disciplines 
 Chemistry manufacturing and controls 
 Clinical microbiology 
 Preclinical pharmacology/toxicology 
 Clinical pharmacology (mechanism of action, 
pharmacodynamics, pharmacokinetics) 
 
Section Content (continued) 
5 Sources of clinical data 
 Tables of studies/clinical trials 
 Review strategy 
 Discussion of individual studies/clinical trials 
6 Review of efficacy 
 Efficacy summary 
 Indication (methods, demographics, subject 
disposition) 
 Protocol violations 
 Analysis of primary endpoints 
 Analysis of secondary endpoints 
 Other endpoints 
 Subpopulations 
 Analysis of clinical information relevant to 
dosing recommendations 
 Additional efficacy issues/analyses 
 
 
 
 
 
Section Content (continued) 
7 Review of safety 
 Safety summary 
 Methods (studies, categorisation, pooling of 
data) 
 Adequacy of safety assessment (overall 
exposure, dose response, special animal 
and/or in vitro testing, 
metabolic/clearance/interaction workup, 
potential AE for similar drugs) 
 Major safety results (deaths, non-fatal SAE, 
dropouts/discontinuation, significant AE, 
specific primary safety concern 
 Supportive safety results (common AE, lab 
findings, vital signs, ECGs, special safety 
studies, immunogenicity) 
 Other safety explorations (dose dependency, 
time dependency, drug-demographic/drug-
disease/drug-drug interactions 
 Additional safety evaluations (human 
carcinogenicity, human 
reproduction/pregnancy data, paediatric and 
effects on growth, overdose/abuse 
potential/withdrawal/rebound 
 Additional submissions/safety issues 
8 Post market experience 
9 Appendices 
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Table 7.3 Format of EMA’s EPAR 
EMA’s EPAR 
Section Content 
 Executive summary 
1 Background information on the procedure 
Submission of the dossier 
Steps taken for the assessment of the product 
2 
 
Scientific discussion 
 Introduction 
Quality aspects 
 Introduction 
 Active substance 
 Finished medicinal product 
 Discussion on chemical, pharmaceutical and 
biological aspects 
 Conclusions on the chemical, pharmaceutical 
and biological aspects 
 Recommendations for future quality 
development 
Non-clinical aspects 
 Introduction 
 Pharmacology 
 Pharmacokinetics 
 Toxicology 
 Ecotoxcitiy/environmental risk assessment 
  
 Discussion on non-clinical aspects 
 Conclusion on non-clinical aspects 
Section Content (continued) 
2 Clinical aspects 
 Introduction 
 Pharmacokinetics 
 Pharmacodynamics 
 Discussion on clinical pharmacology 
 Conclusion on clinical pharmacology 
Clinical efficacy 
 Dose response studies 
 Main studies 
 Supportive studies 
 Discussion on clinical efficacy 
 Conclusion on clinical efficacy 
Clinical safety 
 Discussion on clinical safety 
 Conclusion on clinical safety 
Pharmacovigilance 
User consultation 
3 Benefit-risk balance 
4 Recommendations 
 
 
 
 
 
 
Health Canada’s SBD 
The Health Canada’s Summary Basis of Decision (SBD) consists of eight sections 
(Table 7.4). This is a publicly available document that presents the relevant 
information to support the decision made by Health Canada for the product (Health 
Canada, 2012a and 2012b). Unlike US FDA Medical Review and EPAR, there is no 
separate summary portion as the SBD is meant for this purpose. The agency-specific 
information is related to submission milestones, recent and post-authorisation 
activities. These disparities are not considered to influence the processes on the 
assessment of benefits and risks. 
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Table 7.4 Format of Health Canada’s Summary Basis of Decision 
Health Canada’s Summary Basis of Decision 
Section Content Purpose 
PAAT Post-Authorisation Activities Table List of post-authorisation activities for the approved 
product 
1 What was approved? Information on approved indication, intended 
population, contraindications and product 
presentations 
2 Why was <product> approved? Discussion on basis of benefit-risk balance 
3 What steps led to the approval of 
<product>? 
Submission milestones 
4  What follow-up measures will the 
company take? 
 Information on post-approval commitment 
5  What post-authorisation activity 
has taken place for <product>? 
Information provided as link to earlier section on 
Post-Authorization Activity Table (PAAT) 
6 What other information is available 
about drugs? 
Links to other webpages within Health Canada 
website 
7  What was the scientific rationale 
for Health Canada’s decision? 
 Details on: 
a) Clinical Basis of Decision 
i. Clinical pharmacology 
ii. Clinical efficacy 
iii. Clinical safety 
iv. Safety topics of special interest 
b) Non-clinical Basis of Decision 
c) Quality Basis of Decision 
 
TGA’s AusPAR 
The TGA AusPAR consists of six sections (Table 7.5) (TGA, 2012), the format being 
close to the EPAR but without the Executive Summary. As with the previous formats 
of the other three agencies, agency-specific information are those related to 
individual regulatory and submission information. It is known that the AusPAR 
contains information extracted from the complete, original assessment reports. 
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Table 7.5 Format of TGA’s AusPAR 
TGA’s AusPAR 
Section Content 
1 Introduction to product submission 
 Submission details 
 Product background 
 Regulatory status 
 Product information 
 List of abbreviations 
2 Quality findings 
 Drug substance 
 Drug product 
 Biopharmaceutics 
 Advisory committee considerations 
 Quality summary and conclusions 
3 Non-clinical findings 
 Introduction 
 Pharmacology 
 Pharmacokinetics 
 Toxicology 
 Non-clinical summary and conclusions 
Section Content (continued) 
4 Clinical findings 
 Introduction 
 Pharmacodynamics 
 Pharmacokinetics 
 Dosage selection for pivotal studies 
 Efficacy 
 Safety 
 Clinical summary and conclusions 
5 Pharmacovigilance findings 
 Risk management plan 
6 Overall conclusion and risk/benefit 
assessment 
 Quality  
 Non-clinical 
 Clinical  
 Risk management plan 
 Risk-benefit analysis 
 Outcome 
 
 
Part II – Comparison of the four reference agencies’ report templates with the 
BR Template 
The outcomes showed that the format of the reference agencies’ reports are 
generally similar and when compared with the BR Template, they were all found to 
lack the features that list the identified benefits and risks, application of values and 
weights (relative importance) and visualisation of the assessment outcomes (Table 
7.6). In addition, while it is acknowledged that relevant discussions and 
considerations contributing to the final benefit-risk decision maybe reported in the 
existing reference agencies’ templates, the BR Template allowed for this through a 
structure of guided questions. 
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 US FDA’s Medical Review 
There were two comparison made for the Medical Review. Sections 2 to 9 of the US 
FDA Medical Review format was compared to the BR Template to assess how these 
sections can accommodate the requirements of the BR Template in presenting the 
relevant information. Items found specific to US FDA included submission activities 
and quality, compliance to GCP, financial disclosures and appendices. These were 
found not to directly influence the decision on benefit-risk balance. The principle 
between the two templates is found to be similar – the focus is on the contribution of 
clinical efficacy and safety to the overall benefit-risk balance, with a significant 
contribution of quality, non-clinical and pharmacology concerns succinctly discussed 
(Section 4 of Medical Review, Section 2 of BR Template). The second comparison 
was made between the Risk Benefit Assessment (Section 1 of Medical Review) and 
the BR Template. It was considered that the former could perform the function of the 
BR Template, and hence a separate comparison was conducted. 
 
As the BR Template was not designed to present details of the clinical studies, it 
could not accommodate the US FDA’s section on the discussion of studies and 
clinical trials. In reviewing efficacy, though the BR Template was not structured to 
discuss the demographics, subject disposition and protocol violations, the essential 
messages would have been combined into the general considerations. Similarly, this 
applies to the discussion on the clinical information relevant to dosing 
recommendation which may not be adequately discussed in the BR Template. It was 
however noted that the US FDA Medical Review could not fulfil the entire section 3 of 
the BR Template on listing and justifying the identified benefits. These may be 
generally discussed in the review but not explicitly stated as in the BR Template. 
Likewise, there are no features to openly discuss the role of valuing and weighting 
(relative importance) in their assessment, as in the BR Template, though these may 
have been achieved throughout the document. There was no visualisation function in 
the US FDA Medical Review. 
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Table 7.6 Comparison of sections of reference agencies’ publicly available assessment reports with the BR Template 
BR Template US FDA EMA Health Canada TGA 
Content Medical 
Review 
Section 1 
(Risk Benefit 
Assessment) 
EPAR SBD AusPAR 
1 Background      
1.1 Specify proposed therapeutic 
indication 
Section 2 Analysis of 
condition 
Section 1 – Scientific 
discussion 
Not available Section 1 
1.2 Treatment modalities evaluated Section 2 Analysis of 
condition 
Section 1 – Scientific 
discussion 
Not available Section 1 
1.3 Other current available treatment 
options not considered or evaluated 
Section 2 Current treatment 
options 
Section 1 – Scientific 
discussion 
Not available Section 1 
1.4 Known risks with compounds of 
same therapeutic class 
Section 2 Risk Section 1 – Scientific 
discussion 
Section 7 - Clinical Section 1 
1.5 Medical need Section 2 Analysis of 
condition, Current 
treatment options 
Section 1 – Scientific 
discussion 
Section 2 Section 1 
1.6 Aims of treatment and expected 
treatment size  
Section 2 Analysis of 
condition, Current 
treatment options 
Section 1 – Scientific 
discussion 
Not available Section 1 
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Table 7.6 Comparison of sections of reference agencies’ publicly available assessment reports with the BR Template 
(continued) 
BR Template US FDA EMA Health Canada TGA 
Content Medical 
Review 
Section 1 
(Risk Benefit 
Assessment) 
EPAR SBD AusPAR 
2 Overall Summary      
2.1 Quality overall summary Section 4 Not available Section 2 – Quality 
aspects 
Section 7 - Quality Section 6 - Quality 
2.2 Non-clinical overall summary Section 4 Not available Section 2 – Non-clinical 
aspects 
Section 7 – Non-
clinical  
Section 6 – Non-clinical 
2.2.1 Comments on relevant findings 
and potential implications/ 
investigations required 
Section 4 Not available Section 2 – Non-clinical 
aspects 
Section 7 – Non-
clinical 
Section 3 
2.2.2 Conclusions implicating benefit-
risk assessment for humans 
Section 4 Not available Section 2 – Non-clinical 
aspects 
Section 7 – Non-
clinical 
Section 3 
2.3.1 Human pharmacology: Overall 
summary 
Section 4 Not available Section 2 – Clinical 
aspects 
Section 7 – Clinical 
pharmacology  
Section 4 
2.3.2 Human pharmacology 
Conclusions 
Section 6 Not available Section 2 – Clinical 
aspects 
Section 7 – Clinical 
pharmacology 
Section 6 - Clinical 
2.4.1 Clinical overall summary Section 6 Benefit Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 6 - Clinical 
2.4.2 Clinical conclusions Section 6 Benefit Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 6 - Clinical 
3 Identified benefits and risks      
3.1 Listing of all benefits, and 
justification for inclusion and exclusion 
Not available Not available Not available Not available Not available 
3.2 Listing of all risks, and justification 
for inclusion and exclusion 
Not available Not available Not available Not available Not available 
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Table 7.6 Comparison of sections of reference agencies’ publicly available assessment reports with the BR Template 
(continued) 
BR Template US FDA EMA Health Canada TGA 
Content Medical 
Review 
Section 1 
(Risk Benefit 
Assessment) 
EPAR SBD AusPAR 
4 Benefit and Risk – Study 
information 
     
4.1.1 – 4.1.9 Study details of benefit Section 6 Benefit Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 4 
4.1.11 Discussion of consistency across 
all studies 
Section 6 Benefit (Evidence 
and uncertainties) 
Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 4 
4.1.12 Discussion of evidence in relevant 
subgroups 
Section 6 Benefit (Evidence 
and uncertainties) 
Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 4 
4.1.13 Discussion of confirmation by 
results of non-primary endpoint 
Section 6 Benefit (Evidence 
and uncertainties) 
Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 4 
4.1.14 Discussion on patient reported 
outcomes 
Section 6 Benefit (Evidence 
and uncertainties) 
Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 4 
4.1.15 Overall conclusion Section 6 Benefit (Conclusions 
and reasons) 
Section 2 – Clinical 
efficacy 
Section 7 – Clinical  Section 4 
4.2 Risks: Overall summary      
4.2.1 Overall incidence of adverse 
effects 
Section 7 Risk Section 2 – Clinical safety Section 7 – Clinical  Section 4 
4.2.2 Overall incidence of serious 
adverse effects 
 Risk Section 2 – Clinical safety Section 7 – Clinical  Section 4 
4.2.3 Discontinuation rate due to AEs Section 7 Risk Section 2 – Clinical safety Section 7 – Clinical  Section 4 
4.2.4 Dose reduction rate due to AEs Section 7 Risk Section 2 – Clinical safety Section 7 – Clinical  Section 4 
4.3 Adverse effects Section 7 Risk Section 2 – Clinical safety Section 7 – Clinical  Section 4 
4.3.1 Details of AE Section 7 Risk Section 2 – Clinical safety Section 7 – Clinical  Section 4 
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Table 7.6 Comparison of sections of reference agencies’ publicly available assessment reports with the BR Template 
(continued) 
BR Template US FDA EMA Health Canada TGA 
Content Medical 
Review 
Section 1 
(Risk Benefit 
Assessment) 
EPAR SBD AusPAR 
4.4 Uncertainties (benefits and risks)      
4.4.1 Discussion on choice of dose, 
comparators and endpoints 
Section 5 Evidence and 
uncertainties 
Sections 2 & 3 Section 7 – Clinical Section 6 – Risk-benefit 
analysis 
4.4.2 Discussion on design, conduct 
and statistics 
Section 5 Evidence and 
uncertainties 
Sections 2 & 3 Section 7 – Clinical  Section 6 – Risk-benefit 
analysis 
4.4.3 Discussion on validation of 
measurements and scales 
Section 5 Evidence and 
uncertainties 
Sections 2 & 3 Section 7 – Clinical Section 6 – Risk-benefit 
analysis 
4.4.4 Discussion on negative studies Section 5 & 6 Evidence and 
uncertainties 
Sections 2 & 3 Section 2 & 7 – 
Clinical 
Section 6 – Risk-benefit 
analysis 
4.4.5 Discussion of consistency across 
factors 
Section 5 & 6 Evidence and 
uncertainties 
Sections 2 & 3 Section 2 & 7 – 
Clinical 
Section 6 – Risk-benefit 
analysis 
4.4.6 Interactions with food/ drugs Section 7 Risk Section 2 – Clinical 
safety 
Section 7 – Clinical Section 4 
4.4.7 Limitations of dataset regarding 
safety 
Section 7 Risk (Evidence and 
uncertainties) 
Section 2 – Clinical 
safety 
Section 2 & 7 – 
Clinical  
Section 6 – Risk-benefit 
analysis 
4.4.8 Potential for off label use, 
overdose, abuse and misuse 
Section 7 Risk (Evidence and 
uncertainties) 
Section 2 – Clinical 
safety and pharmaco-
vigilance 
Section 2 & 7 – 
Clinical 
Section 6 – Risk-benefit 
analysis 
4.4.9 Risk with respect to standard of 
care 
Section 7 Risk (Evidence and 
uncertainties) 
Section 2 – Clinical 
safety 
Section 3 – Benefit-
risk assessment 
Section 6 – Risk-benefit 
analysis 
4.4.10 Comments on any other 
uncertainties 
Section 5, 6 
& 7 
Evidence and 
uncertainties 
Sections 2 & 3 Section 2 Section 6 – Risk-benefit 
analysis 
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Table 7.6 Comparison of sections of reference agencies’ publicly available assessment reports with the BR Template 
(continued) 
BR Template US FDA EMA Health Canada TGA 
Content Medical 
Review 
Section 1 
(Risk Benefit 
Assessment) 
EPAR SBD AusPAR 
5 Benefit-risk Summary Table and 
Expert Judgment 
     
5.1 Weighting and valuing of benefits Not available Not available Not available Not available Not available 
5.2 Weighting and valuing of risks Not available Not available Not available Not available Not available 
6 Visualisation Not available Not available Not available Not available Not available 
7 Conclusions      
7.1 Quality conclusions (pre-filled) Section 4 Conclusions and 
reasons 
Section 2 Section 7 - Quality Section 6 – Quality 
7.2 Non-clinical conclusions (pre-filled) Section 4 Conclusions and 
reasons 
Section 2 Section 7 – Non-
clinical 
Section 6 – Non-clinical 
7.3 Human pharmacology conclusions 
(pre-filled) 
Section 4 Conclusions and 
reasons 
Section 2 Section 7 - Clinical Section 6 – Clinical  
7.4 Clinical conclusions (pre-filled) Section 6 Conclusions and 
reasons 
Section 2 Section 7 – Clinical  Section 6 - Clinical 
7.4.1 For negative benefit-risk balance, 
discussion on the harm 
Section 1 
(Benefit-risk 
summary 
assessment) 
Risk Section 2 Section 2 Section 6 – Risk-benefit 
analysis 
7.4.2 Discussion on evolution of the 
benefit-risk balance 
Section 1 
(Benefit-risk 
summary 
assessment) 
Benefit-risk 
summary 
assessment 
Section 3 Section 2 Section 6 – Risk-benefit 
analysis 
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Table 7.6 Comparison of sections of reference agencies’ publicly available assessment reports with the BR Template 
(continued) 
BR Template US FDA EMA Health Canada TGA 
Content Medical 
Review 
Section 1 
(Risk Benefit 
Assessment) 
EPAR SBD AusPAR 
7.4.3 Discussion on outstanding issues 
and other significant information 
(hearings, advisories, patients, 
consumers, stakeholder inputs) 
Section 1 
(Benefit-risk 
summary 
assessment) 
Benefit-risk 
summary 
assessment 
Section 3 Section 2 Section 6 – Risk-benefit 
analysis 
7.4.4 Discussion on pharmacovigilance 
plans and risk mitigation plans 
Section 7, 
Section 1 
(Benefit-risk 
summary 
assessment) 
Risk management Section 2 – Pharmaco-
vigilance 
Section 2 & 4 Section 6 – Risk 
management plan 
7.4.5 Discussion on need for further 
studies 
Section 6, 
Section 1 
(Benefit-risk 
summary 
assessment) 
Risk management Sections 2 & 3 Section 2 & 4 Section 6 – Risk-benefit 
analysis 
7.4.6 Any other information relevant to 
the benefit-risk decision 
Section 1 
(Benefit-risk 
summary 
assessment) 
Benefit-risk 
summary 
assessment 
Section 3 Section 2 Section 6 – Risk-benefit 
analysis 
7.4.7 Conclusion on the benefit-risk 
balance for proposed indication 
Section 1 
(Benefit-risk 
summary 
assessment) 
Benefit-risk 
summary 
assessment 
Sections 3 & 4 Section 2 Section 6 - Outcome 
7.4.8 Recommendation indication Section 1 
(Benefit-risk 
summary 
assessment) 
Benefit-risk 
summary 
assessment 
Section 4 Section 1 Section 6 - Outcome 
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In reviewing safety, it appeared that the US FDA Medical Review’s format is very 
detailed in discussing various safety parameters, including the adequacy of 
assessment and safety explorations (dose dependency, time dependency, etc). As 
noted for the assessment of efficacy, there is no function similar to Section 3 of the 
BR Template to explicitly show the identified risks. Discussion of post-marketing 
experience was absent in the BR Template. While there is no such dedicated section, 
this discussion could have been carried out as part of pharmacovigilance review in 
the BR Template. It is noted that only the US FDA has a specific section on post-
market experience which was not found in the other three agencies’ formats. 
 
For the second comparison between the section of Recommendations/Risk Benefit 
Assessment and the BR Template, the discussion on the assessment of benefits, 
risks, risk management and benefit-risk balance are adequately covered by both 
documents. Again, it was found that the US FDA’s Risk Benefit Assessment did not 
explicitly present evaluations through weighting, valuing, visualisation or listing of 
identified benefits and risks. Moreover, the Risk Benefit Assessment did not appear 
to provide inputs or conclusions on quality, non-clinical and human pharmacology. 
 
Overall, it was observed that the US FDA Medical Review was designed to present 
details of the evaluation processes including those of the studies and considerations, 
while the BR Template presents only the information that will directly contribute to the 
decision on the benefit-risk balance. This can be seen in the detailed structure of the 
US FDA Medical Review, compared to a more concise benefit-risk documentation 
template. In terms of utility, the BR Template and BR Summary Template appear to 
share the US FDA Medical Review’s capability to present critical information 
regarding the benefit-risk decision. The additional details in the US FDA Medical 
Review format may offer an advantage in transparency, but the more explicit display 
using the BR Template’s sections 3 (identified benefits and risks), 5 and 6 (weighting, 
valuing and visualisation) may facilitate this outcome better through a more 
structured format on the discussion for benefit-risk balance and therefore enhance 
communication. 
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EMA’s EPAR  
The EPAR’s format allows appropriate discussion of quality, non-clinical and clinical 
findings, whereas the required details are not accommodated by the BR Template 
(Table 7.1). Identified benefits and risks (Section 3 of BR Template) are not explicitly 
listed in the EPAR, unlike the BR Template. A dedicated section on 
pharmacovigilance is included in the EPAR, but limited information in the BR 
Template. Similarly, an entire section in the EPAR was given to discussing user 
consultation, but is only available as a single question in the BR Template. 
 
In assessing the benefit-risk balance, the BR Template provided more structure 
through the use of guiding questions, while for the EPAR it was a general descriptive 
write-up. Weighting, valuing and visualisation (Sections 5 and 6 of BR Template) are 
not featured in the EPAR. Overall, with the exception of details on quality, non-
clinical, human pharmacology, pharmacovigilance and user consultation, the utility of 
the EPAR is found to be similar to the BR Template in presenting relevant information 
leading to the benefit-risk decision. The BR Template would offer the advantage of 
presenting outcomes on weighting, valuing and visualisation when deciding on the 
benefit-risk balance. This may confer improved transparency as well as 
communicating the basis of the decision. 
 
Health Canada’s Summary Basis of Decision (SBD) 
All eight sections of the SBD were compared to the BR Template to assess if the 
former could fulfil the requirements of the BR Template in presenting information on 
benefit-risk balance. The SBD appears to present quality, non-clinical and clinical 
assessment with a similar focus, which is different from the BR Template which 
attempts to focus on the clinical efficacy, safety and the resulting benefit-risk balance. 
While it may appear that the BR Template lacks details on quality and non-clinical 
assessment outcomes, it should be noted that the intention with the BR Template is 
to communicate only the significant quality, non-clinical and human pharmacology 
issues that contribute to the benefit-risk decision.  
 
In the assessment of efficacy and safety, it appears that the SBD does not provide a 
detailed structure in presenting this information which may lead to a general 
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discussion. Of note, identified benefits and risks may not be explicitly displayed (as in 
Section 3 of the BR Template). This general structure is similarly found in their 
assessment of the benefit-risk balance and recommendations. While the BR 
Template provides specific details by using structured questions, the SBD appears to 
facilitate a general descriptive write-up instead. Weighting, valuing and visualisation 
of benefit-risk balance (sections 5 and 6 of BR Template) are not presented in the 
SBD, an observation common to all the agencies considered in this study. Overall, 
the SBD would require more details than the BR Template for quality, non-clinical 
and human pharmacology assessment. However, they are comparable for the 
documentation of clinical efficacy, safety and benefit-risk assessment. In particular, 
opinions on identified benefits, risks, weighting, valuing and visualisation are only 
available with the BR Template, and may offer a higher level of quality in 
communication compared to the SBD. 
 
TGA’s AusPAR  
All six sections are compared to the BR Template to assess the ability of the AusPAR 
to fulfil the requirements of the BR Template. The BR Template does not 
accommodate the details of quality, non-clinical and human pharmacology as per the 
AusPAR, but presents the relevant and significant findings via the respective 
conclusions. For the AusPAR, the discussion on the efficacy and safety are not 
further structured, unlike in BR Template where these are supported with guided 
questions on identified benefits, risks and uncertainties. There is however a 
dedicated section for pharmacovigilance findings, which is also included as a single 
question in the BR Template. 
 
While there is no defined summary for the AusPAR, the section 6 (Overall conclusion 
and risk/benefit assessment) appears to function similarly to US FDA’s Section 1 
(Recommendations/risk-benefit assessment) and EPAR’s executive summary. 
Section 7 (Conclusions) of the BR Template is closely aligned to this section of the 
AusPAR. As with other formats, Sections 5 and 6 (weighting, valuing and 
visualisation) of the BR Template are not featured in the AusPAR.  In particular, the 
discussion of benefit-risk assessment appears to be better structured in the BR 
Template. Overall, with the exception of details on quality, non-clinical, human 
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pharmacology and pharmacovigilance, the AusPAR meets the requirements and 
utility of the BR Template. As observed with the other agencies, additional features of 
the BR Template may help increase the effectiveness of discussion and 
communication. 
 
Part III – Comparison of the four reference agencies’ report templates with the 
BR Summary Template 
Two reference agencies have defined summaries within the report. The US FDA 
Medical Review has the Recommendations/Risk Benefit Assessment which is a 
discussion based on the benefit-risk framework employed by US FDA (Table 7.7). 
The Executive Summary of the EMA’s EPAR does not have a structure and presents 
the information in a general discussion. The entire Health Canada’s SBD and TGA’s 
AusPAR were compared to the BR Summary, as it is the intent of both to function as 
summaries of the actual assessment reports.  
 
Table 7.7 US FDA’s Benefit-risk framework 
 
 
As there was no information on the official format for the US FDA’s Risk Benefit 
Assessment, a sample of the Risk Benefit Assessment obtained from the Medical 
Review of Zaltrap® was used as a reference. In the Risk Benefit Assessment of 
Zaltrap®, there were six headings: 
1. Analysis of condition 
2. Unmet medical need (corresponding to “Current treatment options” of the 
framework) 
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3. Clinical benefit 
4. Risk 
5. Risk management 
6. Benefit-risk summary assessment 
Given that the format appeared to closely reflect the benefit-risk framework, the 
comparison was conducted using the terms of the US FDA’s benefit-risk framework. 
Although the 5-step benefit-risk framework may appear less comprehensive than 
other existing frameworks, the US FDA is currently reviewing a list of questions that 
should be included under each of these steps, in an approach similar to EMA 
guidance for assessment of benefits and risks. The general findings were similar to 
those for BR Template, with the exception of EMA’s EPAR Executive Summary, as 
there is no format for comparison (Table 7.8). 
 
US FDA’s Risk Benefit Assessment 
The Risk Benefit Assessment was comparable to the BR Summary Template. Similar 
to the observations for the BR Template, the BR Summary Template offered an 
explicit display of identified benefits and risks, weighting and valuing which are 
absent in the US FDA format. This format presents a general write-up under six 
headings, while the BR Summary Template provides guided information through the 
various structured questions in its five sections. Therefore, it appears that the BR 
Summary Template may have the potential to increase transparency for this type of 
communication with the additional features of listing identified benefits and risks, 
weighting, valuing and visualisation. 
 
EMA’s EPAR Executive Summary 
The Executive Summary of the EPAR was compared with the BR Summary 
Template in assessing the utility of the former in fulfilling the requirements of the BR 
Summary Template. Unlike the US FDA’s Risk Benefit Assessment, there is no 
official format to the Executive Summary. As such, the BR Summary Template, which 
presents structured, concise information leading to the benefit-risk decision, exceeds 
the utility of the Executive Summary in the EPAR. The BR Summary Template may 
communicate the outcomes in a more transparent manner than the Executive 
summary in the EPAR. 
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Table 7.8 Comparison of reference agencies’ report templates with the BR Summary Template 
BR Summary Template US FDA EMA Health Canada TGA 
Content Benefit-risk framework EPAR – Executive Summary SBD AusPAR 
1.1 Background (Decision context)     
1.1.1 Specify proposed therapeutic indication Analysis of condition Not available Not available Section 1 
1.1.2 Treatment modalities evaluated Current treatment 
options 
Not available Not available Section 1 
1.1.3 Medical need Analysis of condition Not available Section 2 Section 1 
2.1 Overall summaries  Not available   
2.1.1 Quality conclusions Not available Not available Section 7 - Quality Section 6 
2.1.2 Non-clinical conclusions  Not available Not available Section 7 – Non-
clinical 
Section 6 
2.1.3 Human pharmacology conclusions  Not available Not available Section 7 - Clinical Section 6 
2.1.4 Clinical conclusions  Benefit, Risk Not available Section 7 - Clinical Section 6 
3.1 Identified benefits and risks     
3.1.1 Listing of all benefits, and justification for 
inclusion and exclusion 
Not available Not available Not available Not available 
3.1.2 Listing of all risks, and justification for 
inclusion and exclusion 
Not available Not available Not available Not available 
4.1 Clinical study summary Benefit Not available Section 7 - Clinical Section 4 
5.1 Risks: Overall summary Risk Not available Section 7 - Clinical Section 4 
6.1 Weighting and valuing of benefits and 
risks 
Not available Not available Not available Not available 
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Table 7.8 Comparison of reference agencies’ report templates with the BR Summary Template (continued) 
BR Summary Template US FDA EMA Health Canada TGA 
Content Benefit-risk framework EPAR – Executive Summary SBD AusPAR 
7.1 Conclusion     
7.1.1 For negative benefit-risk balance, 
discussion on the harms 
Benefit-risk summary assessment Not available Section 2 Section 6 
7.1.2 Discussion on evolution of the benefit-
risk balance 
Benefit-risk summary assessment Not available Section 2 Section 6 
7.1.3 Discussion on outstanding issues and 
other significant information (hearings, 
advisories, patients, consumers, stakeholder 
inputs) 
Benefit-risk summary assessment Not available Section 2 Section 6 
7.1.4 Discussion on pharmacovigilance plans 
and risk mitigation plans 
Risk Management Not available Section 2 & 4 Section 6 
7.1.5 Discussion on need for further studies Risk Management Not available Section 2 & 4 Section 6 
7.1.6 Any other information relevant to the 
benefit-risk decision 
Benefit-risk summary assessment Not available Section 2 Section 6 
7.1.7 Conclusion on the benefit-risk balance 
for proposed indication 
Benefit-risk summary assessment Not available Section 2 Section 6 
7.1.8 Recommendation indication Benefit-risk summary assessment Not available Section 1 Section 6 
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Health Canada’s Summary Basis of Decision  
In keeping with the understanding that the SBD was designed as a summary, it is 
therefore important to compare the utility of the SBD in fulfilling the requirements of 
the BR Summary Template. The BR Summary Template allows the conclusions of 
each contributing section (quality, non-clinical, clinical and benefit-risk assessment) 
to be presented. It should be stated that the BR Summary Template, for sections 8.3 
(identified benefits and risks), 8.4 (weighting and valuing) and 8.5 (benefit-risk 
management), was designed to highlight the key concerns in the assessment that led 
to the final recommendations in a more structured and guided manner. The two 
former functions were absent in the SBD.  
 
TGA’s AusPAR  
The AusPAR appears to represent the functional sections (sections 1 to 5) of the BR 
Summary Template, taking into account that the BR Summary Template was not 
designed to accommodate the level of details in the AusPAR.  Section 6 (overall 
conclusion, risk/benefit assessment) of the AusPAR was then compared to the BR 
Summary Template and was found to be at least similar to the contents required, with 
the added potential of the BR Summary Template being able to present outcomes on 
weighting, valuing and visualisations, as well as listing the identified benefits and 
risks. 
 
Part IV – Case study of US FDA’s and EMA’s summary reports on Zaltrap® 
Zaltrap® (aflibercept) was approved by both US FDA and EMA and the publicly 
available Medical Review and EPAR were retrieved from the internet. Only the Risk 
Benefit Assessment (Section 1) from US FDA’s Medical Review and Executive 
Summary of the EPAR were used to complete the fields in the BR Summary 
Template. Both the Risk Benefit Assessment and Executive Summary appear to 
have provided similar information (Table 7.9), but presented in a different manner. 
The Executive Summary was written in a continuous descriptive prose but the Risk 
Benefit Assessment of the US FDA’s was presented under six headings. Overall, the 
BR Summary Template is more structured in presenting the information for the 
benefit-risk decision.  
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Table 7.9 Case study using Zaltrap® – Comparison of US FDA and EMA 
summaries with BR Summary Template 
BR Summary Template US FDA EMA 
Content Risk Benefit 
Assessment 
EPAR – 
Executive 
Summary 
1.1 Background (Decision context)   
1.1.1 Specify proposed therapeutic indication √ √ 
1.1.2 Treatment modalities evaluated √ √ 
1.1.3 Medical need √ √ 
2.1 Overall summaries   
2.1.1 Quality conclusions Not available Not available 
2.1.2 Non-clinical conclusions  Not available Not available 
2.1.3 Human pharmacology conclusions  Not available Not available 
2.1.4 Clinical conclusions  √ √ 
3.1 Identified benefits and risks   
3.1.1 Listing of all benefits, and justification for inclusion and exclusion Not available Not available 
3.1.2 Listing of all risks, and justification for inclusion and exclusion Not available Not available 
4.1 Clinical study summary √ √ 
5.1 Risks: Overall summary √ √ 
6.1 Weighting and valuing of benefits and risks Not available Not available 
7.1 Conclusion   
7.1.1 For negative benefit-risk balance, discussion on the harm Not available Not available 
7.1.2 Discussion on evolution of the benefit-risk balance Not available √ 
7.1.3 Discussion on outstanding issues and other significant information 
(hearings, advisories, patients, consumers, stakeholder inputs) 
Not available Not available 
7.1.4 Discussion on pharmacovigilance plans and risk mitigation plans √ Not available 
7.1.5 Discussion on need for further studies √ √ 
7.1.6 Any other information relevant to the benefit-risk decision √ Not available 
7.1.7 Conclusion on the benefit-risk balance for proposed indication √ √ 
7.1.8 Recommendation indication √ √ 
 
US FDA’s Risk Benefit Assessment 
The BR Summary Template was completed with the information (Figure 7.1) from the 
Risk Benefit Assessment for Zaltrap®. The decision context of the BR Summary 
Template could be sufficiently completed with information from the Risk Benefit 
Assessment section. Similar to the EMA’s Executive Summary, quality, non-clinical 
and human pharmacology conclusions were excluded from the Risk Benefit 
Assessment. However, as both clinical safety and efficacy conclusions were available 
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in the Risk Benefit Assessment, the clinical conclusion in the BR Summary Template 
was completed easily. 
 
The benefits were included for the benefit-risk assessment but no reasons were 
provided for their inclusion. There was no information provided on those benefits 
which were reviewed but subsequently excluded. Safety parameters included were 
inferred by the reasons provided in the Risk Benefit Assessment but the risks 
reviewed and subsequently excluded were not documented. Weighting (relative 
importance) and valuing were not documented, as was the case for the EMA’s 
Executive Summary. However, there were no specific comments on the uncertainties 
relating to the listed benefits and risks. The structured section of the BR Summary 
Template could be completed from this Risk Benefit Assessment.  Overall, the utility 
of the BR Summary Template over the US FDA’s Risk Benefit Assessment appears 
to be in providing a more structured and guided discussion of the decisions leading to 
the eventual benefit-risk balance. 
 
EPAR’s Executive Summary 
The BR Summary Template was completed with the information (Figure 7.1) from the 
EPAR’s Executive Summary. The Executive Summary has no structure and is 
presented in a single section. The quality, non-clinical, human pharmacology 
conclusions of the BR Summary Template could not be completed as they were 
absent from the Executive Summary. As there was no specific safety summary, the 
clinical conclusion of the BR Summary Template was incomplete. The benefits 
presented in the Executive Summary were included for the benefit-risk assessment, 
but no reasons provided for their inclusion. Similarly, as there were no indications for 
inclusion or exclusion, it is assumed that all safety parameters considered were 
included in the Executive Summary. 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
Figure 7.1 The BR Summary Template completed with US FDA Risk Benefit Assessment and EPAR Executive 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
 189 
 
 
 
 
 
 
 
 
US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
No tables or figures available No tables or figures available 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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US FDA Medical Review – Risk Benefit Assessment EMA EPAR – Executive Summary 
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 Sufficient information was provided in the Executive Summary to complete the BR 
Summary Template’s clinical study information and table, but no weights, values or 
comments on uncertainties were available. As for safety information, there was much 
less available information which did not allow any weighting and valuing to be 
documented. The above observations are expected as weighting is carried out 
implicitly but not explicitly in many agencies. However, the safety exposure 
information was written entirely as a paragraph and could not be uploaded as an 
image into the BR Summary Template, thus eliminating the opportunity to present 
these data. The structured discussion of the BR Summary Template was not 
adequately completed using the Executive Summary.  In conclusion, more 
information beyond the EMA’s Executive Summary would be required to complete 
the fields for the BR Summary Template. This is due to the extensive structure and 
guiding questions in the BR Summary Template and the need for conducting the 
exercise on identifying benefits, risks and allocating weights and values. 
 
DISCUSSION 
The comparisons conducted in this study showed that the publicly available 
assessment reports from the four reference agencies are similar and generally allow 
the information generated through the course of the evaluation to be described. The 
differences between these reports are largely due to format arrangement and 
headings provided for each section. While there is no universal template for an 
assessment report, this finding suggests that with small differences among the format 
of these reports, there does not appear to be major discrepancies on how such 
information should be presented. This may also suggest that given the commonalities 
among the formats, only minor changes may be required to their current formats in 
order to achieve a potential universal standard structure.  
 
The publicly available assessment reports are the means for documenting the 
relevant information made available to stakeholders and to communicate the basis 
and justification for these decisions. The US FDA has made recent efforts, as 
detailed in PDUFA V, to provide a Risk benefit assessment, based on their benefit-
risk framework, which detailed their considerations contributing to the regulatory 
decision and features an additional succinct benefit-risk assessment summary. EMA 
had commissioned an external expert to improve its communication of benefits and 
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 risks (EMA, 2011e). The EPAR has been using the Executive summary to provide 
concise information. Health Canada had completed its two phases of the initiative to 
improve documentation and communication to the public, with an emphasis on the 
discussion of the benefit-risk balance and the basis of the decision (Health Canada, 
2012a and 2012b). Likewise, TGA has commenced a project targeted at improving 
communication of information to patients and physicians (TGA, 2013). It can thus be 
concluded that these agencies recognise the need to effectively communicate the 
basis of their decisions through a concise documentation tool and have been active 
in refining these as seen specifically in the initiatives undertaken.  
 
In an effort to improve documentation and communication of benefit-risk decisions, it 
should be determined if these activities are of relevance to the different stakeholders, 
as highlighted in the above EMA study in 2011. The objectives of the regulator 
preparing the document may frequently not meet the expectations of the 
stakeholders who will be receiving the information. Therefore, it is vital to agree on 
who these stakeholders are and assess their expectations. In the traditional 
healthcare model, the key stakeholders are the physicians and their patients. 
However, in the contemporary context of today’s regulatory science, it appears that 
such information on the basis of benefit-risk decisions are also sought by health 
technology assessment agencies, pharmaceutical companies and patient advocacy 
groups.  
 
For most patients, their primary concern would be to know if the product is effective 
and safe, while the physicians would want to know the details to make a better 
informed decision when choosing an optimal treatment for their patients. It is 
therefore important that the basic information on proof of efficacy and safety 
concerns be well documented and explained clearly. For pharmaceutical companies, 
a documented transparent decision-making process will enable them to understand 
the basis of the regulatory decision, the rationale for the inclusion and exclusion of 
benefits and risks as well as the views on the final benefit-risk balance, as described 
as one of the initiatives under US FDA’s PDUFA V on improving the collaboration 
with the industry (FDA, 2012a). This would therefore provide a suitable platform to 
discuss any discrepancies in interpretation or difference in opinions. HTA agencies, 
in their course of evaluating the product for pricing and reimbursement, would also 
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 want to understand the rationale for the approval of a product (MHRA, 2013b). The 
failure to do so would render a product not being accessible to patients and affecting 
the healthcare system in terms of cost and clinical management. The accurate 
documentation of the benefits and risks of a product would also assist in a 
comparison with other existing treatment options, aiding the HTA agencies in 
reviewing the product for inclusion. Importantly, patients and patient advocacy groups 
increasingly seek to understand the decisions taken for the approval and availability 
of a product and provide inputs to decision makers on the issues that matter to them. 
Assessment reports of major regulatory agencies are often accessed by smaller 
agencies in the emerging markets to support their local decisions and thus these 
regulatory agencies should also be considered as key stakeholders for the publicly 
available assessment reports. In lieu of the vast difference in expectations, regulatory 
agencies should seek to understand the spectrum of needs of the various 
stakeholders and assess if the current approaches are valid and effective. As the 
purpose of such documentation is to communicate to stakeholders, further research 
is required to ascertain expectations and obtain more opinions on the way forward. 
 
Certain jurisdictions may require publication of the assessment reports as a move to 
increase the transparency of the decision-making processes while different 
jurisdictions may require varying amounts of information to be made public. As 
discussed above, it is also not known if the current practices of providing the publicly 
available assessment reports actually achieve the transparency required or desired 
by the stakeholders as there are no studies describing this type of feedback from 
pharmaceutical companies, physicians, patients, or regulatory agencies. In the 
process of writing an assessment report, reviewers should provide information to 
support and justify the decisions made. However, achieving transparency through the 
provision of information does not always correlate to effective communication. The 
vast amount of unstructured information provided may possibly hamper 
understanding and thus communication. The use of summaries like the Executive 
Summary of the EPAR and the Risk Benefit Assessment of US FDA aims to further 
improve communication through concise information. However, as seen in this case 
study using Zaltrap®, a more structured and guided discussion may further help 
improve both transparency and communication and prevent the omission of 
information assessed by the reviewer but deemed important to stakeholders. The 
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 comparison of the summaries showed that there are elements missing which could 
facilitate effective communication. As such, the elements from the BR Summary 
Template found missing in the summaries of the reference agencies may serve as a 
starting platform to enhance the effectiveness in communicating benefit-risk 
decisions.  
 
In the pursuit of improved communication, there should be a balance between the 
amount of information provided to satisfy the transparency of the process versus the 
impact of interpretation and understanding by the recipient. Key messages may be 
difficult to find from the vast amount of information in the assessment reports and 
hence mitigate the purpose of these reports. Further studies should be considered to 
investigate the effectiveness of communication using the various templates among 
different stakeholders. It has been observed that although the EMA provided 
guidance on the assessment of benefits and risks, the pertinent considerations by the 
reviewers have not been explicitly featured in the EPAR.  Through this study it was 
found that only the BR Template and BR Summary Template provides an 
appropriate, structured and guided approach based on the EMA’s Reflection paper 
(EMA, 2008). This ensures that the relevant considerations have been taken into 
account and made available to the recipient for their understanding. The provision of 
a list of identified benefits and risks and visualisations aims to facilitate 
communication by reducing the amount of text needed to convey these messages.  
 
As a result of this study, future attempts to improve the quality of communication 
should consider the following and include: 
o A listing of benefits and risks, with justification for their roles in assessing the 
benefit-risk balance 
o Valuing the identified benefits and risks 
o Weighting (relative importance) of the identified benefits and risks 
o Providing visualisations of the outcomes 
o Utilising guided discussions and structured questions (e.g. deliberations on 
uncertainties, consistency of outcomes across studies, additional risks compared 
to standard of care) to illustrate key discussion points leading to benefit-risk 
decisions 
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Given that there are minimal differences among the existing templates of the 
reference agencies, it is timely to consider the feasibility of a universal template. The 
BR Template and BR Summary Template were based on the EMA’s Reflection paper 
for the assessment of benefits and risks and also allow the documentation of these 
considerations in support of the decision. Unlike the existing templates, the guided 
discussion, structure, listings of identified benefits and risks, application of values and 
weights and visualisation, of the BR Template serve to improve effective 
communication. Familiarity with a standard template and its presentation format will 
enhance the stakeholders’ experience in seeking and understanding the key 
messages. A universal framework for the assessment of benefits and risks will be 
required to bring focus among the agencies, which would then facilitate the 
implementation of a standard, universal documentation tool. An 8-step universal 
benefit-risk framework has been developed which incorporated the existing ones by 
major regulatory agencies and those used by pharmaceutical companies. Given that 
the BR Template and BR Summary Template was developed using the principles 
from this universal framework, there is now the opportunity to explore the universal 
use of these two templates. However, as the basis for publicly available assessment 
reports, it would be prudent to seek more confirmative opinions from stakeholders on 
the feasibility and utility of such an initiative through the conduct of further studies. 
 
In the course of this study, some areas for improvement were identified for the BR 
Template and BR Summary Template. These included expanding the discussion on 
pharmacovigilance and RMP/REM, which would then align to the recent 
requirements for PBRER’s and the emphasis on post-market activities. As 
stakeholders are increasingly seeking their opinions to be acknowledged, there 
should also be dedicated and defined areas for inputs from the various stakeholders, 
particularly patients. These improvements may enable the BR Template to 
accommodate the requirements in the post-marketing setting as well as a tool for 
product life cycle management. If used as a universal template, it could trace and 
document the evolution of the benefit-risk balance of a product and provide 
meaningful comparisons using valid baselines. Ultimately, this may translate to an 
increase in consistency, transparency and the quality of decision-making. 
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 SUMMARY 
• The format of existing reports of major regulatory agencies are generally similar 
• The areas found lacking in existing formats are the listing of benefits and risks, 
assigning of weights and values, visualisation and a more detailed, systematic 
standardised structure 
• Given the difference in expectations from various stakeholders, it is important to 
further investigate their needs and how future templates can satisfy these 
requirements 
• The BR Template and BR Summary Template appear to have an advantage over 
existing formats as they are based on the principles of benefit-risk assessment 
common to major regulatory agencies 
• Finally, there is potential for the BR Template and the BR Summary Template to 
be further researched to meet the various needs of the stakeholders 
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General discussion  
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 The evaluation of medicines has traditionally been conducted as separate 
assessments of efficacy and safety, in which a regulatory decision is based on 
proven efficacy supported by clinical studies matched with an acceptable safety 
profile. The trend in the assessment of benefits and risks is currently towards a 
holistic discussion of the benefits, risks and the overall benefit-risk balance. This 
allows for a clear view of the relationship between the benefits identified and the risks 
potentially expected from the treatment and how the eventual balance is achieved to 
justify a regulatory decision for the medicine. Over the years major regulatory 
agencies and pharmaceutical companies have indeed made progress in improving 
the frameworks for the assessment of benefit-risk balances, but these are largely 
based on individual efforts due to the lack of a common universal framework. This 
suggests the beginning of a challenge to implement a universal framework, as these 
stakeholders are striving to develop a framework specific to their own jurisdictions 
and suited to their purposes. Without a universal framework, the current lack of 
consistency in making regulatory decisions and transparency of communication may 
be further perpetuated, leading to misunderstandings among the stakeholders and 
the potential unavailability of important medicines in some jurisdictions. 
 
In reviewing the current environment on the use of benefit-risk assessment 
frameworks, it was found that both agencies and companies were using either 
qualitative or semi-quantitative systems. Among the companies, different approaches 
may be employed for product development and during regulatory submission. The 
majority of organisations who are currently using semi-quantitative systems were not 
satisfied and many expressed concerns about adopting a methodology that did not 
match the requirements of the other stakeholders, given that there is no one 
framework that is recognised by all. It was hoped that a universal framework would 
be structured, standardised and be applied throughout product development to 
submission for registration. Indeed, when the reason was sought as to why semi-
quantitative or quantitative systems were not used, the majority indicated the lack of 
a scientifically, validated universal framework. 
 
A disparity was observed in the opinions of the current methodologies used for the 
assessment of benefits and risks. While the agencies and companies considered  
Bayesian statistics and MCDA as useful and relevant, these were not the main tools 
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 they were utilising, namely the qualitative approach, NNT/NNH and evidence based 
benefit-risk model. In the assessment of benefits and risks, most agencies and 
companies frequently assigned values to these parameters but not the assignment of 
weights or relative importance. It could be that weighting was carried out implicitly 
and considered during the evaluation of the overall benefit-risk balance. In 
communicating benefit-risk decisions, none of the agencies had used visualisation 
tools, while the companies had such tools for internal communication and 
infrequently for health professionals and patients. Therefore this lack of a universal 
framework could have led to the inconsistent approaches in the assessment and 
communication of benefits and risks across the agencies, companies and within 
these organisations themselves.  
 
The agencies and companies believed that a benefit-risk framework should be used 
for the life cycle of a medicine. This is a consistent finding as confirmed by an earlier 
workshop conducted by CIRS (CMR, 2008) for various stakeholders including the 
agencies and companies. Such a framework should enhance the quality of 
communication and enable the assessment of benefit-risk management plans. In 
developing a framework for the future, it would be useful to have a coordinating group 
to guide its direction and application and to involve relevant stakeholders. A framework 
should confer the advantages of an appropriate documentation and the enhancement 
of communication.   
 
Seven factors were identified which both agencies and companies agree would be 
relevant to reviewing a framework. These included logical soundness, 
comprehensiveness, acceptability of results, practicality, specificity and sensitivity, 
presentation (visualisation) and scope. The first four factors are similar to those used 
in the first and second work packages by the EMA in their benefit-risk methodology 
project (EMA, 2010 and 2011b) with the last factor generativeness not being used in 
this research. However, in order to reflect the scientific robustness that is critical for 
the assessment of benefits and risks, statistical concepts of specificity and sensitivity 
was added to the list. As it was then known that the graphical presentation of results 
would help communication (CMR, 2010; CIRS, 2011), visualisation was added as a 
factor to review if the framework would support this up-coming communication 
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 strategy. Lastly, to ensure that the benefit-risk assessment framework would be 
applicable to all scenarios and for the entire product life cycle, scope was added as 
the final factor in reviewing such frameworks. In the review of benefit-risk assessment 
methodologies, the IMI PROTECT (2011b) had referenced the EMA’s criteria in the 
fore-mentioned work packages and had put the required emphasis on visual 
presentation. Therefore, it is believed that this new set of seven factors for reviewing 
a benefit-risk assessment framework not only encompassed those used for two other 
major projects, but is also a reflection of the contemporary ideals among the 
agencies and companies for such frameworks. 
 
The lack of an accepted and validated framework was a significant barrier for 
agencies and companies. Additional barriers included the absence of a consensus 
on the needs of the stakeholders and direction of the purpose and utility of a 
framework, as well as the lack of acceptance by the major regulatory agencies. In 
addition, the universal framework should be comprehensible, easy to understand and 
use, be flexible and accommodate the different scientific methods of assessing 
benefits and risks. The outcomes of EMA’s work packages (2011d and 2012) and IMI 
PROTECT (2011b), both of which utilised the PrOACT-URL framework, confirmed 
that a qualitative and flexible framework would be required to achieve the above.   
 
The requirements for a universal framework ought to be sought from the 
stakeholders whose inputs will directly affect the benefit-risk decision and the final 
regulatory outcome. These have been identified as the regulatory agencies, 
pharmaceutical companies, physicians, HTA agencies and the patients. While this 
study obtained only the views of the agencies and the companies, there are on-going 
studies to assess the contribution of the other stakeholders to the decision-making 
process. These include patients’ involvement (EMA, 2011e; FDA 2013) and health 
technology assessment (HTA) agencies (EMA, 2013c). While the study was 
conducted with major and medium-sized agencies and companies it may not 
represent the entire regulatory environment. 
 
While there is no common framework for major regulatory agencies and companies, 
some do have their own frameworks for the assessment of benefits and risks. The 
EMA’s 8-step PrOACT-URL (EMA, 2010) (also used by the IMI PROTECT), the US 
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 FDA’s 5-step benefit-risk framework (FDA, 2013a), the BRAT 6-step framework 
(Coplan et al, 2011), the CIRS’ 7-step framework (CMR, 2010) and Novo Nordisk’s 
Benefit-Risk Assessment in New and old Drugs (BRAIN; CMR, 2010) were 
compared. With the exception of the US FDA’s framework, the rest were based on 
the principles of MCDA, which was earlier confirmed in the course of this research as 
a useful and relevant methodology. The eventual 8-step framework which has been 
developed in this research includes the defining of the decision context, building the 
value tree, refining the value tree, evaluating the options, assigning relative 
importance of the benefits and risks, evaluating the uncertainties, presenting the 
outcomes in a graphical manner and finally applying expert judgment and 
communicating the decision. Across the frameworks compared and the final 8-step 
framework, there are four common requirements considered fundamental to 
assessment, namely framing the decision, identifying the benefits and risks, 
assessing the benefits and risks and lastly interpreting and recommending a 
decision. However, the differences among the frameworks lie in the activities 
conducted to fulfil these requirements. Apart from the framework used by the US 
FDA, the rest advocated the use of weighting and valuing and the use of either an 
effects table (as in the case of PrOACT-URL) or other appropriate visualisation tools. 
This observation may be related to the fact that these frameworks follow the 
principles of MCDA while the US FDA was a unique qualitative framework. However, 
it should be noted that while the US FDA framework did not explicitly advocate the 
use of the weighting, valuing and visualisation it appears that it would be able to 
accommodate such activities. 
 
Between the final 8-step universal framework (Figure 8.1) and the EMA’s PrOACT-
URL, the latter had more emphasis on the discussion of risk tolerance and the 
consistency of decisions i.e. linked decisions. While this may be discussed as part of 
the uncertainties or implied with the use of weightings under the new framework, 
there may be value in soliciting directly the views on the risks the evaluator is willing 
to accept and how well the basis of the recommended decision aligns to previous 
ones made for similar scenarios. Among the BRAT framework, BRAIN and the new 
8-step framework, it appears the former two encourages the use of quantitative tools 
to provide a metric representation of the effects and scores, while the new framework 
may accommodate a qualitative discussion instead. Overall, the 8-step framework 
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 has struck a balance between more prescriptive frameworks requiring some 
quantitative outcomes and those which otherwise are too general in guiding the 
assessment of benefits and risks. As such, the universal utility of the final 8-step 
benefit-risk assessment framework is supported by the above comparison and it was 
developed with elements common to the other existing frameworks and used by the 
two major regulatory agencies and pharmaceutical companies. Hence, if all the 
processes of the final 8-step framework are carried out, the outcomes are expected 
to complete and fulfil the requirements of the other existing frameworks. This 
universal benefit-risk assessment framework is expected to enhance the objectivity 
and transparency of the decision-making process by providing a structured approach 
that could be adopted by regulatory agencies and pharmaceutical companies.  
 
Figure 8.1 The 8-step universal benefit-risk assessment framework 
 
 
In order to utilize the steps of the framework, a system for documentation of the 
assessment outcomes and effective communication must be in place. In the absence 
of the principles and methodologies for benefit-risk assessment from other major 
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 regulatory authorities, the published reflection paper by EMA (2008) was used as a 
reference for the development of the tool to document and communicate the 
outcomes of assessment and the basis of the decision in a consistent and 
transparent manner. The developmental version of the Benefit-risk (BR) Template 
was tested for functionality by the Consortium, consisting of TGA, Health Canada, 
SwissMedic and HSA. This was carried as a retrospective feasibility study. The final 
version consists of two sections, namely the “BR Template” and “Benefit-risk 
Summary”. The template was then reviewed against the core elements of the 
universal framework, namely framing the decision, identifying the benefits and risks, 
assessing benefits and risks, interpretation and recommendations. In relating to the 
8-step universal framework, the BR Template fully supports these requirements. To 
facilitate the use of the framework and template, a user manual was developed. This 
consisted of two sections, namely a glossary and instructions for completing the 
template. Consequently, the Benefit-risk Assessment Support System (BRASS) was 
developed and consisted of the 8-step Benefit-risk assessment framework, the 
Benefit-risk Template and the User Manual.  
 
It could be argued that the evaluation of BRASS by the four agencies of the 
Consortium would not represent the opinions of all stakeholders and thus 
undermines its utility as a universal framework. However, it should be noted that the 
universal framework was reflective of the current principles used by the major 
reference regulatory authorities and companies. As justified above and also at a 
workshop (CIRS, 2012b) attended by senior decision-makers of agencies and 
companies there was an agreement that the final 8-step universal framework covered 
the essential elements in other existing frameworks.  
 
Subsequently, a prospective study was therefore conducted with three agencies, 
namely TGA, Health Canada and HSA, to review the potential value of the BR 
Template and user manual. In order to achieve consistency in evaluating the 
responses of the agencies, a study evaluation tool was developed which included 
four sections namely user-friendliness, documentation, applicability and general 
comments.  Navigation functions were found sufficient to guide the user in the 
locating different sections of the template. The user manual too was found to be 
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 adequate though more specific details and examples of use could be provided. 
Overall, the BR Template and User Manual were found to be user-friendly.  
 
The BR Template was studied for its appropriateness in documenting relevant 
information supporting the benefit-risk decision, the benefits and risks, weights and 
values, study outcomes, safety information and overall conclusion. For information to 
support the decision, the template was found satisfactory in documenting the various 
relevant conclusions, with proposed modifications to allow greater details to be 
presented. The template was found more acceptable in documenting benefits than 
risks and consequently there were recommendations to provide greater clarity in the 
risk definitions and how these are to be selected for the benefit-risk assessment. 
Divergent views were obtained for the template’s use in documenting weights and 
values. However, this observation is very probably related to the current state of 
knowledge in applying weights and values for the assessment of benefits and risks. It 
is expected that in the future when more assessors are better acquainted with the 
concepts and application of weights and values, the opinions of the use of the 
template for this aspect would be better reflected.  
 
In reviewing its applicability, the BR Template was assessed on its ability to 
contribute to decision-making, consistency in standard of assessment, transparency, 
communication to stakeholders and consistency of decisions between agencies. With 
the exception of one agency, the above functions were deemed to be fulfilled by the 
template. The main concern of Health Canada, who disagreed, was that the template 
was neither able to capture critical thinking, nor other significant contributing factors 
such as the additional analyses that the reviewers requested from sponsors. If 
clarification is provided on the existing availability of appropriate sections in the BR 
Template to discuss these other contributing factors, it is believed that all three 
agencies would agree on the template’s applicability. All the agencies agreed that the 
BR template can ensure consistency in decision-making through improving 
regulatory memory, acting as an audit tool and contributing to post-marketing 
activities. The outcomes demonstrated the value of the template and user manual 
and its potential use in documenting and communicating benefit-risk decisions. 
Overall, all three agencies found the template and user manual fit for purpose with 
amendments. Importantly, all three agencies found the BR Template useful in 
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 documenting the uncertainties relevant to the identified benefits and risks. The 
potential and practicality of the BR Template in documenting, reporting and decision-
conferencing of benefit-risk decisions was therefore demonstrated. It would be of 
interest to evaluate the use of the template with an established mature agency, in 
particular the EMA, since their guidance was the basis of the template (EMA, 2008). 
This would help to convince stakeholders that the BR Template is applicable across 
regulatory agencies of all levels of establishment and maturity. 
 
To assess the template’s ability to act as a suitable tool for communication, the three 
agencies were asked if they are willing the share the completed BR Template and 
the summary section with stakeholders. Though it appeared there are reservations in 
sharing the entire completed BR Template, this view was due to concerns over 
confidentiality and memorandums of understanding with the stakeholders and not the 
functionality of the template. One agency, HSA, however felt that information for the 
public and media should be amended as the BR Template may contain information 
that is too technical for their understanding. Regarding the more succinct BR 
Summary section, the agencies would consider sharing this with stakeholders 
provided more details can be provided in this section and if the information is 
amended to tailor to the level of understanding for patients and media. It is noted that 
both TGA and Health Canada already provide public available reports and would 
thus be comfortable with the inclusion of more in-depth contents. HSA on the other 
hand is establishing itself as a maturing agency and may be more conservative in 
making available the information relating to their decisions. Nonetheless, the BR 
Template and the BR Summary Template allows amendments and can be tailored to 
suit each agency’s needs. 
 
Given the different regulatory capacities and maturation of the regulatory agencies 
across the world, some are leading this field while others, like those from the 
emerging markets, would likely leverage on the decisions of the major regulatory 
agencies. Therefore it is important that the basis of the decisions of the major 
agencies is effectively communicated to the rest of the stakeholders, which would 
include the agencies from the emerging markets. Although there may be publicly 
available assessment reports, these may contain a significant amount of information 
to review that would require both time and scientific capabilities that are not available. 
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 The potential use of the BR Summary section as a stand-alone tool for documenting 
and communicating benefit-risk decisions was thus identified, in the hope that it may 
aid the emerging markets. Consequently, this section was extracted and transformed 
into a stand-alone tool, now known as the BR Summary Template.  
 
A retrospective study was conducted using the BR Summary Template across 
different reviewers and products.  The study evaluation tool and user manual for the 
review of the BR Template were modified to suit the BR Summary Template. In 
general the BR Summary Template was found to be fit for purpose by a group of 
reviewers across a range of products in documenting the benefit-risk outcomes from 
abridged applications. The potential of the BR Summary Template is thus found to be 
suitable in fulfilling its role in documenting, reporting and decision-conferencing of 
benefit-risk decisions. However, there were reservations in sharing with patients, 
patient advocacy groups, media and in public domains as the use of technical terms 
and medical jargon may be lead to confusion and misinterpretation. 
 
Indeed, for the emerging markets that are more resource constrained with respect to 
their scientific capabilities, the BR Summary Template may also serve as a template 
for the assessment of medicines and as an internal standard in their pursuit to 
develop the capabilities of their agencies. There should be further studies to assess 
the use of the BR Summary Template in aiding emerging markets in their pursuit of 
improving their regulatory standards. This is in line with the earlier findings from a 
CIRS workshop (CMR, 2008) to include the emerging markets earlier in the 
development of benefit-risk frameworks, so as to increase the worldwide acceptance 
of a universal framework. The framework, through unifying the current practices by 
major regulatory agencies and pharmaceutical companies, may be seen as the 
definitive standard for a systematic assessment of benefits and risks. Likewise, the 
BR Template and BR Summary Template are useful tools to be considered for 
assessing, documenting and communicating benefit-risks decisions. It is important to 
understand that in the pursuit of an international impact of the developed framework 
and templates, the entire spectrum of stakeholders should be considered. Views from 
the Middle Eastern, Asian and Central American countries and their potential 
contribution have not, as yet, been sought. The implementation of the framework and 
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 templates may serve as a starting point to initiate further collaboration with these 
countries.  
 
As expectations of stakeholders evolve, it is pertinent that all information leading to a 
regulatory decision for a medicine is made available. This communication is vital to 
making an informed decision, especially for physicians in choosing a treatment best 
suited for their patients and HTA agencies in deciding reimbursement. Hence all 
considerations taken for making the decision should be made clear so that the 
stakeholder may relate them to their situation and apply these to their own decisions. 
While it is noted that both EMA (2008, 2010) and US FDA (2013) have undertaken 
initiatives to enhance the benefit-risk evaluation of a product, there is currently no 
standard template for the documentation and communication of the evaluation 
outcomes of benefit-risk decisions. Individual agencies would have their own internal 
evaluation report templates and also those for publicly available assessment reports, 
resulting in similar information being presented in different formats for the 
stakeholders. Earlier findings in the course of this research showed that both 
regulatory agencies and pharmaceutical companies believe that a benefit–risk 
framework would enhance the quality (transparency and consistency) of 
communication and should provide documentation for a structured discussion, acting 
as a tool for communication among peers within the organisation and between the 
organisation and stakeholders. Various agencies including the US FDA, EMA, TGA 
and Health Canada have embarked on improving the communication of information 
relating to benefit-risk decisions, but there is limited information on how well these 
publicly available reports are meeting the needs of the various stakeholders. The BR 
Template and BR Summary Template were designed to enhance effective 
documentation and communication of decisions and have been showed to be fit for 
purpose. The publicly available assessment reports from four major agencies, 
namely the US FDA (Medical Review), EMA (EPAR), Health Canada (SBD) and TGA 
(AusPAR), were therefore compared to see if they would adequately fulfil the 
functions found in the BR Template and BR Summary Template. 
 
The format of the reference agencies’ reports are generally similar but when 
compared with the BR Template were found to lack the key features that list the 
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 identified benefits and risks, application of values and weights (relative importance) 
and visualisation of the assessment outcomes. In addition, the BR Template presents 
a structure of guided questions to document relevant discussions and considerations 
contributing to the final benefit-risk decision. Similar findings were observed when the 
US FDA’s Risk Benefit Assessment, EPAR’s Executive Summary, Health Canada’s 
SBD and TGA’s AusPAR were compared to the BR Summary Template. To further 
illustrate the use of the BR Summary Template, a case study was conducted using a 
recent US FDA Medical Review (FDA, 2012b) and EPAR (EMA, 2013c) for the same 
product, Zaltrap® (aflibercept). This product is indicated for use, in combination with 
5-fluorouracil, leucovorin, irinotecan (known as the FOLFIRI regimen), in patients with 
metastatic colorectal cancer (mCRC) that is resistant to or has progressed following 
an oxaliplatin-containing regimen. Only the Risk Benefit Assessment from US FDA’s 
Medical Review and Executive Summary of the EPAR were used to complete the 
fields in the BR Summary Template. Overall, the BR Summary Template is found to 
be more structured in presenting the information for the benefit-risk decision.  
 
There is a strong implication that the observed failure to list benefits, risks, apply 
weights and values may not allow the effective communication of the decision. It is 
therefore important that these parameters should be documented or stakeholders 
may not fully understand the thought processes that contribute to the benefit-risk 
decision, thus resulting in a major drawback in the impact of communication. It was 
observed that the above features were omitted in the major reference agencies’ 
publicly available assessment reports. Hence, these widely accessible reports may 
not be effective in relaying the basis of decisions, leading to stakeholders 
misinterpreting the information. Such scenarios may lead to the lack of access to the 
patients should the HTA agencies not agree with the decision by the regulator, or a 
lack of trust to the healthcare administration for the perceived lack of transparency. In 
cases of disputes, the lack of appropriate documentation could eliminate a platform 
for discussing the potential areas of disagreement. There should be clear direction in 
providing documentation that communicates accurately the basis of the decision. The 
mere provision of materials may not always achieve this goal. The current reports by 
the reference agencies could afford more explicit opinions through listing the selected 
benefits and risks and their relative importance, as well as a structured discussion on 
the considerations leading to the final decision. While it is understood that relative 
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 importance of the parameters are assessed implicitly, for effective communication of 
benefits and risks (CMR, 2004, 2005 and 2010), it is imperative they are made 
explicit in any publicly available documents.  
 
Visualisation in communication of benefits, risks and the resulting balance was 
unanimously agreed to be of value by both agencies and companies. There is a lack 
of experience with this approach and of any agreement on a global level as to the 
best visualisation tool. It would seem that agencies and companies may prefer the 
incorporation of more details for discussion, while physicians and patients may prefer 
an overview to understand the decision taken. The fifth work package of IMI 
PROTECT (2013c and 2013d) provided various principles for the assessment of 
visualisation techniques, as well as specific techniques for the different benefit-risk 
methodologies. However, it is expected that for the successful implementation of 
visualisation techniques, further work will be required to understand the needs of the 
stakeholders and identify the appropriate corresponding visualisation tools, as well as 
obtain consensus at a global level. It appears that the work by IMI PROTECT would 
be a suitable starting platform for future international collaborations in pursuing 
universal acceptable visualisation tools. Training programs for the application of such 
tools should also be developed, as it is expected that this strategy for communicating 
benefit-risk decisions through graphical representation would be new to many 
stakeholders. 
 
To achieve an appropriate universal benefit-risk documentation template, the BR 
Template should be considered as a platform or reference for further development 
among the reference agencies. It is however acknowledged that due to different 
jurisdictions, it may not be possible to implement a common template for universal 
use as there may be legal obligations or restrictions in the information to be provided. 
It is however noted that the features of the BR Template, including the unique 
structure and use of guiding questions, are recognised as essential criteria for any 
template to effectively document and communicate benefit-risk decisions. 
 
Potential use in product life cycle management and adaptive licencing 
The use of the BR Template in post-marketing activities and pharmacovigilance has 
as yet not been fully investigated. As part of the life cycle approach, a single 
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 document should be used for the effective monitoring of changes in benefit-risk 
balances, as the initial documented benefit-risk for market approval would form the 
baseline for future assessment. As the BR Template documents the context of each 
decision, with the availability of new clinical information for efficacy and safety, each 
assessment can be relevant and consistent. Therefore, the BR Template should be 
considered for use in product life cycle management. 
 
The utility of the BR Template to document and communicate benefit-risk decisions 
should be viewed in the light of the two international reports currently required for 
regulatory submission, namely the Common Technical Document (CTD) (ICH, 2004) 
and the ICH PBRER (EMA, 2013a) meant for documenting pre-approval and post-
marketing information respectively. For initial marketing authorisation, the details of 
the product development are found in Module 3 (Quality), Module 4 (Non-clinical 
study reports) and Module 5 (Clinical study reports). Administration information is 
submitted in Module 1, which is customised to the specific regulatory requirements 
for each jurisdiction. Module 2 contains the summaries and can be considered akin to 
the BR Template and functions to succinctly communicate the rationale of 
development, supporting clinical outcomes and relevance to healthcare. Specifically, 
the CTD Module 2.5 Clinical Overview contains the clinical findings to support the 
submission and consideration for the registration of the product. Hence it appears 
plausible to introduce the 8-step universal benefit-risk assessment framework and 
the BR Template to guide the documentation and communication of the benefits and 
risks of the submitted product. By leveraging the use of an existing international 
submission package, the implementation of the framework and template can be 
consistently carried out. In a similar manner, by incorporating the framework and 
template within the PBRER, the consistent utility of the above can be ensured for the 
entire life cycle. As clinical assessment of new information for benefits and risks are 
required, the universal framework can ensure that consistent standards are being 
applied. It appears that all sections of the BR Template can be incorporated into the 
PBRER, especially for section 18, which is dedicated for the discussion of the 
integrated benefit-risk analysis for the approved indications.  
 
In maintaining the stand for a core documentation tool, it would be an ideal situation 
that a single BR Template be used by all stakeholders. This would commence with 
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 the companies in their submission to the agencies, documenting the benefit-risk 
balance that supports the application. The agencies will conduct the assessment as 
per their current processes, but would input their decisions into the same BR 
Template utilised by the company. This BR Template would then remain as a core 
document for which future benefit-risk information, for example post-marketing 
activities and product variations, would be appended. Indeed, this can be part of the 
proposed solution to have guidance on the universal framework at an international 
level. Future work should include collaborations with ICH and review how the 
universal framework and BR Template could be incorporated and its use continued 
from the CTD to PBRER. 
 
Innovations in regulatory science are now exploring new strategies to allow faster 
access to important medicines, including adaptive licencing (AL). It may involve 
looking at the benefit-risk balance in a specific and limited patient population and 
granting an initial authorisation (Eichler et al., 2012b). Real life data on safety would 
be generated through the actual use of the product post-authorisation, while more 
clinical studies are being completed to show efficacy in another disease aspect or in 
a wider population. The marketing authorisation would be amended to encompass 
the wider use of the product as more safety and efficacy data becomes available 
over time. It is hoped that with such strategies it would reduce the time to obtain the 
full dataset that is currently required for registration and thus allow sick patients faster 
access to a medicine with the potential for treatment. The MHRA (2013b) recently 
confirmed its commitment to allow early access to useful medicines through adaptive 
licensing, effected via the flexibility offered in the current European law for conditional 
approvals. The principle behind this adaptive licencing should be supported by a 
robust framework for assessing benefits and risks, as well as a tool to document the 
various considerations as the benefit-risk balances evolve over time with new data 
becoming available. As indicated by Philippe de Jong et al (2013a and 2013b), there 
must be greater clarity, transparency and consistency in the decision-making 
process, especially for products undergoing the AL procedure. In addition, there 
should be improved public communication to the stakeholders, including patients, on 
the perception of efficacy and safety (Eichler et al., 2012b), as the risk tolerance and 
trade-offs are expectedly different for the drug treatments assessed to be suitable for 
AL. Similarly, scientific communication between regulators and companies should be 
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 optimised and initiated at the early stages of product development (Philippe de Jong 
et al, 2013b). It therefore appears timely to share the findings of the universal 
framework and template developed here with the key leaders of the adaptive 
licencing movement, especially at this time when the major regulatory agencies are 
reviewing the current processes to accommodate the ideals of adaptive licencing. 
However, it was found that across a few regulatory agencies the jurisdiction and legal 
foundations for product registration differ. Hence, as for the framework, the universal 
implementation of AL should consider the legislative differences as a potential barrier 
and how such differences can be accommodated (Oye et al., 2013)  
 
The universal benefit-risk framework and benefit-risk template - Key to a 
cultural change 
Increasingly, patients, through advocacy groups or representatives, express their 
opinions on factors in healthcare so that these can be reviewed during the 
assessment of benefits and risks (Walker et al., 2006). Various regulatory agencies 
like the EMA (2011), MHRA (2013a) and the US FDA (through the Patient-Focused 
Drug Development program of PDUFA V; FDA, 2013a) have initiated projects to 
involve patients more in their regulatory processes. Indeed, the incorporation of 
patients’ opinions and contributions to regulatory decision-making have been the 
recent highlight for workshops on benefit-risk assessments (CIRS, 2012a and 
2013a). Existing frameworks do not explicitly indicate the involvement of patients for 
the assessment of benefits and risks, but these may be discussed during the 
documentation of the outcomes and considerations of the decision. The challenge 
would be to identify the tools to collect such information in an objective manner and 
how these might be incorporated into the proposed practices for weighting and 
valuing. To obtain quantified measures of patients’ input, these could be done 
through patient reported outcomes (PRO). However, the relevance of the PROs 
needs to be validated with the patients themselves. Therefore, it is expected that 
platforms to communicate with patients and their caregivers be established so that 
such pertinent information can be sourced in a systematic manner. There appears to 
be no ideal approach for the above, and the activities may range from direct patient 
meetings as conducted by the US FDA, or having them represented at advisory 
meetings in the EU. To ensure that the universal framework and BR Template remain 
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 relevant and useful, future refinement should look as to how the patients’ contribution 
can be incorporated as part of the framework and effectively documented.  
 
In some jurisdictions the accessibility of a medicine would require the approval of a 
third party insurance payer or a health technology assessment (HTA) agency. 
Therefore it is essential that the relevant information to support the use and 
availability of the medicine be communicated from the regulatory agency to the HTA 
agencies. There are also recent efforts to conduct joint reviews between EMA and 
the HTA agencies (EMA, 2013d), in recognition of the significant contribution of each 
party towards product availability and ultimately healthcare management. The initial 
focus of the collaboration was to review the EPAR’s information on the benefits and 
risks of a medicine and how these can address the needs of HTA agencies. The 
objectives included potential changes to the EPAR template.  
 
Study limitations 
• The prospective study for the BR Template conducted by the three agencies was 
limited to using one product per reviewer. Therefore there is potential bias in the 
opinions received regarding the applicability of the BR Template, as these 
opinions are collected from only a few assessors and may be confounded by 
individual work experience, clinical expertise and previous exposure to other 
frameworks. Moreover, the limited products reviewed could not represent the 
different benefit-risk profiles and risk tolerance that would be encountered for 
regulatory submissions. 
• The studies of the BR Template and BR Summary Template were conducted with 
only four regulatory agencies whose experience and opinions may not represent 
those of the major reference regulatory agencies like the EMA and the US FDA.  
• The study for the BR Summary Template used only one agency from the emerging 
markets (HSA, Singapore) and included only abridged applications where approval 
had been obtained in another country.  
• The case study (Zaltrap®) used for the comparison of publicly available report was 
one product meant for a highly unmet medical need and not across a few products 
for different benefit-risk balances and risk tolerance. 
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 • The industry was not engaged as part of the study to review the utility of the BR 
Template and BR Summary Template. 
 
RECOMMENDATIONS 
• Agencies should include the listing of benefits and risks, assign weighting or 
relative importance and visualisation in their assessment and documentation of 
benefit-risk decisions 
• Consideration should be given to using the BR Summary Template to 
communicate to companies, physicians and other agencies 
• The BR Summary Template should be considered by the emerging markets for the 
exchange of information in support of their own regulatory approval processes 
• The value of the framework should be determined for companies for drug 
development and regulatory submission 
• The utility of both the universal framework and BR Template should be explored 
by HTA agencies 
• Training programs/initiatives for change management should be explored within an 
organisation 
 
FUTURE WORK 
• The development of the universal framework and BR Template and the impact of 
this research should be assessed after 3 years. This may be conducted via the 
same manner to collect information on the stakeholders’ current use of benefit-risk 
assessment frameworks as carried out in Chapter 3. 
• The practicality and validity of the revised BR template should be reviewed again 
in the three agencies and also the EMA, whose guidance formed the basis of the 
template. The study involving the EMA should also elucidate how effectively the 
items in the reflection paper are being represented in the BR template. 
• The applicability of the BR template in the post-marketing setting for assessing, 
documenting and communicating changes in benefit-risk balances (via the 
PBRERs) should be investigated. This would assess the utility of the template for 
product life cycle management. 
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 • The use of the stand-alone BR Summary Template should be further investigated 
by leading emerging agencies, through using different products and evaluations, in 
sharing assessment reports with other emerging markets, including Asian, Central 
American and the Middle Eastern countries. 
• The incorporation of weights and values for the assessment of benefits and risks 
and the presentation of such information into the publicly available assessment 
reports should be studied for its impact on the communication of benefit-risk 
decisions to stakeholders. 
• The framework and the template should be reviewed to optimise the contribution 
of patients, in terms of time involvement and objective information, to the benefit-
risk decision-making process. This may be aligned to the current activities 
undertaken by the US FDA’s PDUFA V. 
• The various needs of the stakeholders for a benefit-risk document should be 
verified as these needs are expected to vary between academia, regulatory affairs, 
healthcare and the lay patients. This would allow the validation of the template to 
communicate effectively according to various stakeholder needs. 
 
In an attempt to ensure the framework and template are used in a contemporary 
setting, the function of the framework should align to the current interests of 
regulatory science, namely life cycle management and adaptive licencing. However 
this can only be achieved if the use in post-marketing activities can be demonstrated. 
To establish the framework as universal, all stakeholders, including those from the 
emerging markets, should be incorporated into future studies to ascertain its value in 
these respective countries. 
 
CONCLUSION 
While there was previously no common framework, the criteria for the development of 
a universal benefit-risk framework have now been identified and it is confirmed that 
the purposes of such a framework are to enhance the documentation and 
communication of decisions to the various stakeholders in a manner that is 
structured, transparent and consistent. The 8-step universal benefit-risk assessment 
framework, a documentation tool and the user manual, have now been developed to 
effectively meet the need for a common universal framework.  
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Introduction 
 
This manual has been developed as an aid for the user in completing the Proforma and 
Summary template. First, it provides guidance to the user on how to complete the 
template, through understanding the terms used in this the glossary and clarifications 
offered at various sections. Then, it assists the user in the technical functions of making 
amendments and manoeuvring through the document. 
 
Throughout this manual, a red arrow “      “ will be used to indicate sections where 
additional clarifications are provided to guide the user in completing the template. 
 
 
Glossary 
 
Term  Definition 
Adverse event* Also known as Adverse experience, it is any untoward medical 
occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this treatment. 
Adverse 
reaction/effect* 
In the pre-approval setting when the therapeutic dose(s) may not 
be established, it is all noxious and unintended responses to a 
medicinal product related to any dose should be considered 
adverse drug reactions. 
For marketed medicinal products, it refers to a response to a drug 
which is noxious and unintended and which occurs at doses 
normally used in man for prophylaxis, diagnosis, or therapy of 
disease or for modification of physiological function. 
Benefit A potential favourable effect seen to be promoting or enhancing 
the current state of health, resulting from the treatment using the 
Product** 
Benefit-risk 
assessment 
Also referred to as Assessment and known as Benefit-risk 
evaluation, it is the review of scientific data in support of the 
proposed indication of the Product, conducted by a 
Reviewer/Assessor 
Benefit-risk balance Also known to as Benefit-risk profile or outcome, it is the expert 
opinion cumulative of the consideration of the benefits and risks - 
weighing the relative contribution and the uncertainties of the 
evidence provided, incorporating the current medical knowledge 
and experience - and recommending a positive or negative 
outcome 
Company/Sponsor Refers to the owner of the Product, and whom initiates the 
Submission 
Comparator An investigational or marketed product (i.e. active control) used 
as a reference in a clinical trial. 
Effect size The quantum of difference arising from the comparison between 
treatment outcomes of the Product with the comparator; it 
contributes to the overall interpretation of effectiveness and 
clinical relevance 
Investigated product Also referred to as the Product, it is the entity on which the 
Submission of an application for market authorization is based, 
and for which the clinical studies are conducted 
Medicines For the purpose of this Template, this refers to pharmacological 
products for use in human with the intention of medical 
 
 
intervention 
Patient reported 
outcomes 
Observations as part of a study related to the results obtained 
directly from the patients, which may include patients’ 
satisfaction, tolerability, symptoms, patient preferences, quality of 
life and interruptions to daily living 
Proforma Part of the Template; consist of various sections providing the 
details of the basis on benefit-risk balance decisions 
Reviewer Also known as evaluator or assessor, personnel trained in the 
scientific evaluation of data, and using clinical judgment to 
provide a recommendation on the benefit-risk balance of the 
Product 
Risk Also known as harm, an unfavourable effect or adverse 
reactions/effects on patients’ health, public health or the 
environment resulting from exposure to the Product** 
Seriousness (of 
adverse 
event/reaction/effect)* 
A serious adverse event (experience) or reaction is any untoward 
medical occurrence that at any dose:  
• results in death,  
• is life-threatening (at risk of death at the time of the event) 
• requires inpatient hospitalisation or prolongation of existing 
hospitalisation,  
• results in persistent or significant disability/incapacity, or  
• is a congenital anomaly/birth defect. 
 
Severity (of adverse 
event/reaction/effect)* 
The intensity of a specific adverse event which may or may not 
be of medical significance or seriousness, which is defined by a 
set of criteria.  
Submission An application sent for review to the regulatory authorities by the 
Company, for the market authorization of the proposed 
indications of the Product 
Summary: Benefit-
Risk 
Part of the Template; consist of the conclusions of various 
aspects of assessment, and the final benefit-risk balance 
Template Refers to the entire document comprising the Summary and 
Proforma 
Valuing An exercise of providing qualitative or quantitative figure (values) 
reflecting of the effect observed from the studies; this assist in the 
interpretation of effect size and relevance of treatment  
Weighting An exercise of expert judgment indicating the relative importance 
of the available options, commonly done through a logical system 
of rank assignment (weights) 
   
*Adapted from ICH Harmonised Tripartite Guideline. E2A – Clinical Safety Data Management: 
Definitions and Standards for Expedited Reporting. October 1994. 
**Adapted from European Medicines Agency (EMA). Benefit-risk methodology project. Work 
Package 2 report: Applicability of current tools and processes for regulatory benefit-risk assessment; 
August 2010. 
 
 
Completing the Benefit/Risk Template – Cover page 
 
The Cover page is meant to provide basic information of the Product for which this assessment will 
be based on. 
 
 
 
 
 
 
 
 
Completing the template – Proforma Sections 
 
The Proforma section provides details of the assessment of benefits and risks, and illustrates the 
basis of decision on benefit-risk balance in a logical flow. It contributes to information in the 
Summary.  
 
Clarifications are provided for selected subsections to guide the user in putting in the correct 
information. 
 
 
Note: Subsections which do not currently have any clarifications attached is due to none being 
raised. Following your use of this template, comments and further clarifications thought to be 
required are welcomed so that these can be included in the next iteration of the user manual. 
 
 
SECTION 1. BACKGROUND  
This section focuses on the justification for the proposed indication and use of the product, in the 
context of medical need. This section helps to address the varying medical needs of countries due 
to medical practices and social differences. 
 
  
 
 
SECTION 2. OVERALL SUMMARY 
 
2.1 QUALITY OVERALL SUMMARY  
This section accounts for the issues observed during assessment of the quality of the product that 
may impact the efficacy and safety. Comments should be provided in the instance where there are 
significant concerns amounting to potential negative consequences in clinical outcomes. 
 
 
 
 
 
 
 
 
 
 
Please tick this box if there are NO findings from the quality 
assessment that may impact the safe and effective use of the 
product.  
 
 
 
2.2  NON-CLINICAL OVERALL SUMMARY 
This section accounts for the issues observed during the assessment of non-clinical data that may 
impact the efficacy and safety in humans. Comments should be provided in the instance where 
there are significant findings & their potential implications for the safe & effective use of the product 
in humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please tick this box if there are NO findings from the non-clinical assessment 
that may impact the safe and effective use of the product in humans.  
If there are SIGNIFICANT findings, please enter these into the box as well as 
the potential implications for the safe and effective use of the product in 
humans. 
 
 
 
SECTION 3.  IDENTIFIED BENEFITS AND RISKS   
This section provides a clear basis for the identification of major benefits and risks parameters that 
will be used in constructing the benefit-risk balance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Benefits and risks of treatment 
should include those observed 
& derived from the submitted 
studies as indicated by the 
Sponsor as well as those 
identified by the reviewer.  
From the list of all benefits 
and risks identified in the 
submitted studies, the 
reviewer should differentiate 
those he has identified but 
not observed by the 
company. This allows any 
additional benefits or risks to 
be highlighted from the 
reviewer’s perspective. 
After a review of the list of 
identified benefits and risks, 
the reviewer should decide 
which are pivotal in making 
the benefit-risk balance. For 
each benefit or risk justified to 
be included, these would be 
auto-populated respectively 
to sections 4.1 (for benefits), 
4.3 (for risks) and 5, where 
detailed information will then 
be further required. 
Reasons must be provided 
for all listed benefits and 
risks as to their inclusion or 
exclusion for further benefit-
risk assessment. 
 
Uncertainties of the identified 
benefits and risks will be 
addressed in template 
section 5.  
 
 Section 4. Benefits and Risks – Study information 
This section expounds on the benefits and risks considered for constructing the benefit-risk balance. Inputs will require information from the studies. The 
considerations for assessment are adapted from the EMA reflection paper (2008) and these are attached in Annexes A and B for benefits and risks 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
List the statistical parameter applied to investigate the 
endpoint used to confirm the benefit, or in the case of 
non-inferiority and equivalence studies, the pre-
defined margins or deltas not to be exceeded. 
 
A “Yes” should be chosen for non-inferiority or 
equivalence studies when the pre-defined 
limits were not exceeded and the objectives 
met.  
 
A “N/A” should be chosen for studies that no 
statistical analyses were conducted e.g. 
observational studies. 
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This refers to the proportion of patients in each of the treatment 
groups who required a reduction in the dose of the study treatment 
as a result of adverse effects. 
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The uncertainties in 
this section concerns 
the studies’ design, 
conclusions and 
consistency.  
 
Inputs for 
uncertainties for 
individual benefits 
and risks should be 
provided in section 
5.1 and 5.2 
respectively. 
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 SECTION 5.  BENEFIT-RISK SUMMARY TABLE & EXPERT JUDGMENT  
This section allows the reviewer to apply his expert judgment on the identified benefits and risks. The use of weighting and valuing enables the review to 
articulate the basis of his recommendation on the benefit-risk balance. Kindly refer to the Glossary for the terms “Weighting” and “Valuing”, as well as the 
pointers in the template. 
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SECTION 6.  VISUALISATION 
This section allows the reviewer to include any graphical presentation of the outcomes from the 
studies or to illustrate the benefit-risk balance of the product. Please note that for images to be 
uploaded into the box, it must be saved in JPEG, GIF or PNG format. 
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SECTION 7.  CONCLUSIONS 
This section collates the conclusions from quality, non-clinical, human pharmacology and clinical 
sections. The final decision on the benefit-risk balance of the Product for the proposed indication 
will be discussed here. Considerations for assessing the benefit-risk balance are adapted from the 
EMA reflection paper (2008) and these are attached in Annex C.  
 
Sections 7.1, 7.2, 7.3 and 7.4 of the template do not require input from the user, and do not allow 
editing of the presented information. The information is auto-populated, and the source of each 
sub-section is denoted by the respective Proforma section in parentheses. Input is only required 
from section 7.4.1 onwards. 
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 Completing the template – Summary Section  
 
The Benefit-Risk Summary Section provides the conclusions of various aspects of benefit-
risk assessment, as well as the resulting benefit-risk balance. It is used as a succinct 
document to communicate the essential decisions for the submission. 
This section of the template does not require input from the user, and does not allow editing 
of the presented information. The information is auto-populated, and the source of each sub-
section is denoted by the respective proforma section in parentheses. An example is shown 
below: 
 
For amendments to this section, it should be done through editing of the respective sources 
in the Proforma section. Please refer to the manual section “Making changes to the template” 
for assistance in making amendments. 
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 Making changes to the template 
To maintain consistency and validity of the information throughout the document, editing has 
been limited to source sections and sections that do no fill another in the document. 
 
The following fields do NOT allow editing of the information: 
• Entire Section 8, the Summary section 
• Sections 5.1 and 5.2 (the selected benefits and risks are populated from source sections 3.1 
and 3.2 respectively) 
• Sections 7.1 to 7.4. 
To edit the above sections, refer to the source location of the information which is usually 
listed at the end of the statement of the subsection. 
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 Navigating through the template 
A taskbar at the top of each page allows instant access to the desired section through a click 
at the relevant tab. 
 
For your convenience, the various tabs are correlated to the sections shown in the figure 
below. 
 
 
 Proforma Summary 
 Section 1 Section 2 Section 3 Section 4 Section 5 Section 6 Section 7 Section 8 
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 Annex A 
Criteria for assessing efficacy or favourable effects* 
 
1. Efficacy (primary endpoint) versus comparator and its clinical relevance  
2. Magnitude of treatment effect  
3. Clinical relevance of the primary endpoints 
4. Statistical significance of the efficacy results 
5. Representiveness of the studied population for the population targeted in the label  
6. Discussion of dose  
7. Evidence for the efficacy in relative subgroups 
8. Design conduct and statistical adequacy of the trial 
9. Confirmation of treatment effect by results of non-primary endpoints 
10. Validation of scales and outcome measures 
11. Patient preferred outcomes  
12. Confirmation of efficacy by results of relevant non-pivotal trials and extensions 
13. Anticipated patient compliance (and patient convenience) 
14. Clustering (consistency) of results of the pivotal trials 
*Adapted from European Medicines Agency (EMA). Reflection Paper on Benefit-risk Assessment 
Methods in the context of the Evaluation of Marketing Authorisation Applications of Medicinal Products 
for Human Use; March 2008. 
291 
 
 Annex B 
 
Criteria for assessing harms or unfavourable effects* 
1. Overall incidence of adverse effects (from clinical trials)  
2. Overall incidence of serious adverse effects (from clinical trials 
3. Discontinuation rate due to adverse effects (from clinical trials) 
4. Incidence, seriousness and duration of specific adverse effects (from clinical trials and 
post-marketing surveillance)  
5. Interaction with other drugs and food  
6. Safety in subgroups (e.g. race and sex) 
7. Potential for off label use leading to safety hazards 
8. Potential for non-demonstrated additional risk due to limitations of clinical trials and/or 
short market exposure. 
9. Potential for non-demonstrated additional risk due to safety issues observed in pre-clinical 
safety studies but not in humans 
10. Potential for non-demonstrated additional risk due to safety issues observed with other 
medicines of the same pharmacological class 
*Adapted from European Medicines Agency (EMA). Reflection Paper on Benefit-risk Assessment 
Methods in the context of the Evaluation of Marketing Authorisation Applications of Medicinal Products 
for Human Use; March 2008. 
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 Annex C 
 
Criteria for assessing benefit-risk balance* 
 Amount of evidence to characterise the benefit-risk balance: 
 Availability of comparative data and their limitations and potential deficiencies 
 Interpret of key benefits and risks 
 from perspectives of different stakeholders, including patients and treating physicians 
 Level of risk acceptability 
 corresponding to the perceived degree of clinical benefit in the specific context 
 Relating the benefits to the risks when possible:  
 Using logical comparisons e.g. potential lives saved as a result of treatment compare to 
potential lives lost as a result of adverse reactions 
 Factors affecting the benefit-risk balance: 
 Situations that may alter the current balance e.g. different patient or disease characteristics 
 Sensitivity of the benefit-risk balance:  
 Discussion on the potential changes to the balance if the fundamental assumptions are to be 
amended 
 Other appropriate discussions:  
 Effectiveness of proposed treatment compared to available options 
 For negative benefit-risk balanced, describe the potential harm incurred upon exposure for 
the claimed indication 
 Evolution of benefit-risk balance over time 
 Outstanding issues, submission or reports to address identified issues 
 Evaluation of pharmacovigilance plan, risk mitigation plan or other post-marketing 
commitments including need for further studies 
 Opinions from scientific experts, patients, consumers or advocates and other stakeholders in 
the benefit-risk assessments 
 Conclusion on the benefit-risk being positive or not for every claimed indication. 
*Adapted from European Medicines Agency (EMA). Reflection Paper on Benefit-risk Assessment 
Methods in the context of the Evaluation of Marketing Authorisation Applications of Medicinal Products 
for Human Use; March 2008. 
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 Appendix III 
 
 
 
Protocol for the Study of Benefit-Risk Summary: Health Sciences Authority, 
Singapore 
 
1.  Background 
Over the past three years, the Centre for Innovation in Regulatory Science (CIRS) in 
association with Health Canada, the TGA in Australia, HSA in Singapore and 
SwissMedic have developed a structured systematic standardised approach to the 
benefit-risk assessment of medicines.   
 
This includes an eight step framework, namely: Step 1: decision context; Step 2: 
building the value tree; Step 3: refining the value tree; Step 4: relative importance of 
benefits and risks; Step 5: evaluating the options; Step 6: evaluating uncertainty; 
Step 7: concise presentation of results (visualisation) and Step 8: expert judgement 
and communication.   
 
A proforma template (in which a Summary is found) based on the EMA guidance 
document for benefit-risk assessment (March 2008) has been developed to 
document the benefit-risk decision-making process in the regulatory review. A user 
manual was also incorporated to guide the user in completing the proforma template. 
 
The Summary portion of this proforma template is now extracted and further 
investigated for use on its own. The User Manual is correspondingly provided for this 
purpose to support the Summary. 
 
 
2.  Objectives 
The overall objective is to evaluate the use of this Summary, supported by the User 
Manual, in documenting and communicating benefit-risk decisions through a 
retrospective study in HSA. 
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 3.  Methodology 
Clinical reviewer involved in the assessment of product applications in the 
Therapeutic Products Branch will be invited to participate in this study. The study is a 
retrospective open-label and non-comparative trial. 
 
Each reviewer will identify an application that had achieved regulatory decision within 
the last 3 months. The applications should be pertaining New Drug Applications via 
either the full or abridged route of evaluation.  
 
Using the respective clinical assessment report, the assessor will transfer the 
relevant information required of the Summary. Upon the completion of this transfer, 
the reviewer will then respond to the survey. This exercise is to be supported by the 
User Manual provided.  
 
All survey outcomes should be completed and submitted by July 2013.  
 
 
4.  Outcome 
The purpose of the study report is to contribute to the overall feasibility of using the 
Summary in documenting the relevant discussions that will help in communicating 
clearly and accurately the benefit-risk decisions. This may be used by regulatory 
agencies of emerging markets as part of their regulatory process, or as a document 
for exchanging information on regulatory decisions. 
 
 
 
James Leong 
Senior Regulatory Specialist 
Therapeutic Products Branch 
Pre-market Division 
 
June 2013 
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